| placebo |
placebo |
378 |
2010 |
| Drug |
amlodipine |
145 |
2010 |
| Drug |
hydrochlorothiazide |
111 |
2014 |
| Drug |
valsartan |
109 |
2014 |
| Drug |
aliskiren |
69 |
2010 |
| Drug |
telmisartan |
55 |
2014 |
| Drug |
losartan |
40 |
2010 |
| Drug |
nebivolol |
40 |
2010 |
| Drug |
olmesartan medoxomil |
36 |
2009 |
| Other |
standard care |
34 |
2017 |
| Drug |
sildenafil |
30 |
2014 |
| Drug |
irbesartan |
28 |
2009 |
| Drug |
ramipril |
25 |
2010 |
| Drug |
chlorthalidone |
24 |
2014 |
| Drug |
fimasartan |
24 |
2013 |
| Drug |
atenolol |
21 |
2013 |
| Drug |
bosentan |
21 |
2010 |
| Other |
control |
21 |
2010 |
| Drug |
ambrisentan |
20 |
2009 |
| Drug |
hctz |
20 |
2017 |
| Drug |
azilsartan medoxomil |
19 |
2008 |
| Drug |
losartan potassium |
18 |
2009 |
| Drug |
bimatoprost |
17 |
2013 |
| Drug |
carvedilol |
17 |
2009 |
| Drug |
lcz696 |
17 |
2010 |
| Drug |
tadalafil |
17 |
2010 |
| Drug |
latanoprost |
16 |
2009 |
| Drug |
lisinopril |
16 |
2011 |
| Drug |
olmesartan |
16 |
2013 |
| Drug |
rosuvastatin |
16 |
2013 |
| Drug |
hydrochlorothiazide (hctz) |
15 |
2009 |
| Device |
renal denervation |
15 |
2020 |
| Drug |
timolol |
15 |
2014 |
| Drug |
amlodipine 5mg |
14 |
2010 |
| Drug |
spironolactone |
14 |
2014 |
| Drug |
enalapril |
13 |
2009 |
| Drug |
metoprolol |
13 |
2009 |
| Drug |
sildenafil citrate |
13 |
2017 |
| Drug |
travoprost 0.004% |
13 |
2014 |
| Drug |
candesartan cilexetil |
12 |
2012 |
| Drug |
latanoprost 0.005% |
12 |
2008 |
| Drug |
macitentan |
12 |
2016 |
| Drug |
valsartan/hydrochlorothiazide |
12 |
2011 |
| Drug |
brinzolamide 1% |
11 |
2008 |
| Behavioral |
exercise |
11 |
2014 |
| Drug |
nifedipine |
11 |
2011 |
| Drug |
perindopril |
11 |
2019 |
| Drug |
riociguat (adempas, bay63-2521) |
11 |
2010 |
| Drug |
saline |
11 |
2017 |
| Other |
aerobic exercise |
10 |
2014 |
| Drug |
bisoprolol |
10 |
2015 |
| Drug |
candesartan |
10 |
2018 |
| Drug |
clevidipine |
10 |
2008 |
| Drug |
eplerenone |
10 |
2008 |
| Drug |
metoprolol succinate |
10 |
2011 |
| Drug |
timolol 0.5% |
10 |
2008 |
| Drug |
timolol 0.5% ophthalmic solution |
10 |
2009 |
| Drug |
amiloride |
9 |
2014 |
| placebo |
comparator: placebo |
9 |
2009 |
| Drug |
cs-3150 |
9 |
2019 |
| Drug |
methylprednisolone |
9 |
2010 |
| Drug |
simvastatin |
9 |
2014 |
| Drug |
valsartan/amlodipine |
9 |
2010 |
| Drug |
5 mg |
8 |
2010 |
| Drug |
amlodipine 5 mg |
8 |
2008 |
| Drug |
atorvastatin |
8 |
2017 |
| Drug |
labetalol |
8 |
2018 |
| Drug |
vehicle |
8 |
2015 |
| Drug |
5mg |
7 |
2019 |
| Drug |
acetazolamide |
7 |
2014 |
| Drug |
allopurinol |
7 |
2014 |
| Drug |
amlodipine 80 |
7 |
2015 |
| Drug |
azilsartan |
7 |
2016 |
| Dietary Supplement |
beetroot juice |
7 |
2013 |
| Drug |
benazepril |
7 |
2012 |
| Behavioral |
home blood pressure monitoring |
7 |
2010 |
| Drug |
hydralazine |
7 |
2012 |
| Drug |
latanoprost ophthalmic solution 0.005% |
7 |
2014 |
| Drug |
nitric oxide |
7 |
2015 |
| Device |
shamed hypoxia (fio2: 20.9) |
7 |
2018 |
| Drug |
timolol fixed combination |
7 |
2006 |
| Drug |
travoprost |
7 |
2012 |
| Drug |
treprostinil diethanolamine |
7 |
2010 |
| Drug |
xalatan |
7 |
2008 |
| Other |
acupuncture |
6 |
2018 |
| Device |
ambulatory blood pressure monitoring |
6 |
2018 |
| Drug |
amlodipine 10 mg |
6 |
2006 |
| Drug |
amlodipine besylate |
6 |
2015 |
| Drug |
ar-13324 ophthalmic solution 0.02% |
6 |
2017 |
| Drug |
azilsartan medoxomil/chlorthalidone |
6 |
2009 |
| Other |
blood sample |
6 |
2010 |
| Drug |
brinzolamide 1% ophthalmic suspension |
6 |
2019 |
| Drug |
clonidine |
6 |
2013 |
| Device |
cpap |
6 |
2008 |
| Drug |
de-117 ophthalmic solution |
6 |
2018 |
| Drug |
iloprost |
6 |
2017 |
| Drug |
indapamide |
6 |
2010 |
| Drug |
irbesartan/hydrochlorothiazide |
6 |
2012 |
| Drug |
l-arginine |
6 |
2011 |
| Drug |
latanoprost ophthalmic solution |
6 |
2014 |
| Drug |
metformin |
6 |
2010 |
| Behavioral |
patient education |
6 |
2014 |
| Drug |
telmisartan 80 mg |
6 |
2006 |
| Drug |
telmisartan/amlodipine |
6 |
2010 |
| Drug |
trandolapril |
6 |
2005 |
| Drug |
valsartan / amlodipine |
6 |
2006 |
| Other |
assessment at low altitude (470m above sea level) |
5 |
2018 |
| Drug |
bimatoprost 0.01% ophthalmic solution |
5 |
2011 |
| Drug |
bimatoprost sr |
5 |
2015 |
| Drug |
brimonidine |
5 |
2005 |
| Drug |
comparator: losartan |
5 |
2009 |
| Other |
conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules |
5 |
2019 |
| Behavioral |
diet |
5 |
2014 |
| Behavioral |
diet, reducing |
5 |
1999 |
| Behavioral |
diet, sodium-restricted |
5 |
1999 |
| Drug |
doxazosin |
5 |
2016 |
| Other |
exposure to high altitude (2500m above sea level) |
5 |
2018 |
| Drug |
hydrochlorothiazide, if necessary |
5 |
2008 |
| Drug |
inhaled treprostinil |
5 |
2015 |
| Drug |
latanoprost-ppds |
5 |
2011 |
| Drug |
latanoprost ophthalmic solution 0.005% (xalatanâ®) |
5 |
2008 |
| Drug |
losartan potassium ( |
5 |
2009 |
| Behavioral |
motivational interviewing |
5 |
2010 |
| Drug |
nifedipine (adalat, baya1040) |
5 |
2011 |
| Drug |
olmesartan medoxomil/hydrochlorothiazide |
5 |
2009 |
| Behavioral |
physical activity |
5 |
2014 |
| placebo |
placebo to aliskiren |
5 |
2009 |
| Drug |
propranolol |
5 |
2018 |
| Drug |
ranolazine |
5 |
2016 |
| Drug |
selexipag |
5 |
2015 |
| Procedure |
sham procedure |
5 |
2012 |
| Device |
simulated altitude (fio2: 15.1%) |
5 |
2018 |
| Drug |
travoprost 0.004%/timolol 0.5% ophthalmic solution |
5 |
2008 |
| Drug |
travoprost ophthalmic solution 0.004% with sofziaâ® preservative system (travatan zâ®) |
5 |
2008 |
| Dietary Supplement |
vitamin d |
5 |
2011 |
| Drug |
xalacom |
5 |
2006 |
| Drug |
) hydrochlorothiazide |
4 |
2007 |
| Drug |
) timolol maleate |
4 |
2007 |
| Drug |
amlodipine 10mg |
4 |
2016 |
| Drug |
amlodipine 300 |
4 |
2008 |
| Drug |
amlodipine/benazepril |
4 |
2011 |
| Drug |
amlodipine/losartan |
4 |
2009 |
| Drug |
amlodipine/valsartan |
4 |
2014 |
| Drug |
aspirin |
4 |
2014 |
| Drug |
beraprost sodium modified release |
4 |
2008 |
| Drug |
bimatoprost 0.01% |
4 |
2013 |
| Drug |
bimatoprost 0.03% |
4 |
2010 |
| Drug |
bimatoprost 0.03% ophthalmic solution |
4 |
2010 |
| Drug |
bol-303259-x |
4 |
2012 |
| Drug |
brimonidine tartrate |
4 |
2010 |
| Drug |
brimonidine tartrate 0.2% ophthalmic suspension |
4 |
2011 |
| Drug |
brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension |
4 |
2011 |
| Drug |
coreg cr |
4 |
2007 |
| Drug |
dapagliflozin |
4 |
2010 |
| Behavioral |
dash diet |
4 |
2009 |
| Drug |
dexmedetomidine |
4 |
2014 |
| Procedure |
endovascular chemical ablation of adrenal gland |
4 |
2017 |
| Behavioral |
enhanced usual care |
4 |
2014 |
| Other |
exercise therapy |
4 |
2016 |
| Drug |
febuxostat |
4 |
2017 |
| Drug |
felodipine |
4 |
2010 |
| Drug |
fimasartan/amlodipine |
4 |
2017 |
| Drug |
hctz 12.5 mg |
4 |
2011 |
| Drug |
hydrochlorothiazide 25 mg |
4 |
2017 |
| Drug |
lacidipine |
4 |
2014 |
| Drug |
latanoprost 0.005% ophthalmic solution |
4 |
2009 |
| Drug |
lercanidipine |
4 |
2010 |
| Drug |
moxonidine |
4 |
2015 |
| Drug |
oxygen |
4 |
2019 |
| Drug |
pioglitazone |
4 |
2011 |
| Device |
renal angiography |
4 |
2018 |
| Device |
renal sympathetic denervation |
4 |
2015 |
| Device |
resperate |
4 |
2010 |
| Device |
telemonitoring |
4 |
2011 |
| Drug |
telmisartan 40 mg |
4 |
2006 |
| Drug |
telmisartan/hydrochlorothiazide |
4 |
2014 |
| Drug |
timolol maleate 0.5% |
4 |
2013 |
| Drug |
timolol maleate ophthalmic solution 0.5% |
4 |
2018 |
| Drug |
timolol maleate ophthalmic solution 0.5% bid |
4 |
2014 |
| Drug |
trandolapril/verapamil |
4 |
2005 |
| Drug |
travoprost ophthalmic solution, 0.004% |
4 |
2011 |
| Drug |
trimethaphan |
4 |
2014 |
| Drug |
ut-15c sr |
4 |
2011 |
| Drug |
valsartan 160 mg |
4 |
2009 |
| Drug |
valsartan 80 mg |
4 |
2008 |
| Drug |
verapamil |
4 |
2005 |
| Drug |
) losartan potassium |
3 |
2006 |
| Drug |
0.005% |
3 |
2017 |
| Drug |
0.5% timolol ophthalmic solution |
3 |
2010 |
| Drug |
12.5 |
3 |
2010 |
| Drug |
2.5 mg |
3 |
2010 |
| Drug |
25 mg |
3 |
2015 |
| Drug |
5 |
3 |
2015 |
| Drug |
ace inhibitor |
3 |
2020 |
| Drug |
acetaminophen |
3 |
2016 |
| Behavioral |
alcohol restriction |
3 |
1999 |
| Drug |
alcon investigational agent |
3 |
2002 |
| Drug |
aliskiren 150 mg |
3 |
2010 |
| Drug |
aliskiren 300 mg |
3 |
2017 |
| Drug |
aliskiren/hctz |
3 |
2010 |
| Drug |
amlodipine 2.5 mg |
3 |
2010 |
| Drug |
amlodipine 40 |
3 |
2015 |
| Drug |
bia 5-1058 |
3 |
2018 |
| Drug |
bimatoprost/timolol fixed combination |
3 |
2006 |
| Behavioral |
blood pressure measurement |
3 |
2017 |
| Drug |
brimonidine tartrate ophthalmic solution |
3 |
2018 |
| Drug |
brimonidine tartrate ophthalmic solution, 0.2% |
3 |
2011 |
| Drug |
brimonidine/timolol fixed combination |
3 |
2006 |
| Drug |
brinzolamide |
3 |
2007 |
| Drug |
brinzolamide 10 mg |
3 |
2015 |
| Drug |
brinzolamide ophthalmic suspension, 1% |
3 |
2011 |
| Drug |
calcium |
3 |
2008 |
| Drug |
chlorthalidone 25mg |
3 |
2013 |
| Drug |
chlorthalidone/amiloride |
3 |
2016 |
| Drug |
cilnidipine |
3 |
2006 |
| Drug |
ckd-330 16 |
3 |
2016 |
| Drug |
ckd-828 |
3 |
2014 |
| Drug |
combination therapy |
3 |
2010 |
| Other |
control diet |
3 |
2016 |
| Biological |
cyt006-angqb |
3 |
2008 |
| Drug |
darusentan |
3 |
2006 |
| Drug |
de-111 ophthalmic solution |
3 |
2011 |
| Drug |
dipyridamole |
3 |
2014 |
| Drug |
distilled water |
3 |
2011 |
| Drug |
dorzolamide hydrochloride ( |
3 |
2007 |
| Drug |
dorzolamide hydrochloride (/) timolol maleate |
3 |
2007 |
| Behavioral |
education |
3 |
2020 |
| Device |
electronic pill bottle |
3 |
2013 |
| Drug |
enalapril maleate |
3 |
2008 |
| Drug |
eprosartan |
3 |
2012 |
| Behavioral |
exercise training |
3 |
2017 |
| Other |
exercise/respiratory therapy |
3 |
2019 |
| Drug |
folic acid |
3 |
2018 |
| Other |
glucose |
3 |
2015 |
| Behavioral |
health coaching |
3 |
2015 |
| Behavioral |
health education |
3 |
2017 |
| Drug |
heparin |
3 |
2014 |
| Drug |
hgp0904 |
3 |
2015 |
| Drug |
high dose of telmisartan |
3 |
2014 |
| Procedure |
hvpg measurement |
3 |
2018 |
| Drug |
hydrochlorothiazide 12.5 mg |
3 |
2008 |
| Drug |
ibuprofen |
3 |
2016 |
| Drug |
inhaled nitric oxide |
3 |
2018 |
| Drug |
intralipid 20% |
3 |
2015 |
| Dietary Supplement |
l-citrulline |
3 |
2018 |
| Drug |
lci699 |
3 |
2008 |
| Drug |
losartan potassium (/) hydrochlorothiazide |
3 |
2007 |
| Other |
low altitude: 470m above sea level |
3 |
2018 |
| Drug |
low dose of telmisartan |
3 |
2014 |
| Behavioral |
low sodium diet |
3 |
2006 |
| Drug |
macitentan 10 mg |
3 |
2012 |
| placebo |
matching placebo |
3 |
2018 |
| Drug |
melatonin |
3 |
2010 |
| Procedure |
microneurography |
3 |
2014 |
| Drug |
mk0954a, hydrochlorothiazide ( |
3 |
2006 |
| Drug |
ml eye drops, suspension |
3 |
2015 |
| Device |
mobiushd |
3 |
2013 |
| Drug |
netarsudil (ar-13324) ophthalmic solution 0.02% |
3 |
2014 |
| Drug |
netarsudil ophthalmic solution 0.02% |
3 |
2019 |
| Drug |
nicardipine |
3 |
2015 |
| Drug |
nifedipine gits |
3 |
2015 |
| Drug |
olmesartan medoxomil / hydrochlorothiazide, if necessary |
3 |
2008 |
| Drug |
perindopril/amlodipine |
3 |
2016 |
| Drug |
pg324 ophthalmic solution 0.02% |
3 |
2014 |
| Drug |
phxa41 |
3 |
2008 |
| Drug |
potassium |
3 |
2008 |
| Drug |
ralinepag |
3 |
2018 |
| Drug |
reserpine |
3 |
2017 |
| Other |
respiratory |
3 |
2011 |
| Other |
respiratory therapy |
3 |
2019 |
| Other |
respiratory/exercise therapy |
3 |
2011 |
| Procedure |
right heart catheterization |
3 |
2010 |
| Drug |
rituximab |
3 |
2018 |
| Drug |
s-amlodipine |
3 |
2014 |
| Other |
sã¤ntis; 2500m above sea level |
3 |
2018 |
| Procedure |
selective laser trabeculoplasty |
3 |
2015 |
| Drug |
sitagliptin |
3 |
2014 |
| Other |
sugar pill |
3 |
2011 |
| Drug |
tafluprost |
3 |
2010 |
| Drug |
telmisartan 80mg |
3 |
2013 |
| Drug |
timolol 5 mg |
3 |
2006 |
| Drug |
timolol fixed combination ophthalmic solution |
3 |
2010 |
| Drug |
timolol maleate |
3 |
2012 |
| Drug |
timolol ophthalmic solution |
3 |
2016 |
| Drug |
timolol ophthalmic solution 0.5% |
3 |
2010 |
| Other |
timolol vehicle |
3 |
2006 |
| Drug |
travoprost ophthalmic solution 0.004% |
3 |
2013 |
| Drug |
treprostinil |
3 |
2019 |
| Drug |
treprostinil sodium |
3 |
2011 |
| Drug |
udenafil |
3 |
2014 |
| Drug |
valsartan 160mg |
3 |
2013 |
| Drug |
NA |
2 |
2007 |
| Drug |
) hydrochlorothiazide (hctz) |
2 |
2009 |
| Drug |
0.005% latanoprost |
2 |
2009 |
| Drug |
0.03% bimatoprost |
2 |
2013 |
| Drug |
0.5% timolol |
2 |
2012 |
| Drug |
10 mg |
2 |
2010 |
| Drug |
10 mg tablet |
2 |
2009 |
| Drug |
12.5 mg |
2 |
2015 |
| Drug |
12.5mg |
2 |
2013 |
| Drug |
12.5mg) |
2 |
2007 |
| Drug |
2.5mg |
2 |
2014 |
| Drug |
25 mg) |
2 |
2010 |
| Drug |
40mg |
2 |
2011 |
| Drug |
5 mg tablet |
2 |
2017 |
| placebo |
5mg placebo |
2 |
2015 |
| Drug |
80mg |
2 |
2011 |
| Drug |
act-385781a (actelion epoprostenol) |
2 |
2010 |
| Drug |
adalat (nifedipine, baya1040) |
2 |
2009 |
| Drug |
adempas (riociguat, bay63-2521) |
2 |
2016 |
| Behavioral |
adherence |
2 |
2005 |
| Behavioral |
adherence intervention |
2 |
2018 |
| Other |
aerobic |
2 |
2016 |
| Behavioral |
aerobic exercise training |
2 |
2016 |
| Behavioral |
aerobic interval training |
2 |
2016 |
| Drug |
ahu377 |
2 |
2011 |
| Drug |
aliskiren 150 |
2 |
2008 |
| Drug |
aliskiren/amlodipine |
2 |
2009 |
| Drug |
aliskiren/amlodipine 300/10 mg tablet |
2 |
2009 |
| Drug |
allisartan isoproxil |
2 |
2017 |
| Drug |
alt-711 |
2 |
2002 |
| Drug |
ama0076 |
2 |
2014 |
| Drug |
amlodipine (150 |
2 |
2010 |
| Drug |
amlodipine 10 mg capsule |
2 |
2009 |
| Drug |
amlodipine 150 |
2 |
2010 |
| Drug |
amlodipine 2.5mg |
2 |
2007 |
| Drug |
amlodipine 5 mg capsules |
2 |
2007 |
| Drug |
amlodipine combination |
2 |
2014 |
| Drug |
amlodipine, if necessary |
2 |
2009 |
| Drug |
amlodipine/atorvastatin single pill |
2 |
2005 |
| Drug |
amlodipine/hydrochlorothiazide |
2 |
2019 |
| Drug |
amlodipine10mg |
2 |
2013 |
| Drug |
anastrozole |
2 |
2017 |
| Drug |
angiotensin ii |
2 |
2011 |
| Drug |
antihypertensive agents |
2 |
1999 |
| Drug |
aprocitentan 25 mg |
2 |
2015 |
| Drug |
ar-12286 ophthalmic solution 0.5% |
2 |
2011 |
| Drug |
ar-13324 ophthalmic solution 0.02% bid |
2 |
2014 |
| Drug |
ar-13324 ophthalmic solution 0.04% |
2 |
2017 |
| Drug |
atorvastatin single pill |
2 |
2005 |
| Drug |
avalide |
2 |
2012 |
| Drug |
avapro |
2 |
2012 |
| Drug |
azelnidipine |
2 |
2009 |
| placebo |
azilsartan medoxomil placebo |
2 |
2014 |
| Procedure |
ballon pulmonary angioplasty |
2 |
2017 |
| Drug |
bardoxolone methyl |
2 |
2017 |
| Drug |
beraprost sodium 314d modified release tablets |
2 |
2013 |
| Drug |
bevacizumab |
2 |
2010 |
| Drug |
bimatoprost ophthalmic solution 0.01% |
2 |
2010 |
| Drug |
bimatoprost ophthalmic solution 0.03% |
2 |
2010 |
| Drug |
bimatoprost/brimonidine tartrate/timolol ophthalmic solution (triple combination therapy) |
2 |
2010 |
| Drug |
bq-123 |
2 |
2016 |
| Drug |
bradykinin |
2 |
2011 |
| Dietary Supplement |
bread |
2 |
2014 |
| Drug |
brimonidine 0.2% |
2 |
2017 |
| Drug |
brimonidine tartrate 0.2% |
2 |
2009 |
| Drug |
brimonidine tartrate 0.2% ophthalmic solution |
2 |
2011 |
| Drug |
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination |
2 |
2009 |
| Drug |
brinzolamide 1.0% |
2 |
2006 |
| Drug |
brinzolamide 10 mg/ml / timolol 5 mg/ml eye drops, suspension |
2 |
2006 |
| Drug |
calcium channel blockers |
2 |
2020 |
| Drug |
calcium channel blockers (amlodipine, azelnidipine) |
2 |
2006 |
| Drug |
candesartan 16mg |
2 |
2016 |
| Drug |
candesartan 16mg/amlodipine 5mg |
2 |
2016 |
| Drug |
candesartan 32mg |
2 |
2014 |
| Drug |
candesartan 8mg |
2 |
2015 |
| Drug |
candesartan cilexetil (gw615775, test formulation) |
2 |
2013 |
| Drug |
candesartan cilexetil (reference treatment) |
2 |
2013 |
| Drug |
candesartan/hydrochlorothiazide |
2 |
2006 |
| Drug |
candesartan32mg |
2 |
2016 |
| Drug |
candsartan cilexetil |
2 |
2005 |
| Drug |
captopril |
2 |
2012 |
| Other |
cardiac mri |
2 |
2012 |
| Procedure |
carotid body excision |
2 |
2012 |
| Drug |
celecoxib |
2 |
2011 |
| Drug |
cholecalciferol |
2 |
2010 |
| Procedure |
circumferential pv isolation |
2 |
2010 |
| Drug |
ckd-330 8 |
2 |
2015 |
| Drug |
ckd-330 8/5mg |
2 |
2015 |
| Drug |
ckd-828 2.5 |
2 |
2011 |
| Drug |
ckd-828 2.5/40mg |
2 |
2011 |
| Drug |
ckd-828(fdc) |
2 |
2010 |
| Drug |
clopidogrel |
2 |
2005 |
| Behavioral |
combined exercise |
2 |
2020 |
| Drug |
comparator : atenolol |
2 |
2007 |
| Drug |
comparator: timolol maleate |
2 |
2007 |
| Drug |
concurrent brimonidine 0.2% |
2 |
2008 |
| Behavioral |
conemo |
2 |
2016 |
| Device |
continuous positive airway pressure |
2 |
2009 |
| Device |
continuous positive airway pressure (cpap) |
2 |
2006 |
| Behavioral |
control values affirmation |
2 |
2017 |
| Other |
conventional treatment/follow up |
2 |
2014 |
| Drug |
coreg cr/lisinopril (fdc) |
2 |
2007 |
| Drug |
cosopt |
2 |
2008 |
| Behavioral |
counseling |
2 |
2008 |
| Procedure |
cta |
2 |
2017 |
| Behavioral |
cvrs intervention |
2 |
2018 |
| Drug |
cxa-10 |
2 |
2018 |
| Drug |
daglutril |
2 |
2005 |
| Dietary Supplement |
dark chocolate |
2 |
2011 |
| placebo |
darusentan placebo |
2 |
2006 |
| Behavioral |
dash diet education |
2 |
2016 |
| Drug |
de-104 ophthalmic solution, high concentration |
2 |
2008 |
| Drug |
de-104 ophthalmic solution, low concentration |
2 |
2008 |
| Drug |
de-104 ophthalmic solution, medium concentration |
2 |
2008 |
| Drug |
de-104 vehicle |
2 |
2008 |
| Drug |
de-117 |
2 |
2016 |
| Behavioral |
dietary supplements |
2 |
1999 |
| Drug |
diltiazem |
2 |
2011 |
| Drug |
diuretics |
2 |
2013 |
| Drug |
dorzolamide 2% |
2 |
2008 |
| Drug |
dorzolamide 20 mg |
2 |
2006 |
| Drug |
dorzolamide 20 mg/ml / timolol 5 mg/ml eye drops, solution (cosopt) |
2 |
2006 |
| Drug |
dorzolamide hcl 2% |
2 |
2009 |
| Radiation |
dual-energy computed tomography investigation |
2 |
2013 |
| Drug |
duowellâ® |
2 |
2018 |
| Drug |
empagliflozin |
2 |
2018 |
| Procedure |
endothelial cell collection |
2 |
2014 |
| Other |
enhanced usual care control |
2 |
2017 |
| Drug |
entecavir |
2 |
2016 |
| Dietary Supplement |
epicatechin |
2 |
2012 |
| Drug |
eplerenone 50 mg tablets sandoz inc., usa |
2 |
2009 |
| Drug |
epoprostenol |
2 |
2011 |
| Drug |
erythropoietin |
2 |
2011 |
| Behavioral |
exercise intervention |
2 |
2016 |
| Dietary Supplement |
extra virgin olive oil |
2 |
2016 |
| Drug |
ezetimibe |
2 |
2019 |
| Drug |
fimasartan 120mg |
2 |
2017 |
| placebo |
fish oil placebo |
2 |
2012 |
| Drug |
fixed combination 0.2% brimonidine tartrate |
2 |
2010 |
| Drug |
fixed combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution |
2 |
2010 |
| Drug |
fixed dose combination of telmisartan |
2 |
2007 |
| Drug |
fixed dose combination of telmisartan/amlodipine |
2 |
2007 |
| Drug |
flolanâ® |
2 |
2010 |
| Drug |
fluoxetine |
2 |
2018 |
| Other |
follow up |
2 |
2014 |
| Procedure |
forearm blood flow |
2 |
2011 |
| Drug |
furosemide |
2 |
2019 |
| Drug |
fuzheng huayu |
2 |
2016 |
| Dietary Supplement |
green tea |
2 |
2015 |
| Drug |
gsk1325760a |
2 |
2007 |
| Drug |
guanfacine |
2 |
2006 |
| Drug |
hctz 12.5mg |
2 |
2010 |
| Drug |
hgp0608 |
2 |
2016 |
| Behavioral |
high blood pressure treatment |
2 |
2009 |
| Drug |
high dose of micardisâ®, once daily |
2 |
2014 |
| Behavioral |
high sodium diet |
2 |
2006 |
| Device |
home monitoring |
2 |
2008 |
| Drug |
hydrochlorothiazide (hctz) tablets |
2 |
2007 |
| Drug |
hydrochlorothiazide 12.5mg |
2 |
2009 |
| Drug |
hydrochlorothiazide tablets |
2 |
2008 |
| Other |
hypocaloric diet |
2 |
2011 |
| Drug |
hypromellose 0.3% |
2 |
2013 |
| Drug |
iloprost nebuliser solution |
2 |
2011 |
| Drug |
imatinib mesylate |
2 |
2009 |
| Drug |
inhaled treprostinil solution |
2 |
2018 |
| Combination Product |
ino |
2 |
2018 |
| Other |
inspiratory muscle training |
2 |
2017 |
| Drug |
inspra 50 mg tablets gd searle llc, usa |
2 |
2009 |
| Behavioral |
intervention |
2 |
2016 |
| Behavioral |
intervention group |
2 |
2017 |
| Behavioral |
intervention values affirmation |
2 |
2017 |
| Drug |
ionis-agt-lrx |
2 |
2019 |
| Drug |
irbesartan (aprovel) |
2 |
2006 |
| Drug |
irbesartan monotherapy |
2 |
2004 |
| Drug |
irbesartan/amlodipine |
2 |
2009 |
| Drug |
irbesartan/hctz |
2 |
2004 |
| Other |
isometric handgrip training |
2 |
2015 |
| Drug |
isosorbide mononitrate |
2 |
2019 |
| Dietary Supplement |
korean red ginseng |
2 |
2008 |
| Procedure |
laparoscopic splenectomy |
2 |
2018 |
| Drug |
latanoprost 0.005% eye drops |
2 |
2014 |
| Drug |
latanoprost 0.005% ophthalmic solution (xalatan) |
2 |
2006 |
| Drug |
latanoprost vehicle |
2 |
2007 |
| Drug |
levitra (vardenafil, bay38-9456) |
2 |
2008 |
| Behavioral |
lifestyle |
2 |
2014 |
| Drug |
liq861 inhaled treprostinil |
2 |
2018 |
| Drug |
liraglutide |
2 |
2012 |
| Drug |
lisinopril (fdc) |
2 |
2007 |
| Drug |
lisinopril/hydrochlorothiazide |
2 |
2012 |
| Drug |
losartan 50 mg |
2 |
2011 |
| Drug |
losartan/amlodipine |
2 |
2018 |
| Drug |
losartan/hydrochlorothiazide |
2 |
2019 |
| Behavioral |
low altitude sojourn |
2 |
2014 |
| Drug |
low dose of micardisâ®, once daily |
2 |
2014 |
| Drug |
lumiracoxib |
2 |
2007 |
| Device |
mandibular advancement device |
2 |
2014 |
| Behavioral |
mat pilates training |
2 |
2019 |
| Drug |
methyldopa |
2 |
2013 |
| Drug |
metoprolol tartrate |
2 |
2007 |
| Device |
mhealth intervention |
2 |
2018 |
| Procedure |
microvascular perfusion assessment using definity |
2 |
2014 |
| Drug |
midazolam |
2 |
2014 |
| Drug |
milrinone |
2 |
2015 |
| Drug |
mk-0954a |
2 |
2011 |
| Drug |
mk-5475 |
2 |
2018 |
| Drug |
mk-8892 |
2 |
2013 |
| Drug |
mk0954, |
2 |
2007 |
| Drug |
ml eye drops, solution |
2 |
2015 |
| Drug |
ml eye drops, solution (cosopt) |
2 |
2006 |
| Device |
mobiushdâ„¢ |
2 |
2016 |
| Behavioral |
moderate altitude sojourn |
2 |
2014 |
| Dietary Supplement |
montmorency tart cherry juice |
2 |
2018 |
| Drug |
moxifloxacin |
2 |
2019 |
| Device |
mri |
2 |
2019 |
| Other |
multicomponent intervention |
2 |
2018 |
| Other |
multidisciplinary assistance |
2 |
2014 |
| Drug |
nebivolol/atenolol |
2 |
2005 |
| Device |
neuromuscular electrical stimulation |
2 |
2018 |
| Drug |
nitroglycerin |
2 |
2010 |
| Drug |
nitroprusside |
2 |
2010 |
| Drug |
non-arb |
2 |
2005 |
| Behavioral |
nutrition education |
2 |
2019 |
| Drug |
olaparib |
2 |
2017 |
| Drug |
olmesartan medoxomil (om) |
2 |
2007 |
| Drug |
olmesartan medoxomil / hydrochlorothiazide |
2 |
2009 |
| Drug |
olmesartan medoxomil / hydrochlorothiazide, if necessary / amlodipine, if necessary |
2 |
2009 |
| Drug |
olmesartan medoxomil tablets |
2 |
2015 |
| Drug |
omega-3 fatty acids |
2 |
2016 |
| Drug |
ono-9054 |
2 |
2014 |
| Drug |
opc-1085el ophthalmic solution |
2 |
2014 |
| Device |
optic nerve ultrasound |
2 |
2015 |
| Drug |
oral treprostinil (ut-15c) sustained release tablets |
2 |
2006 |
| Device |
oxygen supplementation |
2 |
2018 |
| Procedure |
padn |
2 |
2014 |
| Device |
paradise percutaneous renal denervation |
2 |
2012 |
| Behavioral |
patient navigation |
2 |
2011 |
| Drug |
patiromer |
2 |
2017 |
| Drug |
pg324 ophthalmic solution 0.02%/0.005% |
2 |
2016 |
| Behavioral |
pharmaceutical care |
2 |
2009 |
| Behavioral |
pharmacy |
2 |
2014 |
| Behavioral |
physician advice |
2 |
2015 |
| placebo |
placebo eye drops |
2 |
2013 |
| placebo |
placebo for mk-8150 |
2 |
2012 |
| placebo |
placebo for mk-8892 |
2 |
2013 |
| placebo |
placebo ocular insert |
2 |
2013 |
| placebo |
placebo of lcz696 |
2 |
2013 |
| placebo |
placebo of olmesartan |
2 |
2013 |
| placebo |
placebo ophthalmic solution |
2 |
2015 |
| placebo |
placebo tablet |
2 |
2017 |
| placebo |
placebo to hctz |
2 |
2010 |
| placebo |
placebo to mk-0954a |
2 |
2011 |
| Behavioral |
positive affect |
2 |
2009 |
| Drug |
potassium chloride |
2 |
2015 |
| Drug |
potassium chloride powder |
2 |
2016 |
| Drug |
potassium citrate powder |
2 |
2016 |
| Drug |
potassium magnesium citrate (kmgcit) |
2 |
2016 |
| Behavioral |
practice facilitation |
2 |
2018 |
| Drug |
preservative-free tafluprost |
2 |
2009 |
| Drug |
ps433540 |
2 |
2008 |
| Dietary Supplement |
regular salt |
2 |
2013 |
| Behavioral |
relaxation |
2 |
2010 |
| Behavioral |
relaxation response |
2 |
2010 |
| Drug |
remifentanil |
2 |
2014 |
| Behavioral |
reminder |
2 |
2015 |
| Device |
remote ischemic conditioning |
2 |
2018 |
| Diagnostic Test |
renal angiogram |
2 |
2011 |
| Behavioral |
resistance training |
2 |
2017 |
| Procedure |
rhythmic handgrip exercise |
2 |
2011 |
| Drug |
ro5093151 |
2 |
2011 |
| Drug |
rosuvastatin 20mg |
2 |
2016 |
| placebo |
rosuvastatin 20mg placebo |
2 |
2016 |
| Device |
rox coupler |
2 |
2012 |
| Drug |
s-amlodipine 2.5mg |
2 |
2011 |
| Dietary Supplement |
salt substitute |
2 |
2011 |
| Device |
selective vagus nerve stimulation |
2 |
2009 |
| Device |
sham |
2 |
2014 |
| Device |
sham acupuncture |
2 |
2018 |
| Drug |
sham bimatoprost sr |
2 |
2015 |
| Other |
sham control |
2 |
2018 |
| Other |
sham implantation |
2 |
2016 |
| Drug |
sham oxygen (room air) |
2 |
2014 |
| Procedure |
sham selective laser trabeculoplasty |
2 |
2015 |
| Device |
simulated altitude: (fio2: 15.1) |
2 |
2018 |
| Behavioral |
sleep extension |
2 |
2009 |
| Drug |
slx-2101 |
2 |
2007 |
| Dietary Supplement |
sodium |
2 |
2013 |
| Drug |
sorafenib |
2 |
2012 |
| Biological |
sotatercept |
2 |
2018 |
| Behavioral |
standard education |
2 |
2015 |
| Behavioral |
standard education/physician advice |
2 |
2015 |
| Device |
steen solutionâ„¢ |
2 |
2012 |
| Other |
stress echocardiography |
2 |
2018 |
| Behavioral |
structured center-based lifestyle intervention |
2 |
2015 |
| Behavioral |
support |
2 |
2006 |
| Drug |
syl040012 |
2 |
2012 |
| Device |
symplicity spyralâ„¢ multi-electrode renal denervation system |
2 |
2015 |
| Drug |
tafluprost 0.0015% |
2 |
2009 |
| Other |
telehealth |
2 |
2014 |
| Drug |
telmisartan / amlodipine |
2 |
2013 |
| Drug |
telmisartan / hydrochlorothiazide |
2 |
2014 |
| Drug |
telmisartan 40 mg/hctz 12.5 mg |
2 |
2006 |
| Drug |
telmisartan 80 mg / hydrochlorothiazide 25 mg |
2 |
2005 |
| Drug |
telmisartan/hctz |
2 |
2005 |
| Drug |
temisartan |
2 |
2009 |
| Behavioral |
text messaging |
2 |
2014 |
| Behavioral |
the complete health improvement program |
2 |
2017 |
| Device |
therapeutic intra-vascular ultrasound (tivusâ„¢) system |
2 |
2016 |
| Drug |
timolol 0.5% bac-free ophthalmic solution |
2 |
2008 |
| Drug |
timolol 0.5% fixed combination ophthalmic solution |
2 |
2013 |
| Drug |
timolol maleate 0.5% fixed combination |
2 |
2009 |
| Drug |
timolol maleate 0.5% ophthalmic solution |
2 |
2014 |
| Drug |
timolol ophthalmic solution (triple combination therapy) |
2 |
2010 |
| placebo |
timolol vehicle (placebo) |
2 |
2014 |
| Procedure |
transplantation of autologous endothelial progenitor cells |
2 |
2008 |
| Drug |
travatan z |
2 |
2008 |
| Drug |
travoprost 0.004% ophthalmic solution |
2 |
2011 |
| Drug |
travoprost 0.004%/timolol 0.5% bac-free ophthalmic solution |
2 |
2008 |
| Drug |
travoprost ophthalmic solution, 0.001% |
2 |
2011 |
| Drug |
travoprost vehicle |
2 |
2011 |
| Drug |
treprostinil inhalation powder |
2 |
2018 |
| Drug |
valsartan (lcz696) |
2 |
2013 |
| Drug |
valsartan / hctz |
2 |
2008 |
| placebo |
valsartan 160mg placebo |
2 |
2013 |
| Drug |
valsartan 40 mg |
2 |
2008 |
| Drug |
valsartan/amlodipine 80/5 mg |
2 |
2006 |
| Drug |
valsartan/hctz |
2 |
2007 |
| Drug |
vardenafil |
2 |
2010 |
| Device |
venous sinus stenting |
2 |
2011 |
| Drug |
ventavis (iloprost, bayq6256) |
2 |
2006 |
| Drug |
warfarin |
2 |
2014 |
| Behavioral |
weight loss |
2 |
2008 |
| Procedure |
wet cupping |
2 |
2013 |
| Other |
whole body vibration training |
2 |
2014 |
| Drug |
- hctz |
1 |
2006 |
| Drug |
- hydrochlorothiazide |
1 |
2007 |
| Behavioral |
“coco” colour coded blood pressure control |
1 |
2009 |
| Device |
“stampede” vac |
1 |
2011 |
| Drug |
(fimasartan |
1 |
2017 |
| Drug |
(fimasartan/linagliptin) x 7days |
1 |
2017 |
| Drug |
(hyzaar) losartan |
1 |
2005 |
| Drug |
(hyzaar) losartan/hydrochlorothiazide |
1 |
2005 |
| Drug |
(pyr1)apelin-13 |
1 |
2012 |
| Drug |
) amlodipine |
1 |
2011 |
| Drug |
[11c]-gsk2256098 500 mbq |
1 |
2015 |
| Drug |
[18f]fluoro-2-deoxy-2-d-glucose |
1 |
2013 |
| Drug |
0.0015% tafluprost |
1 |
2012 |
| Drug |
0.004% travoprost |
1 |
2011 |
| Drug |
0.005% latanoprost ophthalmic solution |
1 |
2017 |
| Drug |
0.01% bimatoprost ophthalmic solution |
1 |
2012 |
| Drug |
0.01% ro7058584 |
1 |
2017 |
| Drug |
0.03% bimatoprost ophthalmic solution |
1 |
2010 |
| Drug |
0.03% bimatoprost ophthalmic solution/0.5% timolol ophthalmic solution |
1 |
2010 |
| Drug |
0.03% bimatoprost/0.5% timolol ophthalmic solution |
1 |
2010 |
| Drug |
0.1% brimonidine tartrate ophthalmic solution |
1 |
2012 |
| Drug |
0.1% ro7058584 |
1 |
2017 |
| Drug |
0.15% brimonidine tartrate |
1 |
2013 |
| Drug |
0.2% brimonidine |
1 |
2008 |
| Drug |
0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution |
1 |
2008 |
| Drug |
0.2% hypromellose lubricant eye drops |
1 |
2012 |
| Drug |
0.25% ar-12286 |
1 |
2011 |
| Drug |
0.25% ar-12286 / 0.004% travoprost |
1 |
2011 |
| placebo |
0.3%); agn-207281 vehicle ophthalmic solution (placebo) |
1 |
2010 |
| Drug |
0.4 unit |
1 |
2019 |
| Drug |
0.4 unit / cc of vasopressin(group v) |
1 |
2019 |
| Drug |
0.5% ar-12286, 0.004% travoprost |
1 |
2011 |
| Drug |
0.5% timolol fixed combination ophthalmic solution |
1 |
2008 |
| Drug |
0.9% sodium chloride |
1 |
2012 |
| Diagnostic Test |
1-hour blood pressure monitoring (1bpm) |
1 |
2017 |
| Drug |
1 dose of sildenafil |
1 |
2012 |
| Drug |
1 drop of syl040012 (bamosiran) dose a |
1 |
2014 |
| Drug |
1 drop of syl040012 (bamosiran) dose b |
1 |
2014 |
| Drug |
1 drop of syl040012 (bamosiran) dose c |
1 |
2014 |
| Drug |
1 drop of syl040012 (bamosiran) dose d |
1 |
2014 |
| Drug |
1 drop of timolol maleate |
1 |
2014 |
| Drug |
1 x 100mg losartan tablet administered in fasted state |
1 |
2012 |
| Drug |
1% ro7058584 |
1 |
2017 |
| Drug |
10 |
1 |
2010 |
| Drug |
10 mg(oral) |
1 |
2006 |
| Drug |
100 amlodipine |
1 |
2013 |
| Drug |
100 mg |
1 |
2005 |
| Drug |
100 mg losartan |
1 |
2013 |
| placebo |
100 mg placebo |
1 |
2005 |
| Drug |
100mg losartan tablet administered in fasted state |
1 |
2012 |
| Dietary Supplement |
10g cocoa consumption |
1 |
2012 |
| Drug |
10mg |
1 |
2019 |
| Drug |
10mg) |
1 |
2012 |
| Drug |
11c-acetate |
1 |
2013 |
| Combination Product |
11c-metomidate pet |
1 |
2018 |
| Combination Product |
11c-metomidate pet/ct scan |
1 |
2018 |
| Behavioral |
12-week lifestyle modification |
1 |
2010 |
| placebo |
12.5 mg placebo |
1 |
2015 |
| Drug |
12.5 mg) |
1 |
2005 |
| Drug |
120 mg sodium nitrite inhalation solution |
1 |
2011 |
| Drug |
14n nitrate |
1 |
2016 |
| Drug |
14nitrogen sodium nitrite |
1 |
2012 |
| Drug |
15 mg sodium nitrite inhalation solution |
1 |
2011 |
| Drug |
150 mg) |
1 |
2010 |
| Drug |
150mg cxa-10 |
1 |
2018 |
| Drug |
15n nitrate |
1 |
2016 |
| Drug |
16 mcg |
1 |
2019 |
| Drug |
16 mcg / cc of norepinephrine(group n) |
1 |
2019 |
| Drug |
160 |
1 |
2012 |
| Drug |
160mg |
1 |
2015 |
| Drug |
17ãÿ-estradiol (angeliq, bay86-4891) |
1 |
2007 |
| Drug |
17ãÿ-estradiol, bay86-4891) |
1 |
2005 |
| Drug |
20 |
1 |
2013 |
| Other |
20% ethanol |
1 |
2015 |
| Drug |
20mg |
1 |
2019 |
| Drug |
20mg azilsartan tablets |
1 |
2016 |
| Drug |
20mg(combination drug) |
1 |
2019 |
| Device |
22-gauge chiba needle |
1 |
2015 |
| Diagnostic Test |
24-hour ambulatory blood pressure monitoring (abpm) |
1 |
2017 |
| Other |
24-minute video episode of patient education tv sitcom “white coats” |
1 |
2011 |
| Device |
24 hour blood pressure measurement |
1 |
2005 |
| Other |
24 month ppcm bp |
1 |
2009 |
| placebo |
25 mg placebo |
1 |
2015 |
| Drug |
25% mtd sodium nitrite inhalation solution |
1 |
2011 |
| Drug |
25mg |
1 |
2007 |
| Device |
260-cm-long stiff shaft wire |
1 |
2015 |
| Procedure |
2d |
1 |
2017 |
| Procedure |
2d doppler echo with definity solution |
1 |
2013 |
| Procedure |
2d/3d trans-thoracic echocardiography |
1 |
2017 |
| Diagnostic Test |
3-d ct scanning |
1 |
2018 |
| Device |
3-d ultrasound scanner |
1 |
2005 |
| Drug |
300 |
1 |
2010 |
| Drug |
300 mg |
1 |
2005 |
| Dietary Supplement |
32-gram oral fat load |
1 |
2007 |
| Device |
3d-vhps |
1 |
2016 |
| Procedure |
3d trans-thoracic echocardiography |
1 |
2017 |
| Drug |
40 mg telmisartan |
1 |
2011 |
| Drug |
40mg (combination drug) |
1 |
2019 |
| Drug |
40mg (combination drug), ezetimibe |
1 |
2019 |
| Drug |
40mg azilsartan tablets |
1 |
2016 |
| Drug |
45 mg sodium nitrite inhalation solution |
1 |
2011 |
| Other |
4d flow magnetic resonance imagery |
1 |
2019 |
| Drug |
5 mg (fdc) |
1 |
2015 |
| Drug |
5 mg amlodipine |
1 |
2011 |
| Drug |
5 mg fixed combination |
1 |
2008 |
| Drug |
5 mg tablets |
1 |
2008 |
| Other |
5% dextrose solution |
1 |
2010 |
| Drug |
5.0mg of timolol in 1ml |
1 |
2019 |
| Drug |
50 amlodipine |
1 |
2013 |
| Drug |
50 mg losartan |
1 |
2013 |
| Other |
50g dark chocolate. |
1 |
2011 |
| Dietary Supplement |
5g cocoa consumption |
1 |
2012 |
| Drug |
5mg - a |
1 |
2016 |
| Drug |
5mg - b |
1 |
2016 |
| Drug |
5mg) |
1 |
2012 |
| Device |
6-french sheath |
1 |
2015 |
| Drug |
6 mg (oral) |
1 |
2006 |
| Other |
6 minute walking test |
1 |
2019 |
| Drug |
600 mg) |
1 |
2010 |
| Dietary Supplement |
60ml tart montmorency cherry juice |
1 |
2014 |
| Dietary Supplement |
64-gram oral fat load |
1 |
2007 |
| Drug |
6r-bh4 (sapropterin dihydrochloride) |
1 |
2006 |
| Drug |
75 |
1 |
2010 |
| Drug |
75mg cxa-10 |
1 |
2018 |
| Drug |
80 |
1 |
2007 |
| Drug |
80 mg telmisartan |
1 |
2011 |
| Other |
9 month ppcm bp |
1 |
2009 |
| Drug |
90 mg sodium nitrite inhalation solution |
1 |
2011 |
| Procedure |
a ‘tight’ group |
1 |
2005 |
| Other |
a 4-week diet, low in sodium. |
1 |
2011 |
| Other |
a biobank will be created from blood samples taken at admission, days 3 |
1 |
2019 |
| Other |
a biobank will be created from blood samples taken at admission, days 3/days 7 |
1 |
2019 |
| Drug |
a ccb |
1 |
2009 |
| Behavioral |
a chronic disease self management course. |
1 |
2005 |
| Drug |
a diuretic |
1 |
2009 |
| Device |
a dual chamber pacing system (backbeat medical) |
1 |
2015 |
| Drug |
a preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost |
1 |
2019 |
| Drug |
a preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1ml |
1 |
2019 |
| Drug |
a preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost/5.0mg of timolol in 1ml |
1 |
2019 |
| Drug |
a5 |
1 |
2011 |
| Procedure |
ab interno trabeculectomy |
1 |
2019 |
| Procedure |
abdominal aortic aneurysm |
1 |
2008 |
| Drug |
abi-009, nab-rapamycin, albumin-bound rapamycin |
1 |
2015 |
| Other |
ablation) |
1 |
2012 |
| Procedure |
abpm |
1 |
2006 |
| Other |
abpm service by pharmacists |
1 |
2019 |
| Dietary Supplement |
ac mycelia |
1 |
2015 |
| Drug |
accupril, alpha lipoic acid |
1 |
2008 |
| placebo |
accupril, placebo |
1 |
2008 |
| Drug |
ace inhibition |
1 |
2005 |
| Drug |
ace inhibitor ramipril |
1 |
2009 |
| Drug |
acebutolol |
1 |
1999 |
| Drug |
acei (including spirapril, enalapril, quinapril, lisinopril) |
1 |
2006 |
| Drug |
acei/ccb |
1 |
2018 |
| Drug |
acei/diu |
1 |
2018 |
| Drug |
acetylcholine |
1 |
2010 |
| Drug |
acetylcholine, sodium nitroprusside, angiotensin-ii, norepinephrine, phentolamine |
1 |
2016 |
| Drug |
acetylsalicylic morning |
1 |
2012 |
| Dietary Supplement |
acidified milk |
1 |
2016 |
| Drug |
act-280778 |
1 |
2010 |
| Drug |
act-293987 |
1 |
2010 |
| Device |
act-293987 (ns-304) |
1 |
2009 |
| Drug |
act-385781a |
1 |
2011 |
| Device |
activator iv adjusting instrument |
1 |
2012 |
| Device |
active autoricâ® (cric treatment) |
1 |
2017 |
| Other |
active comparator: control group |
1 |
2019 |
| Drug |
active comparator: timolol 0.5% |
1 |
2014 |
| Drug |
active control |
1 |
2011 |
| Device |
active cpap |
1 |
2009 |
| Other |
active outreach to patients |
1 |
2010 |
| Other |
active outreach to patients/providers |
1 |
2010 |
| Drug |
acute infusion of nitroglycerine into the pulmonary artery |
1 |
2007 |
| Drug |
add-on angiotensin receptor blockade |
1 |
2005 |
| Drug |
add on dosing |
1 |
2007 |
| Procedure |
adenotonsillar surgery |
1 |
2018 |
| Behavioral |
adherence feedback |
1 |
2013 |
| Biological |
adipose derived mesenchymal stem cells |
1 |
2019 |
| Behavioral |
adjusted diet |
1 |
2007 |
| Other |
adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmhg range) |
1 |
2019 |
| Other |
adjustment to end-tidal carbon dioxide concentrations (24-26 mmhg range) |
1 |
2019 |
| Other |
adjustment to mean arterial pressure (100-110 mmhg range) |
1 |
2019 |
| Other |
adjustment to mean arterial pressure (60-80 mmhg range) |
1 |
2019 |
| placebo |
administration of placebo |
1 |
2011 |
| Drug |
administration of somatostatin |
1 |
2011 |
| Procedure |
adrenal artery ablation |
1 |
2020 |
| Drug |
adx415 |
1 |
2008 |
| Other |
aerobic exercise . |
1 |
2017 |
| Other |
aerobic training |
1 |
2017 |
| Behavioral |
aerobic training (heat) |
1 |
2015 |
| Other |
aerobic training group |
1 |
2017 |
| Other |
aerobic/resistance exercise |
1 |
2017 |
| Drug |
aerosolized iloprost |
1 |
2005 |
| Other |
aesop service system |
1 |
2018 |
| Dietary Supplement |
aged garlic extract |
1 |
2017 |
| Drug |
agn-207281 ophthalmic solutions (0.1% |
1 |
2010 |
| Drug |
agn-207281 ophthalmic solutions (0.1%/0.3%); agn-207281 vehicle ophthalmic solution (placebo) |
1 |
2010 |
| placebo |
agn-207281 vehicle ophthalmic solution (placebo) |
1 |
2010 |
| Drug |
agn-210669 |
1 |
2011 |
| Drug |
agn-210669 ophthalmic solution, 0.025% |
1 |
2008 |
| Drug |
agn-210669 ophthalmic solution, 0.05% |
1 |
2008 |
| Drug |
agn-210669 ophthalmic solution, 0.075% |
1 |
2008 |
| Drug |
agn-210669 vehicle ophthalmic solution |
1 |
2008 |
| Drug |
agn-210961 formulation 1 |
1 |
2010 |
| Drug |
agn-210961 formulation 2 |
1 |
2010 |
| Drug |
agn-210961 formulation 3 |
1 |
2010 |
| Drug |
agn-210961 formulation 4 |
1 |
2010 |
| Drug |
agn-210961 formulation 5 |
1 |
2010 |
| Drug |
agn-210961 formulation 6 |
1 |
2010 |
| Drug |
agn-210961 formulation 7 |
1 |
2010 |
| Drug |
agsav301 |
1 |
2012 |
| Drug |
air001 inhalation solution (expansion arm) |
1 |
2008 |
| Device |
airsenseâ„¢ 10 autoset |
1 |
2016 |
| Drug |
akb-9778 |
1 |
2020 |
| Drug |
al-12182 0.003% ophthalmic solution |
1 |
2003 |
| Drug |
al-12182 0.01% ophthalmic solution |
1 |
2003 |
| Drug |
al-12182 0.03% ophthalmic solution |
1 |
2003 |
| Other |
al-12182 ophthalmic solution vehicle |
1 |
2003 |
| Drug |
al-37807 |
1 |
2006 |
| Other |
al-37807 ophthalmic solution vehicle |
1 |
2008 |
| Drug |
al-37807 ophthalmic suspension, 0.1% |
1 |
2008 |
| Drug |
al-37807 ophthalmic suspension, 1.0% |
1 |
2006 |
| Other |
al-37807 vehicle |
1 |
2006 |
| Drug |
al-3862 |
1 |
2007 |
| Drug |
al-3862/timolol ophthalmic suspension |
1 |
2007 |
| Drug |
al-39256 ophthalmic suspension, 1% |
1 |
2008 |
| Drug |
albuterol |
1 |
2013 |
| placebo |
albuterol first then placebo |
1 |
2017 |
| Drug |
alcohol |
1 |
2018 |
| Drug |
aldosterone antagonist |
1 |
2014 |
| Drug |
alemtuzumab |
1 |
2018 |
| Drug |
ali |
1 |
2010 |
| Drug |
ali/amlo 150/2.5 mg |
1 |
2010 |
| Drug |
aliskiren (150 |
1 |
2010 |
| Drug |
aliskiren (150/300/600 mg) |
1 |
2010 |
| Drug |
aliskiren (300 mg) |
1 |
2008 |
| Drug |
aliskiren (37.5 |
1 |
2010 |
| Drug |
aliskiren (37.5/75/150 mg) |
1 |
2010 |
| Drug |
aliskiren (6.25 |
1 |
2010 |
| Drug |
aliskiren (6.25/12.5/25 mg) |
1 |
2010 |
| Drug |
aliskiren /amlodipine/hydrochlorothiazide |
1 |
2008 |
| Drug |
aliskiren 150 mg tablet |
1 |
2008 |
| Drug |
aliskiren 150/300 mg |
1 |
2005 |
| Drug |
aliskiren 3.125 mini-tablets |
1 |
2009 |
| Drug |
aliskiren 300 mg tablet |
1 |
2008 |
| Drug |
aliskiren 75 mg |
1 |
2008 |
| Drug |
aliskiren hydrochlorothiazide |
1 |
2008 |
| Drug |
aliskiren hydrochlorothiazide (hctz): 8 weeks |
1 |
2008 |
| placebo |
aliskiren placebo |
1 |
2005 |
| Drug |
aliskiren/ valsartan |
1 |
2009 |
| Drug |
aliskiren/amlodipine (150/5 mg/day, 300/10 mg/day) , aliskiren/amlodipine/hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day) |
1 |
2010 |
| Drug |
aliskiren/amlodipine 150/10 mg tablet |
1 |
2008 |
| Drug |
aliskiren/amlodipine 150/2.5 mg |
1 |
2010 |
| Drug |
aliskiren/amlodipine 150/5 mg |
1 |
2010 |
| Drug |
aliskiren/amlodipine 150/5 mg tablet |
1 |
2008 |
| Drug |
aliskiren/amlodipine 300/10 mg |
1 |
2008 |
| Drug |
aliskiren/amlodipine 300/5 mg |
1 |
2008 |
| Drug |
aliskiren/amlodipine 300/5 mg tablet |
1 |
2008 |
| Drug |
aliskiren/amlodipine/aliskiren/amlodipine/hctz |
1 |
2010 |
| Drug |
aliskiren/amlodipine/hydrochlorothiazide (hctz) |
1 |
2009 |
| Drug |
aliskiren/hctz - phase 2 |
1 |
2009 |
| Drug |
aliskiren/hctz/amlodipine - phase 3 |
1 |
2009 |
| Drug |
aliskiren/hydrochlorothiazide (hctz) (300/25 mg) |
1 |
2008 |
| Drug |
aliskiren/placebo |
1 |
2007 |
| Other |
all- 6 month pharmacist intervention |
1 |
2008 |
| Drug |
all approved antihypertensive drugs; all approved statins |
1 |
2012 |
| Other |
all patients |
1 |
2017 |
| placebo |
allisartan isoproxil placebo |
1 |
2017 |
| Biological |
allogeneic human cardiosphere-derived stem cells |
1 |
2017 |
| Drug |
aln-agt01 |
1 |
2019 |
| placebo |
aln-agt01-matching placebo |
1 |
2019 |
| Drug |
alpha lipoic acid |
1 |
2008 |
| Drug |
alphagan |
1 |
2008 |
| Procedure |
alt |
1 |
2010 |
| Drug |
alt-711 (alagebrium chloride) |
1 |
2006 |
| Drug |
altace (ramipril) 10 capsule (aventis pharmaceutical) |
1 |
2009 |
| Drug |
altace (ramipril) 10 mg capsule (aventis pharmaceutical) |
1 |
2009 |
| Other |
alternate nostril breathing |
1 |
2016 |
| Other |
alternative upper extremity exercises |
1 |
2015 |
| Drug |
alz-1101 |
1 |
2013 |
| Drug |
am 5 |
1 |
2012 |
| Drug |
am 5 / dm 0 |
1 |
2012 |
| Drug |
am 5 / dm 2.5 |
1 |
2012 |
| Drug |
am 5 / dm 30 |
1 |
2012 |
| Drug |
am 5 / dm 7.5 |
1 |
2012 |
| Drug |
amb new formulation (1 mg) |
1 |
2019 |
| Drug |
ambrisentan upfront combination therapy |
1 |
2010 |
| Device |
ambulatory blood pressure monitor (abpm) |
1 |
2016 |
| Procedure |
ambulatory blood pressure monitoring (abpm) |
1 |
2005 |
| Drug |
amiloride 10 mg |
1 |
2019 |
| Drug |
amiloride 2,5 |
1 |
2006 |
| Drug |
amiloride 2,5/d/enalapril/d 10 mg |
1 |
2006 |
| Drug |
amiloride 20 mg |
1 |
2019 |
| Drug |
amiloride hcl 5mg tablets) |
1 |
2017 |
| Drug |
aminophylline |
1 |
2012 |
| Drug |
aminophylline/ambrisentan |
1 |
2012 |
| Drug |
amlessaâ® |
1 |
2018 |
| Drug |
amlo 150 |
1 |
2010 |
| Drug |
amlodipin |
1 |
2012 |
| Drug |
amlodipine - phase 3 |
1 |
2009 |
| Drug |
amlodipine (10 mg |
1 |
2019 |
| Drug |
amlodipine (10 mg/d). |
1 |
2019 |
| Drug |
amlodipine (300 |
1 |
2012 |
| Drug |
amlodipine (5mg) |
1 |
2007 |
| Drug |
amlodipine (amlodipine failed group) |
1 |
2013 |
| Drug |
amlodipine (bisoprolol failed group) |
1 |
2013 |
| Drug |
amlodipine (norvasc) |
1 |
2012 |
| Drug |
amlodipine (norvascâ®) |
1 |
2009 |
| Drug |
amlodipine (optional) |
1 |
2013 |
| Drug |
amlodipine / hctz |
1 |
2006 |
| Drug |
amlodipine / olmesartan medoxomil combination |
1 |
2008 |
| Drug |
amlodipine 10 |
1 |
2009 |
| Drug |
amlodipine 10 mg / hydrochlorothiazide 12.5 mg |
1 |
2005 |
| Drug |
amlodipine 10 mg capsules |
1 |
2008 |
| Drug |
amlodipine 10 mg/losartan 100 mg / amlodipine 5 mg |
1 |
2005 |
| Drug |
amlodipine 10mg/candesartan 32mg |
1 |
2014 |
| Drug |
amlodipine 160 |
1 |
2009 |
| Drug |
amlodipine 2.5mg/atorvastatin 10mg |
1 |
2007 |
| Drug |
amlodipine 2.5mg/atorvastatin 5mg |
1 |
2007 |
| Drug |
amlodipine 5 |
1 |
2006 |
| Drug |
amlodipine 5 mg / delapril 30 mg |
1 |
2008 |
| Drug |
amlodipine 5 mg capsule |
1 |
2008 |
| Drug |
amlodipine 5/10 mg(oral) |
1 |
2006 |
| placebo |
amlodipine 5mg placebo |
1 |
2015 |
| Drug |
amlodipine 5mg/atorvastatin 10mg |
1 |
2007 |
| Drug |
amlodipine 5mg/atorvastatin 5mg |
1 |
2007 |
| Drug |
amlodipine 5mg/valsartan 80 mg |
1 |
2010 |
| Drug |
amlodipine besilate |
1 |
2007 |
| Drug |
amlodipine besylate (mk-0954e) |
1 |
2011 |
| Drug |
amlodipine besylate tablets |
1 |
2018 |
| Drug |
amlodipine besylate/atorvastatin calcium single pill combination |
1 |
2006 |
| Drug |
amlodipine besylate/benazepril hydrochloride |
1 |
2005 |
| Drug |
amlodipine camsylate |
1 |
2011 |
| Drug |
amlodipine combination tablet |
1 |
2011 |
| Drug |
amlodipine combination, valsartan, amlodipine |
1 |
2006 |
| Drug |
amlodipine fixed dose combination |
1 |
2010 |
| Drug |
amlodipine maleate |
1 |
2010 |
| Drug |
amlodipine monocomponent |
1 |
2011 |
| placebo |
amlodipine placebo |
1 |
2017 |
| Drug |
amlodipine tablets |
1 |
2011 |
| Drug |
amlodipine, hydralazine, terazosin |
1 |
2014 |
| Drug |
amlodipine, hydralazine, terazosin/hydrochlorothiazide |
1 |
2014 |
| Drug |
amlodipine, rosuvastatin |
1 |
2017 |
| Drug |
amlodipine/atorvastatin |
1 |
2006 |
| Drug |
amlodipine/atorvastatin 5/20mg |
1 |
2019 |
| Drug |
amlodipine/hydrochlorothiazide(hctz) |
1 |
2007 |
| Drug |
amlodipine/losartan/chlorthalidone |
1 |
2018 |
| Drug |
amlodipine/metformin |
1 |
2007 |
| Drug |
amlodipine/olmesartan 10/40mg (combination drug) |
1 |
2019 |
| Drug |
amlodipine/olmesartan 10/40mg (combination drug), ezetimibe/rosuvastatin 10/20mg(combination drug) |
1 |
2019 |
| Drug |
amlodipine/olmesartan medoxomil tablets |
1 |
2008 |
| Drug |
amlodipine/rosuvastatin |
1 |
2014 |
| Drug |
amlodipine/terazosin |
1 |
2008 |
| Drug |
amlodipine: 8 weeks |
1 |
2008 |
| Drug |
amlodipine5 |
1 |
2008 |
| Drug |
amlodipine5mg |
1 |
2010 |
| Drug |
amlopinâ® |
1 |
2018 |
| Drug |
amosartan |
1 |
2015 |
| Drug |
amosartanâ® tab |
1 |
2013 |
| Drug |
ampreloxetine |
1 |
2019 |
| Drug |
anakinra |
1 |
2016 |
| Drug |
analgesic mouth rinses (dissolved aspirin) |
1 |
2016 |
| Procedure |
analysis of cytokine production |
1 |
2010 |
| Drug |
anecortave acetate sterile suspension, 30 mg |
1 |
2008 |
| Drug |
anecortave acetate sterile suspension, 30 mg/ml |
1 |
2008 |
| Drug |
anecortave acetate sterile suspension, 60 mg |
1 |
2008 |
| Drug |
anecortave acetate sterile suspension, 60 mg/ml |
1 |
2008 |
| Drug |
anecortave acetate sterile suspension, 75 mg |
1 |
2008 |
| Drug |
anecortave acetate sterile suspension, 75 mg/ml |
1 |
2008 |
| Other |
anecortave acetate vehicle |
1 |
2008 |
| Drug |
angeliq (drospirenone |
1 |
2005 |
| Drug |
angeliq (drospirenone/17ãÿ-estradiol, bay86-4891) |
1 |
2005 |
| Procedure |
angiographic renal revascularization |
1 |
2005 |
| Other |
angiography |
1 |
2008 |
| Other |
angiography/computed tomography |
1 |
2008 |
| Drug |
angiotensin-(1-7) |
1 |
2018 |
| Other |
angiotensin-ii, valsartan |
1 |
2016 |
| Drug |
angiotensin (1-7) |
1 |
2014 |
| Drug |
angiotensin ii receptor antagonists |
1 |
2005 |
| Other |
anm |
1 |
2018 |
| Dietary Supplement |
annona muricata |
1 |
2019 |
| Behavioral |
anonymity |
1 |
2015 |
| Procedure |
anterior chamber paracentesis |
1 |
2009 |
| Dietary Supplement |
anthocyans |
1 |
2008 |
| Procedure |
anthropometric measurements |
1 |
2010 |
| Behavioral |
anthroposophic speech therapy |
1 |
2015 |
| Drug |
anti-hypertensive medication - |
1 |
2012 |
| Drug |
anti-hypertensive therapy |
1 |
2014 |
| Other |
anti-hypertensive therapy to sbp 130 mm hg |
1 |
2011 |
| Other |
anti-hypertensive therapy to sbp 145 mm hg |
1 |
2011 |
| Drug |
antihypertensive drug |
1 |
2005 |
| Drug |
antihypertensive drugs |
1 |
2013 |
| Drug |
antihypertensive medication according to the study’s algorithm |
1 |
2019 |
| Other |
antihypertensive medication intensification |
1 |
2014 |
| Drug |
antihypertensive treatment |
1 |
2012 |
| Drug |
antihypertensive treatment will be stopped for 1 year unless hypertension recurrence |
1 |
2014 |
| Dietary Supplement |
antioxidants capsules |
1 |
2018 |
| Drug |
any angiotensin receptor blockers |
1 |
2011 |
| Drug |
any antihypertensive medication alone |
1 |
2008 |
| Drug |
any antihypertensive medication alone/in combination |
1 |
2008 |
| Drug |
apabetalone |
1 |
2018 |
| Drug |
apd811 |
1 |
2014 |
| Drug |
apixaban |
1 |
2019 |
| Other |
apple |
1 |
2009 |
| Drug |
aprepitant |
1 |
2014 |
| Drug |
aprocitentan 10 mg |
1 |
2015 |
| Drug |
aprocitentan 12.5 mg |
1 |
2018 |
| Drug |
aprocitentan 5 mg |
1 |
2015 |
| Drug |
aprocitentan 50 mg |
1 |
2015 |
| Drug |
ar-12286 |
1 |
2013 |
| Drug |
ar-12286 0.5% ophthalmic solution |
1 |
2011 |
| Drug |
ar-13324 ophthalmic solution 0.01% |
1 |
2012 |
| placebo |
ar-13324 ophthalmic solution placebo |
1 |
2017 |
| Other |
ar-13324 ophthalmic solution vehicle |
1 |
2012 |
| Drug |
ar9281 |
1 |
2009 |
| Drug |
arb (including valsartan, telmisartan, olmesartan) |
1 |
2006 |
| Procedure |
arb management |
1 |
2010 |
| Device |
ardian |
1 |
2012 |
| Device |
ardian symplicityâ„¢ catheter |
1 |
2007 |
| Device |
arfi ultrasound |
1 |
2012 |
| Dietary Supplement |
arm c (control group) |
1 |
2018 |
| Procedure |
arm cycling exercise |
1 |
2013 |
| Dietary Supplement |
arm d (diet group) |
1 |
2018 |
| Dietary Supplement |
arm s (supplementation group) |
1 |
2018 |
| Device |
aromatherapy |
1 |
2015 |
| Drug |
arotinolol hydrochloride |
1 |
2015 |
| Drug |
arterial infusion of autologous mesenchymal stem cells |
1 |
2013 |
| Drug |
artificial tears |
1 |
2017 |
| Drug |
artificial tears preserved with benzalkonium chloride |
1 |
2009 |
| Drug |
asa evening |
1 |
2012 |
| Drug |
aspirin (aggrenox) |
1 |
2005 |
| Drug |
aspirin enteric coated pellests 100mg |
1 |
2006 |
| Other |
assessment of drug compliance |
1 |
2017 |
| Device |
associated app |
1 |
2019 |
| Other |
at-home blood pressure monitoring |
1 |
2018 |
| Behavioral |
at home |
1 |
2010 |
| Drug |
atacand |
1 |
2005 |
| Drug |
atacand tablet |
1 |
2012 |
| Drug |
atenolol (drug), lisinopril (drug) |
1 |
2005 |
| Drug |
atenolol (tenormin) 100 mg tablets zeneca (astra zeneca pharmaceutical) |
1 |
2009 |
| Drug |
atenolol 100 mg tablets |
1 |
2008 |
| Drug |
atenolol 100 mg tablets (geneva pharmaceutical, inc.) |
1 |
2009 |
| Drug |
atenolol 50 mg tablets |
1 |
2008 |
| Drug |
atenolol tablets 100 mg (cord laboratories) |
1 |
2009 |
| Drug |
atenolol tablets 100 mg (stuart pharmaceutical) |
1 |
2009 |
| Drug |
atenolol thiazide |
1 |
2005 |
| Drug |
atenolol/ hydrochlorothiazide / amlodipine / hydralazine if necessary to control blood pressure |
1 |
2008 |
| Drug |
atenolol/hctz/trandolapril |
1 |
2005 |
| Other |
athena-cds-htn |
1 |
2006 |
| Other |
athena-cds-htn/guideline link |
1 |
2006 |
| Behavioral |
athena decision support system, an automated clinical decision support system for health care providers |
1 |
2005 |
| Behavioral |
atkins diet (low carbohydrate diet) |
1 |
2005 |
| Drug |
atorvastatin 10mg |
1 |
2007 |
| Drug |
atorvastatin 5 |
1 |
2019 |
| Drug |
atorvastatin 5mg |
1 |
2007 |
| Drug |
atorvastatin 80 mg |
1 |
2007 |
| Drug |
atorvastatin a |
1 |
2011 |
| Drug |
atorvastatin b |
1 |
2011 |
| Drug |
atorvastatin calcium |
1 |
2018 |
| Drug |
atorvastatin calcium single pill combination |
1 |
2006 |
| Drug |
atorvastatin fixed dose combination |
1 |
2016 |
| Drug |
ats907 |
1 |
2012 |
| Other |
attempt target dose |
1 |
2010 |
| Behavioral |
attention-control |
1 |
2010 |
| Other |
attention control |
1 |
2012 |
| Behavioral |
audiotaped counseling session |
1 |
2018 |
| Behavioral |
autogenic relaxation training |
1 |
2008 |
| Biological |
autologous epcs transfected with human enos |
1 |
2016 |
| placebo |
autologous epcs transfected with human enos followed by placebo |
1 |
2016 |
| Device |
automated blood pressure recording device omron hem 705cp |
1 |
2008 |
| Behavioral |
automated feedback regarding drug adherence |
1 |
2006 |
| Behavioral |
automated messages |
1 |
2017 |
| Other |
automated messaging |
1 |
2019 |
| Behavioral |
automated telephone program |
1 |
2005 |
| Drug |
ave7688 |
1 |
2006 |
| Drug |
azarga (brinzolamide 1% |
1 |
2010 |
| Drug |
azarga (brinzolamide 1% / timolol 0.5%) |
1 |
2010 |
| Drug |
azd2171 |
1 |
2005 |
| Drug |
azd4017 |
1 |
2013 |
| Drug |
azilsartan medoximil |
1 |
2013 |
| Drug |
azilsartan medoxomil - chlorthalidone |
1 |
2011 |
| Drug |
azilsartan medoxomil with |
1 |
2008 |
| Drug |
azilsartan medoxomil with/without add-on chlorthalidone |
1 |
2008 |
| Drug |
azilsartan medoxomil with/without add-on hydrochlorothiazide |
1 |
2008 |
| Drug |
azilsartan medoxomil, with |
1 |
2008 |
| Drug |
azilsartan medoxomil, with/without chlorthalidone/other non-angiotensin ii receptor blocker antihypertensive medications. |
1 |
2008 |
| Drug |
azilsartan medoxomil/amlodipine |
1 |
2007 |
| Drug |
azilsartan medoxomil/hydrochlorothiazide |
1 |
2009 |
| Drug |
azilsartan medoxomil/olmesartan |
1 |
2008 |
| Drug |
azilsartan medoxomil/placebo |
1 |
2011 |
| placebo |
azilsartan placebo tablets |
1 |
2015 |
| Drug |
azilsartan tablets |
1 |
2015 |
| Drug |
azopt |
1 |
2008 |
| Drug |
azopt (brinzolamide) |
1 |
2003 |
| Drug |
azopt 1% |
1 |
2019 |
| Drug |
azopt 1% ophthalmic suspension |
1 |
2019 |
| Procedure |
azygoportal disconnection with intraoperative endoscopic variceal ligation |
1 |
2020 |
| Biological |
b244 |
1 |
2016 |
| Device |
backbeat-phc |
1 |
2016 |
| Device |
backbeat moderato system |
1 |
2018 |
| Device |
backbeat moderato sytsem |
1 |
2018 |
| Other |
balloon atrial septostomy |
1 |
2018 |
| Device |
balloon catheter |
1 |
2015 |
| Drug |
bambuterol |
1 |
2012 |
| Other |
barbershop-based bp measurement |
1 |
2014 |
| Device |
bare metal stent |
1 |
2015 |
| Procedure |
bariatric surgery |
1 |
2014 |
| Device |
baroreceptor stimulation |
1 |
2011 |
| Device |
baroreceptor stimulation with barostim neo tm |
1 |
2015 |
| Device |
barostim neo system |
1 |
2011 |
| Behavioral |
baseline bp screening |
1 |
2006 |
| Other |
baseline washout phase |
1 |
2018 |
| Device |
bat |
1 |
2015 |
| Drug |
bay1237592 |
1 |
2018 |
| Behavioral |
beach tennis session |
1 |
2019 |
| Dietary Supplement |
beauty drink |
1 |
2018 |
| Dietary Supplement |
beetroot juice (brj) |
1 |
2012 |
| Behavioral |
behavior intervention |
1 |
2018 |
| Behavioral |
behavior therapy |
1 |
1999 |
| Behavioral |
behavioral |
1 |
2009 |
| Behavioral |
behavioral communication strategy |
1 |
2013 |
| Behavioral |
behavioral communication strategy, |
1 |
2013 |
| Behavioral |
behavioral communication strategy,/smartphone-based tool |
1 |
2013 |
| Behavioral |
behavioral feedback |
1 |
2008 |
| Behavioral |
behavioral neurocardiac training |
1 |
2008 |
| Behavioral |
behavioral therapy |
1 |
2009 |
| Drug |
benazepril hydrochloride |
1 |
2005 |
| Drug |
benazepril) |
1 |
2005 |
| Drug |
benazepril/hydrochlorothiazide |
1 |
2006 |
| Drug |
bendrofluazide |
1 |
2014 |
| Drug |
bendroflumethiazide 2.5mg od; amlodipine 10mg od |
1 |
2007 |
| Dietary Supplement |
beneflaxâ® |
1 |
2015 |
| Drug |
benzbromarone |
1 |
2016 |
| Drug |
beraprost sodium |
1 |
2017 |
| Other |
best practice clinic-based care |
1 |
2016 |
| Drug |
besylsartan |
1 |
2015 |
| Drug |
beta-blocker monotherapy |
1 |
2013 |
| Drug |
beta blockers (including nebivolol, atenolol, carvedilol) |
1 |
2006 |
| Drug |
betaxolol eye drops |
1 |
2015 |
| Drug |
betaxon (levobetaxolol hcl) |
1 |
2003 |
| Drug |
betoptic s (betaxolol hcl) |
1 |
2003 |
| Drug |
bexagliflozin |
1 |
2017 |
| Drug |
bh4, l-nmma, vitamin c, vitamin e, î±-lipoic acid |
1 |
2016 |
| Drug |
bh4, l-nmma, vitamin c, vitamin e, î±-lipoic acid/l-ascorbate |
1 |
2016 |
| Other |
bi-directional texting |
1 |
2016 |
| Drug |
bia 5-453 |
1 |
2017 |
| Drug |
bibr 277 |
1 |
2014 |
| Drug |
bibr277 high dose |
1 |
2014 |
| Drug |
bibr277 low dose |
1 |
2014 |
| Drug |
bibr277 medium dose |
1 |
2014 |
| Behavioral |
bidirectional text messaging |
1 |
2016 |
| Procedure |
bilateral radiofrequency sympathetic renal denervation |
1 |
2011 |
| Drug |
bimatoprost (sr) |
1 |
2019 |
| Drug |
bimatoprost .03% sterile ophthalmic solution |
1 |
2009 |
| Drug |
bimatoprost /timolol formulation a fixed combination ophthalmic solution |
1 |
2010 |
| Drug |
bimatoprost 0.015% formulation 1 ophthalmic solution |
1 |
2008 |
| Drug |
bimatoprost 0.015% formulation 2 ophthalmic solution |
1 |
2008 |
| Drug |
bimatoprost 0.02% ophthalmic solution |
1 |
2008 |
| Drug |
bimatoprost 0.03% eye drops |
1 |
2007 |
| Drug |
bimatoprost 0.03% formulation b ophthalmic solution |
1 |
2010 |
| Drug |
bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops |
1 |
2010 |
| Drug |
bimatoprost 0.03%, travoprost 0.004%, timolol 0.5% |
1 |
2006 |
| Drug |
bimatoprost 0.03%/timolol 0.5% |
1 |
2015 |
| Drug |
bimatoprost 10 âµg generation 1 |
1 |
2010 |
| Drug |
bimatoprost 10 âµg generation 2 |
1 |
2010 |
| Drug |
bimatoprost 15 âµg generation 1 |
1 |
2010 |
| Drug |
bimatoprost 15 âµg generation 2 |
1 |
2010 |
| Drug |
bimatoprost 20 âµg generation 2 |
1 |
2010 |
| Drug |
bimatoprost 6 âµg generation 2 |
1 |
2010 |
| Drug |
bimatoprost eye drops |
1 |
2007 |
| Drug |
bimatoprost sustained-release |
1 |
2014 |
| Drug |
bimatoprost vehicle |
1 |
2011 |
| Drug |
bimatoprost vehicle ophthalmic solution |
1 |
2008 |
| Drug |
bimatoprost/bimatoprost/timolol fixed combination. |
1 |
2009 |
| Drug |
bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution |
1 |
2010 |
| Drug |
bimatoprost/timolol fixed combination ophthalmic solution |
1 |
2010 |
| Other |
bioactive peptides |
1 |
2018 |
| Behavioral |
biofeedback |
1 |
2001 |
| Device |
biolimus-eluting stents |
1 |
2011 |
| Device |
biosense webster celcius thermacool catheter |
1 |
2012 |
| Drug |
bisoprolol/amlodipine (amlodipine failed group) |
1 |
2013 |
| Drug |
bisoprolol/amlodipine (bisoprolol failed group) |
1 |
2013 |
| Dietary Supplement |
black soy peptide |
1 |
2012 |
| Dietary Supplement |
blackberry beverage with minimal polyphenol concentrations |
1 |
2015 |
| Dietary Supplement |
blackberry polyphenol enriched beverage |
1 |
2015 |
| Other |
blood draw |
1 |
2007 |
| Device |
blood pressure |
1 |
2013 |
| Behavioral |
blood pressure education |
1 |
2009 |
| Behavioral |
blood pressure education/walking program |
1 |
2009 |
| Behavioral |
blood pressure measurement standardization |
1 |
2016 |
| Behavioral |
blood pressure measurement/pharmacy |
1 |
2018 |
| Procedure |
blood pressure measurements |
1 |
2006 |
| Device |
blood pressure monitor with telemetry |
1 |
2011 |
| Device |
blood pressure monitoring |
1 |
2011 |
| Device |
blood pressure reference device: yuyue medical blood pressure meter, yybp-2 |
1 |
2012 |
| Behavioral |
blood pressure self-monitoring |
1 |
2018 |
| Device |
blood pressure transtek wrist blood pressure monitor, tmb-1117 |
1 |
2012 |
| Device |
blood pressure/heart rate |
1 |
2013 |
| Dietary Supplement |
blueberry powder |
1 |
2017 |
| Device |
bluetooth-enabled glucometer |
1 |
2006 |
| Drug |
bnp |
1 |
2018 |
| Device |
body mass index |
1 |
2013 |
| Behavioral |
booster |
1 |
2011 |
| Behavioral |
booster/ low resource |
1 |
2011 |
| Drug |
bosentam tracleer |
1 |
2005 |
| Drug |
bosentan administration |
1 |
2005 |
| Device |
boston scientific vessix renal denervation system |
1 |
2012 |
| Behavioral |
botanical therapy (hibiscus sabdariffa) |
1 |
2005 |
| Device |
bp-ican |
1 |
2019 |
| Other |
bp cuff at workplace |
1 |
2008 |
| Behavioral |
bp education |
1 |
2010 |
| Behavioral |
bp education/bp self-regulation |
1 |
2010 |
| Behavioral |
bp educational materials |
1 |
2014 |
| Other |
bp management policies |
1 |
2011 |
| Behavioral |
bp measurement |
1 |
2014 |
| Behavioral |
bp measurement/pharmacy |
1 |
2014 |
| Drug |
bp medication uptitration |
1 |
2013 |
| Device |
bp monitor |
1 |
2005 |
| Behavioral |
bp monitoring daily via text messaging |
1 |
2018 |
| Behavioral |
bp monitoring weekly via text messaging |
1 |
2018 |
| Behavioral |
bp self-regulation |
1 |
2010 |
| Other |
bp track |
1 |
2016 |
| Drug |
bps-314d-mr |
1 |
2013 |
| Device |
bptru |
1 |
2006 |
| Drug |
bq-123, mitoq, bh4 |
1 |
2016 |
| Drug |
brain natriuretic peptide |
1 |
2011 |
| Device |
branches |
1 |
2016 |
| Dietary Supplement |
bread with added beta-glucans |
1 |
2014 |
| Other |
breath control |
1 |
2017 |
| Behavioral |
brief behavioral treatment for insomnia |
1 |
2015 |
| Behavioral |
brief lifestyle counseling |
1 |
2009 |
| Drug |
brimonidine 0,2% |
1 |
2008 |
| Drug |
brimonidine 0,2% / timolol 0,5% fixed combination |
1 |
2008 |
| Drug |
brimonidine 0.2% ophthalmic solution |
1 |
2008 |
| Drug |
brimonidine 0.2% ophthalmic suspension |
1 |
2013 |
| Drug |
brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution |
1 |
2008 |
| Drug |
brimonidine 2 mg |
1 |
2015 |
| Drug |
brimonidine 2 mg/ml eye drops, solution |
1 |
2015 |
| Drug |
brimonidine fc |
1 |
2017 |
| Drug |
brimonidine ophthalmic solution 0.1% |
1 |
2008 |
| Drug |
brimonidine ophthalmic solution 0.2% |
1 |
2008 |
| Drug |
brimonidine purite 0.15% |
1 |
2008 |
| Drug |
brimonidine tartarate |
1 |
2009 |
| Drug |
brimonidine tartrate 0.025% |
1 |
2012 |
| Drug |
brimonidine tartrate 0.2% fixed combination ophthalmic suspension |
1 |
2011 |
| Drug |
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy |
1 |
2009 |
| Drug |
brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy. |
1 |
2009 |
| Drug |
brimonidine tartrate ophthalmic solution 0.2% |
1 |
2013 |
| Drug |
brimonidine tartrate ophthalmic suspension |
1 |
2018 |
| Drug |
brimonidine tartrate/timolol fixed combination ophthalmic solution |
1 |
2010 |
| Drug |
brinzolamide 1% / timolol 0.5% fixed combination ophthalmic suspension |
1 |
2011 |
| Drug |
brinzolamide 1% / timolol 0.5% maleate fixed combination |
1 |
2011 |
| Drug |
brinzolamide 1% added to travoprost 0.004% |
1 |
2006 |
| Drug |
brinzolamide 1% ophthalmic suspension azoptâ® |
1 |
2014 |
| Drug |
brinzolamide 1%/brimonidine 0.2% ophthalmic suspension |
1 |
2013 |
| Drug |
brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension |
1 |
2011 |
| Drug |
brinzolamide 1%/timolol maleate 0.5% fixed combination ophthalmic suspension |
1 |
2014 |
| Drug |
brinzolamide 1.0% / timolol 0.5% ophthalmic suspension |
1 |
2011 |
| Drug |
brinzolamide 10 mg/ml (azopt) eye drops, suspension |
1 |
2006 |
| Drug |
brinzolamide 10 mg/ml / brimonidine 2 mg/ml fixed combination eye drops, suspension |
1 |
2015 |
| Drug |
brinzolamide 10 mg/ml eye drops, suspension |
1 |
2015 |
| Drug |
brinzolamide suspension vehicle |
1 |
2014 |
| Drug |
brinzolamide/brimonidine fc |
1 |
2017 |
| Drug |
brinzolamide/timolol |
1 |
2006 |
| Behavioral |
brochure |
1 |
2016 |
| Drug |
bsf 208075 |
1 |
2002 |
| Drug |
bunazosin |
1 |
2005 |
| Drug |
bupivacaine |
1 |
2015 |
| Drug |
bupivacaine-fentanyl |
1 |
2018 |
| Drug |
c-kad ophthalmic solution |
1 |
2009 |
| Device |
c-mac videolaryngoscope |
1 |
2017 |
| Behavioral |
c) |
1 |
2005 |
| Dietary Supplement |
ca-caseinate |
1 |
2013 |
| Drug |
caduet |
1 |
2010 |
| Drug |
caffeine |
1 |
2014 |
| Dietary Supplement |
calcitriol |
1 |
2014 |
| Dietary Supplement |
calcium arm |
1 |
2020 |
| Drug |
calcium channel blocker [ccb]) |
1 |
2008 |
| Behavioral |
calm approache |
1 |
2006 |
| Other |
can 1 |
1 |
2014 |
| Other |
can 2 |
1 |
2014 |
| Drug |
canagliflozin |
1 |
2013 |
| Drug |
candemore tablet |
1 |
2012 |
| Drug |
candesartan (atacand, bay 12-9333) |
1 |
2011 |
| Drug |
candesartan (bay 98-7106) |
1 |
2011 |
| Drug |
candesartan 32mg/amlodipine 10mg |
1 |
2014 |
| Drug |
candesartan 8mg/amlodipine 5mg |
1 |
2014 |
| Drug |
candesartan cilexetil (atacand) |
1 |
2005 |
| Drug |
candesartan cilexetil (atacand), 16 mg |
1 |
2011 |
| Drug |
candesartan cilexetil (atacand), 32 mg |
1 |
2011 |
| Drug |
candesartan cilexetil (atacand), 4 mg |
1 |
2011 |
| Drug |
candesartan cilexetil (atacand), 8 mg |
1 |
2011 |
| Drug |
candesartan cilexetil 16mg |
1 |
2016 |
| Drug |
candesartan cilexetil 32mg |
1 |
2007 |
| Drug |
candesartan cilexetil 8mg |
1 |
2016 |
| Drug |
candesartan cilexetil fdc(bay98-7106) |
1 |
2013 |
| Drug |
candesartan cilexetil/hydrochlorothiazide |
1 |
2009 |
| Drug |
candesartan thiazide |
1 |
2005 |
| Drug |
candesartan/hct 32/25 mg |
1 |
2007 |
| Drug |
candesartan/hctz - phase 1 |
1 |
2009 |
| Drug |
candesartan/metformin |
1 |
2007 |
| placebo |
candesartan32mg placebo |
1 |
2016 |
| Drug |
canrenone 50 vs canrenone 100 mg |
1 |
2016 |
| Behavioral |
canteen |
1 |
2018 |
| Other |
canteen only |
1 |
2018 |
| Behavioral |
canteen/behavior intervention |
1 |
2018 |
| Diagnostic Test |
capnography |
1 |
2017 |
| Drug |
captopril pill |
1 |
2017 |
| Other |
carb rich diet |
1 |
2017 |
| Drug |
carbidopa |
1 |
2005 |
| Procedure |
cardiac catheterization |
1 |
2019 |
| Device |
cardiac impedancemetry |
1 |
2018 |
| Radiation |
cardiac pet imaging using f-18-fdg, n-13 ammonia( nh3) |
1 |
2014 |
| Device |
cardiac resynchronization therapy (crt) |
1 |
2017 |
| Dietary Supplement |
cardioflex q10 |
1 |
2018 |
| Dietary Supplement |
cardiopressin |
1 |
2016 |
| Diagnostic Test |
cardiopulmonary exercise test protocol |
1 |
2017 |
| Other |
cardiopulmonary exercise test,hypoxia |
1 |
2016 |
| Other |
cardiopulmonary exercise test,hypoxia/hypercapnia test |
1 |
2016 |
| Dietary Supplement |
cardiovascular health dietary supplement |
1 |
2015 |
| Behavioral |
care partner reminders |
1 |
2017 |
| Other |
care team |
1 |
2010 |
| Drug |
carteolol (mikelan), timolol (timoptol), latanoprost (xalatan) |
1 |
2009 |
| Drug |
carteolol long-acting ophthalmic solution |
1 |
2014 |
| Drug |
carvedilol / simvastatin |
1 |
2015 |
| Drug |
carvedilol controlled release |
1 |
2008 |
| Drug |
carvedilol controlled release formulation |
1 |
2006 |
| Drug |
carvedilol controlled release/lisinopril |
1 |
2008 |
| Drug |
carvedilol cr |
1 |
2008 |
| Drug |
carvedilol cr capsules |
1 |
2007 |
| Drug |
carvedilol ir 25mg, bid |
1 |
2012 |
| Drug |
carvedilol ir 25mg, qd |
1 |
2012 |
| Drug |
carvedilol phosphate modified release formulation |
1 |
2006 |
| Drug |
carvedilol sr 32mg, qd |
1 |
2012 |
| Drug |
carvedilol sr 64mg, qd |
1 |
2012 |
| Other |
case management |
1 |
2016 |
| Other |
casein protein |
1 |
2018 |
| Drug |
catapresan tts 2 |
1 |
2007 |
| Procedure |
cataract |
1 |
2019 |
| Procedure |
cataract extraction |
1 |
2011 |
| Procedure |
catheter ablation |
1 |
2019 |
| Device |
cbp |
1 |
2018 |
| Drug |
cc of norepinephrine(group n) |
1 |
2019 |
| Drug |
cc of vasopressin(group v) |
1 |
2019 |
| Drug |
ccb |
1 |
2018 |
| Drug |
celecoxib (celebrex) |
1 |
2008 |
| Device |
celsiusâ® thermocoolâ® rd |
1 |
2012 |
| Device |
celsiusâ® thermocoolâ® renal denervation |
1 |
2014 |
| Procedure |
cesarean section |
1 |
2018 |
| Drug |
cf101 |
1 |
2009 |
| Other |
changing posture |
1 |
2015 |
| Device |
chart reminder |
1 |
2005 |
| Device |
chemical block |
1 |
2015 |
| Behavioral |
chinese square dancing group |
1 |
2019 |
| Drug |
chlorothiazide |
1 |
1999 |
| Drug |
chlortalidone |
1 |
2016 |
| Drug |
chlorthalidone 25 mg |
1 |
2019 |
| Dietary Supplement |
cholecalciferol (vitamin d) |
1 |
2011 |
| Other |
chronotherapy |
1 |
2016 |
| Procedure |
chronotherapy, timing of antihypertensive medication |
1 |
2006 |
| Behavioral |
chw intervention |
1 |
2017 |
| Drug |
cilnidipine/valsartan |
1 |
2015 |
| Procedure |
circumferential pvi |
1 |
2010 |
| Procedure |
circumferential pvi/renal denervation |
1 |
2010 |
| Drug |
ckd-330 |
1 |
2018 |
| Drug |
ckd-330 16/5mg |
1 |
2015 |
| Drug |
ckd-330 16/5mg - a |
1 |
2016 |
| Drug |
ckd-330 16/5mg - b |
1 |
2016 |
| Drug |
ckd-330 16/5mg placebo |
1 |
2015 |
| Drug |
ckd-330/d086 |
1 |
2018 |
| Drug |
ckd-333 formulation i |
1 |
2018 |
| Drug |
ckd-333 formulation ii |
1 |
2018 |
| Drug |
ckd-385 tab. 1t |
1 |
2018 |
| Drug |
ckd-828 2.5/80mg |
1 |
2011 |
| Drug |
ckd-828 40 |
1 |
2011 |
| Drug |
ckd-828 40/2.5mg |
1 |
2011 |
| Drug |
ckd-828 40/5mg |
1 |
2011 |
| Drug |
ckd-828 5 |
1 |
2012 |
| Drug |
ckd-828 5/40mg |
1 |
2012 |
| Drug |
ckd-828 5/80mg |
1 |
2012 |
| Behavioral |
class instruction of breathing exercises |
1 |
2017 |
| Other |
clinical |
1 |
2017 |
| Other |
clinical decision support |
1 |
2018 |
| Behavioral |
clinical decision support (cds) |
1 |
2013 |
| Drug |
clinical hypertension specialist-no specific med. any anti-hypertension meds. |
1 |
2008 |
| Behavioral |
clinical pharmacist-based intervention |
1 |
2007 |
| Other |
clinical treatment |
1 |
2013 |
| Device |
cloud-based home bp monitoring |
1 |
2014 |
| Diagnostic Test |
cmri |
1 |
2010 |
| Drug |
co-amlessaâ® |
1 |
2018 |
| Behavioral |
coaching |
1 |
2015 |
| Behavioral |
coaching dash group (c-dash) |
1 |
2017 |
| Dietary Supplement |
cocoa |
1 |
2009 |
| Other |
cocoa extract rich in polyphenols |
1 |
2010 |
| Dietary Supplement |
cocoa polyphenols |
1 |
2008 |
| Drug |
codiovanâ® 160 |
1 |
2015 |
| Drug |
codiovanâ® 160/12.5mg |
1 |
2015 |
| Dietary Supplement |
coenzyme q-10 in normal control subjects |
1 |
2010 |
| Dietary Supplement |
coenzyme q-10 in pulmonary hypertension subjects |
1 |
2010 |
| Other |
coffee |
1 |
2019 |
| Other |
cogmed |
1 |
2016 |
| Behavioral |
cognitive behavioral therapy |
1 |
2014 |
| Behavioral |
cognitive behavioral therapy for insomnia (cbt-i) |
1 |
2019 |
| Other |
cognitive training |
1 |
2018 |
| Device |
coil |
1 |
2018 |
| Procedure |
cold pressor test |
1 |
2013 |
| Behavioral |
collaborations in health (coach) |
1 |
2013 |
| Behavioral |
collaborative care team intervention |
1 |
2016 |
| Other |
collaborative model of primary care |
1 |
2015 |
| Other |
collaborative model of primary care/subspecialty care |
1 |
2015 |
| Drug |
combigan two times daily (bid) |
1 |
2014 |
| Other |
combination intervention to include medical practice improvement |
1 |
2006 |
| Other |
combination intervention to include medical practice improvement/patient education/support |
1 |
2006 |
| Drug |
combination iop lowering therapy |
1 |
2003 |
| Drug |
combination medication treatment group |
1 |
2017 |
| Drug |
combination pill of losartan |
1 |
2008 |
| Drug |
combination pill of losartan/hydrochlorothiazide |
1 |
2008 |
| Procedure |
combination therapy in essential hypertension |
1 |
2006 |
| Other |
combined |
1 |
2016 |
| Other |
combined exercise training |
1 |
2018 |
| Behavioral |
combined exercise/diet program |
1 |
2006 |
| Other |
combined exercises |
1 |
2015 |
| Other |
combined intervention (chemoembolization |
1 |
2012 |
| Other |
combined intervention (chemoembolization/ablation) |
1 |
2012 |
| Behavioral |
combined training |
1 |
2017 |
| Behavioral |
commitment mailing |
1 |
2015 |
| Other |
commune hypertension management |
1 |
2012 |
| Behavioral |
communication skills training |
1 |
2013 |
| Other |
community-based pre-eclampsia |
1 |
2019 |
| Other |
community-based pre-eclampsia/eclampsia detection/management |
1 |
2019 |
| Behavioral |
community-based treatment of overweight |
1 |
2013 |
| Behavioral |
community-based treatment of overweight/obesity |
1 |
2013 |
| Behavioral |
community based multiple risk factor intervention strategies |
1 |
2007 |
| Behavioral |
community health worker |
1 |
2014 |
| Behavioral |
community health worker (chw) intervention |
1 |
2013 |
| Behavioral |
community health worker referral |
1 |
2016 |
| Drug |
comparator : atenolol /duration of treatment : 16 weeks |
1 |
2007 |
| Drug |
comparator : atenolol /duration of treatment : 5 years |
1 |
2006 |
| Other |
comparator group |
1 |
2015 |
| Drug |
comparator: amlodipine |
1 |
2010 |
| Drug |
comparator: amlodipine besylate |
1 |
2008 |
| Drug |
comparator: candesartan cilexetil |
1 |
2009 |
| Drug |
comparator: carvedilol |
1 |
2007 |
| Drug |
comparator: carvedilol ( |
1 |
2007 |
| Drug |
comparator: carvedilol (/) hydrochlorothiazide |
1 |
2007 |
| Drug |
comparator: dorzolamide hcl |
1 |
2007 |
| Drug |
comparator: dorzolamide hcl/timolol maleate / prostaglandin |
1 |
2007 |
| Drug |
comparator: dorzolamide hydrochloride |
1 |
2007 |
| Drug |
comparator: hydrochlorothiazide |
1 |
2008 |
| Drug |
comparator: ismn er |
1 |
2010 |
| Drug |
comparator: isosorbide mononitrate (ismn) |
1 |
2009 |
| Drug |
comparator: losartan ( |
1 |
2007 |
| Drug |
comparator: losartan (/) hydrochlorothiazide (hctz) |
1 |
2007 |
| Drug |
comparator: losartan / ismn |
1 |
2009 |
| Drug |
comparator: losartan //- hctz |
1 |
2006 |
| Drug |
comparator: losartan, hctz, amlodipine, atenolol |
1 |
2005 |
| Drug |
comparator: losartan, hctz, amlodipine, atenolol/duration of treatment: 18 weeks |
1 |
2005 |
| Drug |
comparator: mk3614 .75 mg 1st |
1 |
2009 |
| Drug |
comparator: mk3614 multiple rising dose |
1 |
2009 |
| Drug |
comparator: mk3614 titrating down dose |
1 |
2009 |
| Drug |
comparator: pbo |
1 |
2009 |
| placebo |
comparator: placebo (unspecified) |
1 |
2007 |
| placebo |
comparator: placebo panel a |
1 |
2009 |
| placebo |
comparator: placebo panel b-c |
1 |
2009 |
| placebo |
comparator: placebo panel d |
1 |
2009 |
| placebo |
comparator: placebo panel e |
1 |
2009 |
| placebo |
comparator: placebo to aliskiren |
1 |
2009 |
| placebo |
comparator: placebo to hctz |
1 |
2009 |
| placebo |
comparator: placebo to ismn |
1 |
2009 |
| placebo |
comparator: placebo to losartan |
1 |
2009 |
| placebo |
comparator: placebo, losartan, hydrochlorothiazide |
1 |
2004 |
| Drug |
comparator: timolol |
1 |
2009 |
| Drug |
comparator: valsartan ( |
1 |
2007 |
| Drug |
comparator: valsartan (/) hydrochlorothiazide |
1 |
2007 |
| Device |
comparison test to yuyue medical bp meter, yybp-212 |
1 |
2011 |
| Behavioral |
comparison to peers |
1 |
2013 |
| Behavioral |
complex quality improvement intervention |
1 |
2011 |
| Behavioral |
complex tailored intervention |
1 |
2012 |
| Behavioral |
comprehensive intervention |
1 |
2013 |
| Behavioral |
comprehensive lifestyle modification |
1 |
2014 |
| Behavioral |
comprehensive medication management |
1 |
2013 |
| Behavioral |
comprehensive pharmacy care program |
1 |
2006 |
| Other |
computed tomography |
1 |
2008 |
| Behavioral |
computer |
1 |
2005 |
| Behavioral |
computer-based decision support system |
1 |
2018 |
| Behavioral |
computer behavioral education |
1 |
2005 |
| Behavioral |
computer controlled telephone counseling |
1 |
2011 |
| Procedure |
computer generated statements about guideline concordance of drug therapy deliver to clinicians |
1 |
2001 |
| Behavioral |
computer intervention |
1 |
2005 |
| Behavioral |
computer intervention/reduction of financial barrier |
1 |
2005 |
| Behavioral |
computerized reminders about treatment guidelines to providers who care for hypertensive patients |
1 |
2012 |
| Drug |
concomitant administrations of amlodipine, losartan, |
1 |
2010 |
| Drug |
concomitant use of tafluprost ophthalmic solution 0.0015% |
1 |
2011 |
| Drug |
concomitant use of tafluprost ophthalmic solution 0.0015%/timolol ophthalmic solution 0.5% |
1 |
2011 |
| Dietary Supplement |
concord grape juice |
1 |
2006 |
| Drug |
concurrent brimonidine 0.2%/0.5% timolol |
1 |
2008 |
| Drug |
concurrent brimonidine 0.2%/timolol 0.5% ophthalmic solution |
1 |
2008 |
| Device |
confidenht system |
1 |
2016 |
| Drug |
conjugated equine (prempro tm) |
1 |
2007 |
| Other |
connected-device |
1 |
2017 |
| Other |
consult-bp educational intervention |
1 |
2017 |
| Device |
contec cms50ew |
1 |
2019 |
| Behavioral |
contingency management |
1 |
2011 |
| Other |
continued current care |
1 |
2018 |
| Other |
continued daily lifestyle |
1 |
2012 |
| Device |
continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter |
1 |
2019 |
| Device |
continuous positive airway pressure (cpap)/patient education |
1 |
2019 |
| Procedure |
continuous positive airway pressure treatment |
1 |
2012 |
| Behavioral |
control-edi |
1 |
2019 |
| Other |
control -listened to a brochure |
1 |
2014 |
| Dietary Supplement |
control (carbohydrate) |
1 |
2008 |
| Dietary Supplement |
control by dietitian |
1 |
2020 |
| Behavioral |
control by psychiatrist |
1 |
2020 |
| Behavioral |
control condition |
1 |
2010 |
| Drug |
control group who are advised for proper life style modification by the physician such as regular exercise |
1 |
2012 |
| Drug |
control group who are advised for proper life style modification by the physician such as regular exercise/healthy diet without active intervention. |
1 |
2012 |
| Dietary Supplement |
control oil |
1 |
2019 |
| Other |
control session |
1 |
2016 |
| Other |
control: standard care |
1 |
2014 |
| Other |
convenient medicine access |
1 |
2016 |
| Drug |
conventional antihypertensive drugs |
1 |
2005 |
| Behavioral |
conventional blood pressure monitoring |
1 |
2015 |
| Drug |
conventional drug therapy(expectorant<bronchodilator) |
1 |
2019 |
| Other |
conventional exercise |
1 |
2012 |
| Other |
conventional holter monitoring |
1 |
2013 |
| Device |
conventional mercury sphygmomanometry |
1 |
2006 |
| Procedure |
conventional renal denervation |
1 |
2016 |
| Other |
conventional therapy - control group |
1 |
2017 |
| Drug |
coracten |
1 |
2008 |
| Drug |
corever |
1 |
2015 |
| Drug |
corgard (1 x 80 mg) tablets (bristol laboratories) |
1 |
2009 |
| Dietary Supplement |
corn starch |
1 |
2008 |
| Dietary Supplement |
cornstarch |
1 |
2008 |
| Drug |
corvitol |
1 |
2009 |
| Drug |
cosmofer |
1 |
2011 |
| Drug |
cosopt (dorzolamide 2% |
1 |
2010 |
| Drug |
cosopt (dorzolamide 2% / timolol 0.5%) |
1 |
2010 |
| Behavioral |
counseling letter |
1 |
2017 |
| Device |
covered stent |
1 |
2015 |
| Device |
covidien oneshotâ„¢ system |
1 |
2012 |
| Drug |
cozaarâ® |
1 |
2013 |
| Drug |
cozaarâ®/pro tab |
1 |
2013 |
| Other |
cp |
1 |
2015 |
| Device |
cpap (continuous positive airway pressure) |
1 |
2005 |
| Device |
cpap nasal |
1 |
2013 |
| Procedure |
cpap therapy for newly diagnosed obstructive sleep apnea (osa) |
1 |
2009 |
| Device |
cpap treatment during sleep |
1 |
2007 |
| Behavioral |
cpr instruction |
1 |
2000 |
| Procedure |
cryo-therapy |
1 |
2014 |
| Device |
cryoablation |
1 |
2014 |
| Drug |
cs8635 20 |
1 |
2013 |
| Drug |
cs8635 20/5/12.5mg/placebo |
1 |
2013 |
| Other |
ct imaging, functional pet imaging |
1 |
2011 |
| Combination Product |
ct scan |
1 |
2018 |
| Device |
cuff device (omron hbp-1300-e pro) |
1 |
2015 |
| Procedure |
culture of mononuclear cells |
1 |
2010 |
| Dietary Supplement |
curcumin |
1 |
2018 |
| Dietary Supplement |
curd |
1 |
2018 |
| Drug |
current marketed flolan (epoprostenol sodium) |
1 |
2011 |
| Drug |
current treatment |
1 |
2018 |
| Behavioral |
cv toolkit components |
1 |
2016 |
| Device |
cvrx rheos baroreflex hypertension therapy system |
1 |
2008 |
| Drug |
cyclophosphamide |
1 |
2018 |
| Procedure |
cytokine |
1 |
1999 |
| Procedure |
cytokine/leukocyte activation profile |
1 |
1999 |
| Drug |
d |
1 |
2006 |
| Drug |
d 10 mg |
1 |
2006 |
| Drug |
d&g 1g |
1 |
2009 |
| Drug |
d&g 2g |
1 |
2009 |
| Drug |
d) |
1 |
2019 |
| Drug |
d). |
1 |
2019 |
| Drug |
d013 |
1 |
2018 |
| Drug |
d013, d326 |
1 |
2018 |
| Drug |
d013, d326, d337 |
1 |
2020 |
| Drug |
d013, d326/d337 |
1 |
2018 |
| placebo |
d013, placebo of d326, placebo of d337 |
1 |
2020 |
| Drug |
d086 |
1 |
2018 |
| Drug |
d326 |
1 |
2018 |
| Drug |
d326/d337 |
1 |
2018 |
| Drug |
d337 |
1 |
2018 |
| Drug |
d935 cap. 1t |
1 |
2018 |
| Behavioral |
dairy |
1 |
2007 |
| Other |
dairy diet |
1 |
2013 |
| Behavioral |
dairy peptides |
1 |
2005 |
| Dietary Supplement |
dark chocolate 25 g |
1 |
2008 |
| Dietary Supplement |
dark chocolate 25 g/day |
1 |
2008 |
| Dietary Supplement |
dark chocolate 6 g |
1 |
2008 |
| Dietary Supplement |
dark chocolate 6 g/day |
1 |
2008 |
| Other |
dark chocolate) |
1 |
2011 |
| Dietary Supplement |
darkchocolate |
1 |
2011 |
| Behavioral |
dash |
1 |
2009 |
| Behavioral |
dash-4-teens |
1 |
2007 |
| Behavioral |
dash - c |
1 |
2012 |
| Behavioral |
dash approach |
1 |
2006 |
| Behavioral |
dash diet (high carbohydrate diet) |
1 |
2005 |
| Behavioral |
dash diet counseling |
1 |
2019 |
| Behavioral |
dash diet/weight loss |
1 |
2007 |
| Behavioral |
dash eating plan |
1 |
2015 |
| Other |
dash education |
1 |
2019 |
| Behavioral |
dash groceries |
1 |
2016 |
| Behavioral |
dash groceries / weekly sessions |
1 |
2016 |
| Behavioral |
dash mobile mhealth enhanced coaching |
1 |
2014 |
| Behavioral |
dash plus |
1 |
2012 |
| Behavioral |
dash/sodium-restricted diet (srd) |
1 |
2009 |
| Behavioral |
dashna-cc |
1 |
2015 |
| Other |
data |
1 |
2012 |
| Other |
data collection |
1 |
2009 |
| Dietary Supplement |
day |
1 |
2008 |
| Drug |
day after des implantation |
1 |
2011 |
| Drug |
day) |
1 |
2010 |
| Drug |
day) , aliskiren |
1 |
2010 |
| Drug |
day, 300 |
1 |
2010 |
| Other |
days 7 |
1 |
2019 |
| Drug |
de-104 high concentration |
1 |
2009 |
| Drug |
de-104 medium concentration |
1 |
2009 |
| Drug |
de-104 ophthalmic solution |
1 |
2008 |
| Drug |
de-112 |
1 |
2011 |
| Drug |
de-112 vehicle solution |
1 |
2011 |
| Drug |
de-117 high dose ophthalmic solution |
1 |
2014 |
| Drug |
de-117 low |
1 |
2014 |
| Drug |
de-117 low dose ophthalmic solution |
1 |
2014 |
| Drug |
de-117 low/middle dose ophthalmic solution |
1 |
2014 |
| Drug |
de-117 middle |
1 |
2014 |
| Drug |
de-117 middle dose ophthalmic solution |
1 |
2014 |
| Drug |
de-117 middle/high dose ophthalmic solution |
1 |
2014 |
| Drug |
de-117 ophthalmic solution bid |
1 |
2019 |
| Drug |
de-117 ophthalmic solution high |
1 |
2015 |
| Drug |
de-117 ophthalmic solution low |
1 |
2015 |
| Drug |
de-117 ophthalmic solution qd |
1 |
2019 |
| Drug |
de-117/0.0015% tafluprost |
1 |
2012 |
| Drug |
de-130a |
1 |
2019 |
| Procedure |
decompressive craniectomy |
1 |
2018 |
| Other |
decreasing dialysate sodium from 138 mmol |
1 |
2011 |
| Other |
decreasing dialysate sodium from 138 mmol/l to 136 mmol/l |
1 |
2011 |
| Drug |
definityâ® infusion |
1 |
2014 |
| Drug |
dehydrated alcohol |
1 |
2016 |
| Drug |
delapril 30 mg |
1 |
2008 |
| Behavioral |
delayed intervention |
1 |
2009 |
| Behavioral |
delayed intervention control |
1 |
2011 |
| Dietary Supplement |
delivery |
1 |
2010 |
| Device |
delivery microcatheter |
1 |
2019 |
| Dietary Supplement |
delivery/return of chocolate |
1 |
2010 |
| Drug |
desmopressin (ddavp) |
1 |
2005 |
| Procedure |
determination of blood pressure |
1 |
2010 |
| Device |
device-guided breathing (resperate - intercure, israel) |
1 |
2011 |
| Device |
device guided breathing |
1 |
2020 |
| Drug |
dextrose infusion |
1 |
2014 |
| Drug |
dhea tablet |
1 |
2018 |
| Other |
diabetes group management visits |
1 |
2006 |
| Behavioral |
diabetic macular edema treatment |
1 |
2009 |
| Drug |
dichloroacetate sodium |
1 |
2010 |
| Behavioral |
diet high in fruits, vegetables, |
1 |
2007 |
| Behavioral |
diet high in fruits, vegetables,/dairy |
1 |
2007 |
| Behavioral |
diet program |
1 |
2006 |
| Behavioral |
diet therapy |
1 |
1999 |
| Behavioral |
diet, magnesium supplementation |
1 |
1999 |
| Behavioral |
diet, potassium supplementation |
1 |
1999 |
| Behavioral |
diet, reducing (phase iii) |
1 |
1999 |
| Behavioral |
diet, sodium-restricted (phase iii) diet, sodium-restricted |
1 |
1999 |
| Behavioral |
diet/lifestyle |
1 |
2013 |
| Behavioral |
dietary |
1 |
2012 |
| Behavioral |
dietary approaches to stop hypertension-the dash diet |
1 |
2008 |
| Behavioral |
dietary cardiovascular risk reduction coaching |
1 |
2019 |
| Behavioral |
dietary counseling |
1 |
2014 |
| Behavioral |
dietary counselling |
1 |
2018 |
| Other |
dietary intervention |
1 |
2019 |
| Dietary Supplement |
dietary nitrate |
1 |
2015 |
| Behavioral |
dietary prescription |
1 |
2019 |
| Other |
dietary salt reduction |
1 |
2017 |
| Dietary Supplement |
dietary sodium |
1 |
2017 |
| Behavioral |
dietary sodium reduction |
1 |
2019 |
| Dietary Supplement |
dietary supplement consumption |
1 |
2019 |
| Behavioral |
dietetic intervention |
1 |
2014 |
| Behavioral |
dietitian-led approach |
1 |
2018 |
| Drug |
diovan |
1 |
2012 |
| Drug |
diovan (valsartan) |
1 |
2009 |
| Drug |
diphenhydramine |
1 |
2010 |
| Drug |
dipyridamole/ aspirin (aggrenox) |
1 |
2005 |
| Other |
direct input of home blood pressure readings via mychart |
1 |
2017 |
| Other |
direct observed therapy |
1 |
2015 |
| Behavioral |
disclosure of adherence report to clinician |
1 |
2010 |
| Device |
discman with freely chosen music |
1 |
2008 |
| Procedure |
distal renal denervation |
1 |
2016 |
| Drug |
diu |
1 |
2018 |
| Drug |
diuretic-based |
1 |
2005 |
| Drug |
diuretic-based/non-diuretic based hypertension therapy |
1 |
2005 |
| Drug |
diuretics (torasemide, indapamide, htcz) |
1 |
2006 |
| Drug |
diuretics (torasemide, indapamide, htcz)/doxazosin |
1 |
2006 |
| Drug |
dm 0 |
1 |
2012 |
| Drug |
dm 2.5 |
1 |
2012 |
| Drug |
dm 30 |
1 |
2012 |
| Drug |
dm 7.5 |
1 |
2012 |
| Other |
dna extraction |
1 |
2010 |
| Other |
dna extraction/genotyping |
1 |
2010 |
| Drug |
dnb-001 |
1 |
2008 |
| Other |
door-to-door |
1 |
2011 |
| Procedure |
doppler ultrasound |
1 |
2016 |
| Drug |
dorzolamide |
1 |
2007 |
| Drug |
dorzolamide-timolol-brimonidine |
1 |
2010 |
| Drug |
dorzolamide 2 % eye drops solution |
1 |
2009 |
| Drug |
dorzolamide 2.0% |
1 |
2011 |
| Drug |
dorzolamide 2.0% / timolol 0.5% ophthalmic solution |
1 |
2011 |
| Drug |
dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination |
1 |
2009 |
| Drug |
dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy. |
1 |
2009 |
| Drug |
dorzolamide hcl 2%/timolol maleate 0.5% fixed combination |
1 |
2009 |
| Drug |
dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy |
1 |
2009 |
| Drug |
dorzolamide hydrochloride 1% |
1 |
2014 |
| Drug |
dorzolamide hydrochloride 1%/timolol maleate 0.5% ophthalmic solution |
1 |
2014 |
| Drug |
dorzolamide/timolol ophthalmic solution |
1 |
2007 |
| Drug |
dose level a |
1 |
2014 |
| Drug |
dose level a / brinzolamide 1% ophthalmic suspension |
1 |
2014 |
| Drug |
dose level b |
1 |
2014 |
| Drug |
dose level b / brinzolamide 1% ophthalmic suspension |
1 |
2014 |
| Drug |
dose level c |
1 |
2014 |
| Drug |
dose level c / brinzolamide 1% ophthalmic suspension |
1 |
2014 |
| Drug |
doxazosin (drug) |
1 |
2006 |
| Drug |
doxazosin 4 mg japanese marketed ir tablet |
1 |
2011 |
| Drug |
doxazosin 4 mg odt with water |
1 |
2011 |
| Drug |
doxazosin 4 mg odt without water |
1 |
2011 |
| Drug |
doxazosin gastrointestinal therapeutic system (gits) |
1 |
2008 |
| Drug |
dp-r208 |
1 |
2016 |
| placebo |
dp-r208 placebo |
1 |
2016 |
| Drug |
drospirenone |
1 |
2007 |
| Drug |
drospirenone/17ãÿ-estradiol (angeliq, bay86-4891) |
1 |
2007 |
| Behavioral |
drug dispensing |
1 |
2008 |
| Device |
ds-mce |
1 |
2018 |
| Device |
ds-mce/egd |
1 |
2018 |
| Device |
dual 24-hour abpm |
1 |
2020 |
| Other |
dual combination |
1 |
2019 |
| Other |
dual energy ct scans |
1 |
2019 |
| Drug |
duotrav |
1 |
2010 |
| Drug |
duotrav (travoprost-timolol ophthalmic drops) |
1 |
2009 |
| Drug |
duration of treatment : 16 weeks |
1 |
2007 |
| Drug |
duration of treatment : 5 years |
1 |
2006 |
| Drug |
duration of treatment: 12 weeks |
1 |
2006 |
| Drug |
duration of treatment: 18 weeks |
1 |
2005 |
| Drug |
duration of treatment: 6 weeks |
1 |
2006 |
| Drug |
duration of treatment: part 1) 6 wk timolol maleate run in |
1 |
2005 |
| Behavioral |
dvd instruction of breathing exercises |
1 |
2017 |
| Drug |
dwj1276 |
1 |
2013 |
| Behavioral |
e-counseling |
1 |
2012 |
| Behavioral |
e-counseling/usual care |
1 |
2012 |
| Diagnostic Test |
ecg |
1 |
2019 |
| Diagnostic Test |
echocardiography scan |
1 |
2018 |
| Other |
eclampsia detection |
1 |
2019 |
| Behavioral |
ecological nurse case management |
1 |
2015 |
| Other |
ed sbirt-htn |
1 |
2017 |
| Behavioral |
education group |
1 |
2018 |
| Other |
education intervention |
1 |
2005 |
| Other |
education meetings |
1 |
2008 |
| Behavioral |
educational |
1 |
2009 |
| Behavioral |
educational coaching |
1 |
2010 |
| Other |
educational intervention |
1 |
2018 |
| Behavioral |
educational intervention for diet |
1 |
2011 |
| Behavioral |
educational intervention for diet/physical activity |
1 |
2011 |
| Behavioral |
educational message on skin cancer awareness |
1 |
2011 |
| Behavioral |
educational/behavioral |
1 |
2009 |
| Behavioral |
educore intervention |
1 |
2010 |
| Behavioral |
effects of dark chocolate |
1 |
2004 |
| Drug |
effects of doxazosin on morning surge in diabetic patients |
1 |
2006 |
| Drug |
efi |
1 |
2011 |
| Drug |
efi/act-385781a |
1 |
2011 |
| Device |
egd |
1 |
2018 |
| Dietary Supplement |
egg albumin-derived peptide |
1 |
2014 |
| Behavioral |
ehmi |
1 |
2012 |
| Behavioral |
eim exercise classes |
1 |
2019 |
| Behavioral |
eim exercise classes/intervention |
1 |
2019 |
| Drug |
elafin |
1 |
2018 |
| Procedure |
electrial mapping, nerve stimulation guided renal denervation procedure |
1 |
2015 |
| Device |
electrical block |
1 |
2015 |
| Procedure |
electrical mapping, nerve stimulation checked renal denervation procedure |
1 |
2015 |
| Procedure |
electro-acupuncture control |
1 |
2009 |
| Procedure |
electro-acupuncture test |
1 |
2009 |
| Other |
electronic personal health record |
1 |
2011 |
| Drug |
empagliflozin high dose |
1 |
2014 |
| Drug |
empagliflozin low dose |
1 |
2014 |
| Drug |
empagliflozin tablets |
1 |
2019 |
| Other |
empower-par intervention |
1 |
2012 |
| Drug |
emricasan |
1 |
2016 |
| Behavioral |
enacts |
1 |
2018 |
| Drug |
enalapril 10mg |
1 |
2008 |
| Drug |
enalapril 5mg |
1 |
2008 |
| Drug |
enalapril high dose |
1 |
2014 |
| Drug |
enalapril low dose |
1 |
2014 |
| Drug |
enalapril maleate 20 mg |
1 |
2013 |
| Drug |
enalapril maleate tablets(as the program-based antihypertension) |
1 |
2015 |
| Drug |
enalapril maleate/folic acid tablets (yiye) |
1 |
2018 |
| Drug |
enalapril maleate/folic acid tablets(as the program-based antihypertension) |
1 |
2015 |
| Drug |
enalapril medium dose |
1 |
2014 |
| Drug |
enalapril pill |
1 |
2017 |
| Drug |
enalapril/folic acid |
1 |
2008 |
| Drug |
enalaprilat |
1 |
2008 |
| Drug |
enalaprilat (ace inhibitor) |
1 |
2011 |
| Procedure |
endoscopic therapy |
1 |
2018 |
| Procedure |
endoscopic treatment |
1 |
2013 |
| Diagnostic Test |
endoscopic ultrasound |
1 |
2019 |
| Procedure |
endoscopy |
1 |
2013 |
| Biological |
endothelin-3 |
1 |
2010 |
| Procedure |
endotracheal tube |
1 |
2012 |
| Behavioral |
endurance training |
1 |
2018 |
| Other |
energy expenditure |
1 |
2015 |
| Other |
energy restriction |
1 |
2012 |
| Behavioral |
enhanced brief lifestyle counseling |
1 |
2009 |
| Behavioral |
enhanced health education |
1 |
2008 |
| Other |
enhanced label |
1 |
2010 |
| Behavioral |
enhanced nutritional care classes |
1 |
2006 |
| Other |
enhanced pharmacist care |
1 |
2009 |
| Behavioral |
enhanced sc |
1 |
2018 |
| Behavioral |
enhanced standard diabetes education |
1 |
2010 |
| Behavioral |
enhanced usual care group |
1 |
2019 |
| Behavioral |
enhancedsc |
1 |
2016 |
| Behavioral |
enhancing the awareness of blood pressure self-management |
1 |
2018 |
| Other |
enhancing village doctors’ability. |
1 |
2018 |
| Device |
enlightnâ„¢ renal artery ablation catheter |
1 |
2013 |
| Biological |
enos transfected epcs will be delivered via a pa line |
1 |
2007 |
| Drug |
entecavir / fuzheng huayu |
1 |
2016 |
| Drug |
entecavir/carvedilol |
1 |
2016 |
| Drug |
entecavir/carvedilol/ fuzheng huayu |
1 |
2016 |
| Dietary Supplement |
enteral l-citrulline |
1 |
2018 |
| Drug |
env515-1 travoprost xr |
1 |
2015 |
| Drug |
env515-3-2 travoprost xr |
1 |
2015 |
| Drug |
env515-3 travoprost xr |
1 |
2015 |
| Drug |
eplerenone 50 mg tab |
1 |
2017 |
| Drug |
eplerenone vs amlodipine |
1 |
2018 |
| Drug |
eposartan 600mg |
1 |
2011 |
| Drug |
eposartan 600mg/day after des implantation |
1 |
2011 |
| Drug |
eprosartan mesylate |
1 |
2012 |
| Drug |
eprosartan/hctz |
1 |
2005 |
| Other |
equal to 92 mm hg |
1 |
2020 |
| Drug |
era as specific pah treatment |
1 |
2013 |
| Drug |
ertugliflozin 1 mg |
1 |
2010 |
| Drug |
ertugliflozin 25 mg |
1 |
2010 |
| Drug |
ertugliflozin 5 mg |
1 |
2010 |
| Drug |
erythropoietin/hydroxyurea |
1 |
2005 |
| Drug |
escitalopram |
1 |
2005 |
| Drug |
esmolol |
1 |
2010 |
| Procedure |
esofagic varices ligation |
1 |
2007 |
| Drug |
esomeprazole |
1 |
2009 |
| Diagnostic Test |
esophagogastroduodenoscopy |
1 |
2019 |
| Other |
essential eucalyptus oil |
1 |
2016 |
| Other |
establishing a chronic disease management system |
1 |
2018 |
| Other |
establishing a hierarchical management system for patients |
1 |
2018 |
| Behavioral |
establishing a self-management group |
1 |
2018 |
| Other |
establishing a supervision mechanism for the effect |
1 |
2018 |
| Other |
establishing patient encouragement system |
1 |
2018 |
| Drug |
estracomb tts |
1 |
2019 |
| Drug |
etc-1002 |
1 |
2014 |
| Device |
eted, cpet, rhc |
1 |
2008 |
| Behavioral |
ethnicity |
1 |
2016 |
| Dietary Supplement |
eucommia |
1 |
2008 |
| Device |
evaluation of the impact of a guideline based computerized decision support system. |
1 |
2006 |
| Other |
evidence-based hypertension treatment |
1 |
2019 |
| Other |
evidence based, dss enabled, health care delivery model |
1 |
2013 |
| Drug |
evolocumab 140 mg |
1 |
2019 |
| Drug |
evolocumab 140 mg/ml |
1 |
2019 |
| Dietary Supplement |
ex |
1 |
2015 |
| Other |
exercise group |
1 |
2017 |
| Other |
exercise intervention) |
1 |
2012 |
| Behavioral |
exercise only |
1 |
2015 |
| Behavioral |
exercise program |
1 |
2006 |
| Other |
exercise programs |
1 |
2020 |
| Other |
exercise rehab |
1 |
2019 |
| Other |
exercise rehabilitation |
1 |
2014 |
| Behavioral |
exercise self-monitoring |
1 |
2018 |
| Behavioral |
exercise support |
1 |
2010 |
| Other |
exercise test |
1 |
2018 |
| Behavioral |
exercise therapy with supplemental oxygen |
1 |
2015 |
| Behavioral |
exercise training effect on hypertension |
1 |
2019 |
| Behavioral |
exercise training effect on hypertension/gut dysbiosis |
1 |
2019 |
| Behavioral |
exercise training for 6 months |
1 |
2005 |
| Other |
exercise type |
1 |
2019 |
| Other |
exercise using stationary bicycle |
1 |
2011 |
| Behavioral |
exercise/respiratory training |
1 |
2011 |
| Drug |
exforge 10 |
1 |
2012 |
| Drug |
exforge 10/160 |
1 |
2012 |
| Other |
expanded community health worker services |
1 |
2018 |
| Drug |
experimental dosing of labetalol |
1 |
2019 |
| Behavioral |
experimental: e-blended lerarning |
1 |
2017 |
| Behavioral |
experimental: individual orientation |
1 |
2017 |
| Other |
experimental: pharmacist-bidirectional texting group |
1 |
2019 |
| Drug |
experimental: single iv infusion vasomera (pb1046) |
1 |
2013 |
| Behavioral |
experimental: vle for distance learning |
1 |
2017 |
| Behavioral |
expert-driven group |
1 |
2017 |
| Other |
extensive implementation programme |
1 |
2007 |
| Device |
extra-vascular lung water measurements by ultrasound |
1 |
2017 |
| Behavioral |
extras |
1 |
2018 |
| Drug |
ezetimibe/rosuvastatin |
1 |
2019 |
| Procedure |
face-to-face care management |
1 |
2005 |
| Drug |
famotidine 20 mg |
1 |
2018 |
| Dietary Supplement |
farlong notoginsengâ„¢ (farlong ginseng plusâ®) |
1 |
2017 |
| Other |
favor one of two thiazides for new prescriptions |
1 |
2010 |
| Other |
favor one of two thiazides for new prescriptions/attempt target dose |
1 |
2010 |
| Behavioral |
fchv visit |
1 |
2015 |
| Drug |
fdc |
1 |
2011 |
| Drug |
fdc 5 |
1 |
2013 |
| Drug |
fdc 5/100 amlodipine /losartan |
1 |
2013 |
| Drug |
fdc 5/50 amlodipine/ losartan |
1 |
2013 |
| Drug |
fdc macitentan |
1 |
2019 |
| Drug |
fdc macitentan/tadalafil |
1 |
2019 |
| Drug |
fdc of candesartan cilexetil 16 mg |
1 |
2014 |
| Drug |
fdc of candesartan cilexetil 16 mg/hctz 12.5mg |
1 |
2014 |
| Drug |
felodipin |
1 |
2011 |
| Drug |
felodipine sustained-release tablet |
1 |
2012 |
| Drug |
felodipine tablet (plendil) |
1 |
2014 |
| Drug |
felodipine tablet (plendil) alone |
1 |
2014 |
| Drug |
felodipine tablet (plendil)/hydrochlorothiazide |
1 |
2014 |
| Drug |
felodipine tablet (plendil)/metoprolol tablet (betaloc zok) |
1 |
2014 |
| Drug |
felodipine tablets (plendil) |
1 |
2014 |
| Drug |
felodipine tablets (plendil)/lisinopril (zestril) |
1 |
2014 |
| Drug |
fenofibrate |
1 |
2009 |
| Drug |
fenoldopam |
1 |
2011 |
| Drug |
ferinject |
1 |
2011 |
| Drug |
ferinject/cosmofer |
1 |
2011 |
| Dietary Supplement |
fermented milk |
1 |
2016 |
| Drug |
fexofenadine, ranitidine |
1 |
2016 |
| Device |
fibroscan: liver |
1 |
2015 |
| Device |
fibroscan: liver/spleen elastography |
1 |
2015 |
| Procedure |
filtration surgery with ex-press |
1 |
2011 |
| Drug |
fimasartan (br-a-657•k) 180 mg |
1 |
2009 |
| Drug |
fimasartan (br-a-657•k) 20 mg |
1 |
2009 |
| Drug |
fimasartan (br-a-657•k) 60 mg |
1 |
2009 |
| placebo |
fimasartan , amlodipine, placebo |
1 |
2012 |
| Drug |
fimasartan / amlodipine |
1 |
2016 |
| Drug |
fimasartan / rosuvastatin |
1 |
2016 |
| Drug |
fimasartan 120 mg group |
1 |
2009 |
| Drug |
fimasartan 60 mg group |
1 |
2009 |
| Drug |
fimasartan 60mg |
1 |
2010 |
| Drug |
fimasartan, rosuvastatin |
1 |
2017 |
| Drug |
fimasartan/amlodipine combination |
1 |
2014 |
| Drug |
fimasartan/amlodipine, rosuvastatin |
1 |
2017 |
| Drug |
fimasartan/fimasartan/hydrochlorothiazide |
1 |
2017 |
| Drug |
fimasartan/hctz combination |
1 |
2010 |
| Drug |
fimasartan/rosuvastatin |
1 |
2014 |
| Drug |
fimasartan/rosuvastatin combination |
1 |
2014 |
| Drug |
fimasartan; hydrochlorothiazide |
1 |
2015 |
| Behavioral |
financial incentive (arms b |
1 |
2005 |
| Behavioral |
financial incentive (arms b/c)/health educator phone call (arm c) |
1 |
2005 |
| Behavioral |
financial incentive group i |
1 |
2011 |
| Behavioral |
financial incentive group ii |
1 |
2011 |
| Other |
first phase insulin secretion (fpir), hyperinsulinemic euglycemic clamp (hec), glucose tracer, |
1 |
2012 |
| Other |
first phase insulin secretion (fpir), hyperinsulinemic euglycemic clamp (hec), glucose tracer,/palmitate tracer |
1 |
2012 |
| Device |
fitbit charge hr |
1 |
2017 |
| Drug |
fixed-combination bimatoprost |
1 |
2013 |
| Drug |
fixed-combination bimatoprost/brimonidine |
1 |
2013 |
| Drug |
fixed-dose combination of telmisartan 40mg |
1 |
2008 |
| Drug |
fixed-dose combination of telmisartan 40mg/amlodipine 10mg |
1 |
2008 |
| Drug |
fixed-dose combination of telmisartan 80mg |
1 |
2008 |
| Drug |
fixed-dose combination of telmisartan 80mg/amlodipine10mg |
1 |
2008 |
| Drug |
fixed combination |
1 |
2016 |
| Drug |
fixed combination latanoprost-timolol |
1 |
2008 |
| Drug |
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% |
1 |
2008 |
| Drug |
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution |
1 |
2008 |
| Drug |
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution |
1 |
2010 |
| Drug |
fixed combination of timolol 0.5% |
1 |
2007 |
| Drug |
fixed combination of timolol 0.5%/dorzolamide 2%/travoprost vehicle |
1 |
2007 |
| Other |
fixed combination vehicle |
1 |
2010 |
| Drug |
fixed dose combination 1: 1 x 5mg amlodipine |
1 |
2012 |
| Drug |
fixed dose combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state |
1 |
2012 |
| Drug |
fixed dose combination 2: 1 x 5mg amlodipine |
1 |
2012 |
| Drug |
fixed dose combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state |
1 |
2012 |
| Drug |
fixed dose combination of tafluprost |
1 |
2011 |
| Drug |
fixed dose combination of tafluprost/timolol |
1 |
2011 |
| Drug |
fixed dose combination telmisartan 80 mg |
1 |
2005 |
| Drug |
fixed dose combination telmisartan 80 mg / hctz 12.5 mg |
1 |
2005 |
| Drug |
fixed dose combination telmisartan 80 mg / hctz 25 mg |
1 |
2005 |
| Drug |
fixed dose combination therapy |
1 |
2005 |
| Drug |
fk506 level < 2 ng |
1 |
2012 |
| Drug |
fk506 level < 2 ng/ml |
1 |
2012 |
| Drug |
fk506 level 2-3 ng |
1 |
2012 |
| Drug |
fk506 level 2-3 ng/ml |
1 |
2012 |
| Drug |
fk506 level 3-5 ng |
1 |
2012 |
| Drug |
fk506 level 3-5 ng/ml |
1 |
2012 |
| Other |
flavanol-rich dark chocolate |
1 |
2012 |
| Dietary Supplement |
flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) |
1 |
2018 |
| Behavioral |
flavonoid depleted chocolate drink |
1 |
2005 |
| Behavioral |
flavonoid rich |
1 |
2005 |
| Behavioral |
flavonoid rich/flavonoid depleted chocolate drink |
1 |
2005 |
| Dietary Supplement |
flaxseed |
1 |
2013 |
| Behavioral |
flexibility training |
1 |
2015 |
| Procedure |
flow mediated vasodilation |
1 |
2014 |
| Drug |
fludeoxyglucose |
1 |
2016 |
| Drug |
fluticasone propionate inhaler |
1 |
2014 |
| Drug |
fluvastatin |
1 |
2009 |
| Device |
focused ultrasound |
1 |
2012 |
| Drug |
folic acid tablets (yiye) |
1 |
2018 |
| Drug |
folic acid tablets(as the program-based antihypertension) |
1 |
2015 |
| Behavioral |
follow up post intervention 21 months |
1 |
2015 |
| Behavioral |
follow up post intervention 24 months |
1 |
2015 |
| Behavioral |
follow up post intervention 27 months |
1 |
2015 |
| Behavioral |
follow up post intervention 30 months |
1 |
2015 |
| Behavioral |
follow up post intervention 33 months |
1 |
2015 |
| Procedure |
food anamnesis |
1 |
2010 |
| Device |
foot reflexology |
1 |
2016 |
| Behavioral |
forced desynchrony |
1 |
2018 |
| Behavioral |
formal weight loss counselling program |
1 |
2009 |
| Dietary Supplement |
formula salt with very low sodium (brand name: manlikang) |
1 |
2017 |
| Drug |
formulation e1 of l-ppds |
1 |
2009 |
| Drug |
formulation e2 of l-ppds |
1 |
2009 |
| Drug |
fosinopril |
1 |
2011 |
| Other |
free |
1 |
2016 |
| Other |
free/convenient medicine access |
1 |
2016 |
| Dietary Supplement |
freeze-dried blueberry powder |
1 |
2012 |
| Procedure |
frequent blood pressure measurements |
1 |
2005 |
| Behavioral |
fresh start |
1 |
2015 |
| Behavioral |
fresh start framing |
1 |
2015 |
| Dietary Supplement |
fruit |
1 |
2017 |
| Dietary Supplement |
fruit/vegetable juice supplement |
1 |
2017 |
| Radiation |
ftha, fdg pet imaging. |
1 |
2012 |
| Behavioral |
full social interaction program) |
1 |
2013 |
| Other |
full support m.a.p. bp improvement program |
1 |
2019 |
| Drug |
fulvestrant |
1 |
2016 |
| Drug |
furosemide oral tablets |
1 |
2005 |
| Drug |
furosemide, |
1 |
2016 |
| Other |
gaba-rich cheese diet |
1 |
2016 |
| Drug |
ganfort |
1 |
2010 |
| Drug |
ganfortâ® |
1 |
2017 |
| Drug |
gastrodia |
1 |
2019 |
| Drug |
gastrodia/uncaria granule |
1 |
2019 |
| Drug |
gb002 |
1 |
2019 |
| Device |
ge logiq e9 ultrasound system |
1 |
2013 |
| Other |
gel-based artificial saliva |
1 |
2014 |
| Device |
generator |
1 |
2016 |
| Device |
generic dry powder inhaler |
1 |
2019 |
| Behavioral |
generic information |
1 |
2008 |
| Genetic |
genetic based analysis of identifying predictors of blood pressure in patients after renal denervation |
1 |
2020 |
| Drug |
geneticure panel for htn therapy |
1 |
2016 |
| Other |
genotyping |
1 |
2010 |
| Dietary Supplement |
ginseng |
1 |
2012 |
| Dietary Supplement |
gk#10 |
1 |
2012 |
| Other |
glass |
1 |
2014 |
| Drug |
glaucoma therapy |
1 |
2003 |
| Drug |
glibenclamide |
1 |
2013 |
| Other |
glow cap system - deactivated |
1 |
2009 |
| Other |
glowcaps connect system |
1 |
2009 |
| Drug |
glucagon-like peptide 1 |
1 |
2011 |
| Dietary Supplement |
glucose solution |
1 |
2008 |
| Device |
glucose/lipids |
1 |
2013 |
| Device |
glycosylated hemoglobin a1c |
1 |
2013 |
| Drug |
gm-csf |
1 |
2018 |
| Drug |
gnrh antagonist |
1 |
2018 |
| Drug |
gnrh antagonist / methyltestosterone 5 mg |
1 |
2018 |
| Behavioral |
goals |
1 |
2016 |
| Device |
goldbal detachable balloon |
1 |
2019 |
| Device |
goldbal detachable balloon/delivery microcatheter |
1 |
2019 |
| Device |
goldmann |
1 |
2010 |
| Device |
goldmann/perkins applanation tonometry |
1 |
2010 |
| Drug |
gr-md-02 |
1 |
2015 |
| Dietary Supplement |
grape seed extract |
1 |
2009 |
| Drug |
grape seed extract (meganatural bp, polyphenolics, inc.) |
1 |
2010 |
| Other |
graphic card |
1 |
2016 |
| Other |
green tea extract |
1 |
2010 |
| Behavioral |
groceries |
1 |
2016 |
| Behavioral |
groceries / brochure |
1 |
2016 |
| Other |
ground-based walking training |
1 |
2018 |
| Dietary Supplement |
group |
1 |
2018 |
| Drug |
group a: valsartan |
1 |
2013 |
| Drug |
group a: valsartan/chlorthalidone |
1 |
2013 |
| Drug |
group b: valsartan |
1 |
2013 |
| Drug |
group c: chlorthalidone |
1 |
2013 |
| Drug |
group i |
1 |
2017 |
| Drug |
group i (telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg) |
1 |
2017 |
| Drug |
group ii |
1 |
2017 |
| placebo |
group ii (telmisartan 80 mg, amodipine 10 mg, rosuvastatin placebo) |
1 |
2017 |
| placebo |
group iii (telmisartan 80 mg, amlodipine placebo, rosuvastatin 20 mg) |
1 |
2017 |
| Behavioral |
group medical visits |
1 |
2005 |
| Behavioral |
group treatment |
1 |
2011 |
| Behavioral |
group treatment/par |
1 |
2011 |
| Behavioral |
group visits |
1 |
2007 |
| Dietary Supplement |
group/arm c (control group) |
1 |
2018 |
| Dietary Supplement |
group/arm d (diet group) |
1 |
2018 |
| Dietary Supplement |
group/arm s (supplementation group) |
1 |
2018 |
| Drug |
gsk2586881 |
1 |
2017 |
| Drug |
gsk2944404 fdc |
1 |
2013 |
| Drug |
gsk3074477 fdc - 1 |
1 |
2014 |
| Drug |
gsk3074477 fdc - 2 |
1 |
2014 |
| Drug |
gsk3542503 (hctz 50mg |
1 |
2017 |
| Drug |
gsk3542503 (hctz 50mg/amiloride hcl 5mg tablets) |
1 |
2017 |
| Drug |
gsk587323 |
1 |
2014 |
| Procedure |
gss questionnaire |
1 |
2005 |
| Dietary Supplement |
gt |
1 |
2015 |
| Dietary Supplement |
gt/ex |
1 |
2015 |
| Behavioral |
guided breathing |
1 |
2006 |
| Behavioral |
guided imagery |
1 |
2006 |
| Other |
guideline link |
1 |
2006 |
| Other |
guideline link only |
1 |
2006 |
| Behavioral |
gut dysbiosis |
1 |
2019 |
| Drug |
h12.5 |
1 |
2011 |
| Device |
hans unit |
1 |
2007 |
| Dietary Supplement |
hawthorn |
1 |
2011 |
| Device |
hbpm |
1 |
2009 |
| Device |
hbpm/pharmaceutical care |
1 |
2009 |
| Drug |
hcp0605 |
1 |
2016 |
| Drug |
hcp1302 |
1 |
2015 |
| Drug |
hcp1401 |
1 |
2016 |
| Drug |
hcp1701 |
1 |
2019 |
| Drug |
hcp1803 |
1 |
2019 |
| Drug |
hct 25mg |
1 |
2008 |
| Drug |
hct 32 |
1 |
2007 |
| Drug |
hctz - phase 1 |
1 |
2009 |
| Drug |
hctz - phase 2 |
1 |
2009 |
| Drug |
hctz / amlodipine |
1 |
2007 |
| Drug |
hctz 12.5 mg tablet |
1 |
2014 |
| Drug |
hctz 25 mg |
1 |
2005 |
| Drug |
hctz 40 |
1 |
2007 |
| Drug |
hctz combination |
1 |
2010 |
| Drug |
hctz monotherapy |
1 |
2004 |
| Behavioral |
hctz prescription conversion to chlorthalidone |
1 |
2015 |
| Drug |
hctz with concomitant losartan |
1 |
2008 |
| Drug |
hctz with concomitant losartan/lisinopril |
1 |
2008 |
| Other |
head-up tilt. |
1 |
2005 |
| Behavioral |
health behavior education |
1 |
2005 |
| Behavioral |
health coach |
1 |
2013 |
| Behavioral |
health coaching/home titration |
1 |
2009 |
| Behavioral |
health education with support by trained female health volunteer |
1 |
2016 |
| Behavioral |
health educator phone call (arm c) |
1 |
2005 |
| Behavioral |
health insurance only |
1 |
2013 |
| Combination Product |
health it |
1 |
2017 |
| Combination Product |
health it/peer support intervention |
1 |
2017 |
| Behavioral |
health literacy-focused high blood pressure intervention |
1 |
2006 |
| Behavioral |
health literacy-focused self-help |
1 |
2011 |
| Behavioral |
health system: htn intervention |
1 |
2015 |
| Behavioral |
healthy behavior texts |
1 |
2018 |
| Drug |
healthy diet without active intervention. |
1 |
2012 |
| Behavioral |
healthy lifestyle |
1 |
2014 |
| Behavioral |
healthy lifestyle program |
1 |
2019 |
| Behavioral |
healthy lifestyle/adherence |
1 |
2014 |
| Behavioral |
healthy sleep habits |
1 |
2014 |
| Behavioral |
heart-rate controlled 12 week exercise program |
1 |
2006 |
| Procedure |
heart catheterization |
1 |
2004 |
| Behavioral |
heart health 4 new moms |
1 |
2018 |
| Behavioral |
heart health education |
1 |
2013 |
| Device |
heart rate |
1 |
2013 |
| Behavioral |
heat |
1 |
2015 |
| Behavioral |
heat/aerobic training (heat) |
1 |
2015 |
| Behavioral |
hei |
1 |
2006 |
| Drug |
heparin/rivaroxaban |
1 |
2019 |
| Other |
hepatic elastography |
1 |
2016 |
| Behavioral |
herbal therapy |
1 |
2005 |
| Behavioral |
herbal therapy/botanical therapy (hibiscus sabdariffa) |
1 |
2005 |
| Drug |
herbs |
1 |
2013 |
| Device |
herculink elite renal stent system |
1 |
2007 |
| Drug |
hgp0816 |
1 |
2016 |
| placebo |
hgp0816 placebo |
1 |
2016 |
| placebo |
hgp0904 placebo |
1 |
2016 |
| Drug |
hgp1206 |
1 |
2013 |
| Drug |
hgp1405 |
1 |
2014 |
| Behavioral |
high |
1 |
2011 |
| Other |
high-frequency pasive vibration |
1 |
2013 |
| Behavioral |
high-intensity interval training (hit) |
1 |
2018 |
| Dietary Supplement |
high-sodium diet |
1 |
2014 |
| Behavioral |
high blood pressure management education |
1 |
2018 |
| Dietary Supplement |
high dose fish oil |
1 |
2014 |
| Drug |
high dose of bibr 277 |
1 |
2014 |
| Drug |
high dose of cozaarâ® |
1 |
2014 |
| Drug |
high dose of cozaarâ® / lorzaarâ®, once daily |
1 |
2014 |
| Drug |
high dose of cozaarâ®, once daily |
1 |
2014 |
| Drug |
high dose of losartan |
1 |
2014 |
| Drug |
high dose of micardisâ® |
1 |
2014 |
| Dietary Supplement |
high dose olive oil |
1 |
2014 |
| Drug |
high dose ophthalmic solution |
1 |
2014 |
| Other |
high intensity intervention |
1 |
2008 |
| Dietary Supplement |
high phosphate phase |
1 |
2017 |
| Other |
high potassium diet |
1 |
2015 |
| Other |
high potassium meal |
1 |
2015 |
| Other |
high salt (nacl) intake |
1 |
2017 |
| Dietary Supplement |
high salt diets |
1 |
2009 |
| Behavioral |
high salt intake |
1 |
2012 |
| Other |
high sodium diet/low sodium diet |
1 |
2013 |
| Behavioral |
high/level 2 resource intensity |
1 |
2011 |
| Other |
hiit |
1 |
2017 |
| Device |
hip circumference |
1 |
2013 |
| Device |
hirrem |
1 |
2018 |
| Other |
hitcm |
1 |
2015 |
| Other |
hitcm-only |
1 |
2015 |
| Other |
hitcm/cp |
1 |
2015 |
| Drug |
hl-040xc |
1 |
2012 |
| Other |
hold |
1 |
2017 |
| Behavioral |
home blood pressure measurement |
1 |
2018 |
| Other |
home blood pressure monitor |
1 |
2009 |
| Other |
home blood pressure monitor group |
1 |
2010 |
| Device |
home blood pressure monitor without telemetry |
1 |
2011 |
| Diagnostic Test |
home blood pressure monitoring (hbpm) |
1 |
2017 |
| Device |
home blood pressure monitoring device (qardio arm) |
1 |
2020 |
| Behavioral |
home blood pressure self-monitoring |
1 |
2018 |
| Device |
home blood pressure tele-management system. |
1 |
2008 |
| Device |
home bp |
1 |
2018 |
| Behavioral |
home bp monitors |
1 |
2017 |
| Behavioral |
home bp;secure messaging;pharmaceutical care; |
1 |
2005 |
| Behavioral |
home health |
1 |
2010 |
| Behavioral |
home health/primary care collaboration |
1 |
2010 |
| Behavioral |
home self blood pressure monitoring |
1 |
2019 |
| Behavioral |
home titration |
1 |
2009 |
| Other |
homeopathy |
1 |
2014 |
| Other |
homoeopathic complex |
1 |
2015 |
| Behavioral |
hot yoga |
1 |
2018 |
| Drug |
hour |
1 |
2007 |
| Other |
hplc-ms |
1 |
2017 |
| Other |
hplc-ms/ms-guided intervention |
1 |
2017 |
| Drug |
hr |
1 |
2014 |
| Device |
hrv |
1 |
2018 |
| Device |
hrv/respiratory coherence biofeedback |
1 |
2018 |
| Behavioral |
hs dosing |
1 |
2007 |
| Other |
htn pra app |
1 |
2016 |
| Other |
hug |
1 |
2017 |
| Behavioral |
hula |
1 |
2013 |
| Behavioral |
hula/heart health education |
1 |
2013 |
| Drug |
human recombinant regular insulin infusion |
1 |
2014 |
| Procedure |
hvpg |
1 |
2015 |
| Procedure |
hvpg measurement baseline |
1 |
2015 |
| Procedure |
hvpg measurement day 28 |
1 |
2015 |
| Drug |
hydralazine if necessary to control blood pressure |
1 |
2008 |
| Drug |
hydrochlorothiazide (300 |
1 |
2010 |
| Drug |
hydrochlorothiazide (80mg |
1 |
2007 |
| Drug |
hydrochlorothiazide (hct) |
1 |
2008 |
| Drug |
hydrochlorothiazide (hctz) - combination arm |
1 |
2009 |
| Drug |
hydrochlorothiazide (hctz) - monotherapy |
1 |
2009 |
| Drug |
hydrochlorothiazide (hctz) (300 |
1 |
2008 |
| Drug |
hydrochlorothiazide (hctz) 20mg |
1 |
2007 |
| Drug |
hydrochlorothiazide (hctz)) |
1 |
2006 |
| Drug |
hydrochlorothiazide (hctz)/olmesartan |
1 |
2009 |
| Drug |
hydrochlorothiazide [hctz] |
1 |
2008 |
| Drug |
hydrochlorothiazide 25mg |
1 |
2014 |
| Drug |
hydrochlorothiazide 50 mg |
1 |
2019 |
| Drug |
hydrochlorothiazide 50mg tablet |
1 |
2017 |
| Drug |
hydrochlorothiazide combination drug) |
1 |
2008 |
| placebo |
hydrochlorothiazide placebo |
1 |
2017 |
| Drug |
hydrochlorothiazide(hctz) |
1 |
2007 |
| Drug |
hydrochlorothiazide) |
1 |
2010 |
| Drug |
hydrochlorothiazide, captopril, nitrendipine, aspirin |
1 |
2020 |
| Drug |
hydrochlorothiazide, if necessary. |
1 |
2010 |
| Drug |
hydrochlorothiazide/telmisartan |
1 |
2013 |
| Drug |
hydroclororthiazide |
1 |
2009 |
| Drug |
hydroclorothiazide |
1 |
2005 |
| Drug |
hydroxyurea |
1 |
2005 |
| Other |
hypercapnia test |
1 |
2016 |
| Other |
hyperlipidemia |
1 |
2015 |
| Other |
hyperoxia with dopamine |
1 |
2015 |
| Other |
hyperoxia without dopamine |
1 |
2015 |
| Behavioral |
hypertension alert |
1 |
2005 |
| Other |
hypertension management intervention |
1 |
2014 |
| Behavioral |
hypertension management model |
1 |
2020 |
| Other |
hypertensive disorder of pregnancy |
1 |
2012 |
| Other |
hyperventilation test |
1 |
2018 |
| Other |
hypoxia with dopamine |
1 |
2015 |
| Other |
hypoxia without dopamine |
1 |
2015 |
| Drug |
hyzaarâ® |
1 |
2012 |
| Drug |
i. fixed combination of latanoprost 0.005% |
1 |
2009 |
| Drug |
i. fixed combination of latanoprost 0.005%/timolol 0.5% |
1 |
2009 |
| Drug |
i.v. selexipag |
1 |
2017 |
| Drug |
î±1-adrenergic block |
1 |
2020 |
| Drug |
ibuprofen 600 mg |
1 |
2019 |
| Drug |
ibuprofen 600 mg tid |
1 |
2008 |
| Drug |
ibuprofen, brimonidine, latanoprost |
1 |
2006 |
| Drug |
ibuprofen, latanoprost, brimonidine |
1 |
2006 |
| Device |
icastâ„¢ rx stent system |
1 |
2012 |
| Behavioral |
identification |
1 |
2015 |
| Drug |
idn-6556 |
1 |
2014 |
| Drug |
if necessary, hydrochlorothiazide |
1 |
2010 |
| Drug |
ifetroban |
1 |
2016 |
| Device |
ihealth bp7-wireless blood pressure wrist monitor, |
1 |
2015 |
| Other |
ihg home training |
1 |
2017 |
| Drug |
ik-3001 |
1 |
2013 |
| Drug |
illoprost |
1 |
2016 |
| Drug |
illoprost/nitric oxide administration |
1 |
2016 |
| Drug |
iloprost (5 âµg) |
1 |
2008 |
| Drug |
iloprost (ventavis inhaled, bayq6256) |
1 |
2011 |
| Drug |
iloprost (ventavis) |
1 |
2009 |
| Drug |
iloprost inhalation |
1 |
2007 |
| Drug |
iloprost inhalation solution (ventavis) |
1 |
2005 |
| Drug |
iloprost nebuliser solusion |
1 |
2011 |
| Drug |
iloprost/placebo |
1 |
2004 |
| Drug |
imatinib |
1 |
2011 |
| Behavioral |
imb model-based initiation of antihypertensive medication |
1 |
2015 |
| Other |
immediate genetic testing |
1 |
2014 |
| Other |
impedance cardiography |
1 |
2012 |
| Device |
implantable loop recorder |
1 |
2013 |
| Device |
implantable loop recorder (medtronic reveal linq(tm)) |
1 |
2014 |
| Device |
implantation of the rheos system |
1 |
2010 |
| Behavioral |
improve clinic based measurement of blood pressure |
1 |
2012 |
| Behavioral |
improving outcomes using group clinics for older patients |
1 |
2007 |
| Drug |
in association with bosentan |
1 |
2012 |
| Drug |
in combination |
1 |
2008 |
| Drug |
in combination with hydrochlorothiazide |
1 |
2005 |
| Behavioral |
in home health messaging device |
1 |
2005 |
| Behavioral |
in person |
1 |
2010 |
| Procedure |
in vitro vascular responses |
1 |
1999 |
| Other |
incentive |
1 |
2008 |
| Other |
incentivized care |
1 |
2017 |
| Other |
increasing energy expenditure |
1 |
2015 |
| Other |
increasing energy expenditure/changing posture |
1 |
2015 |
| Drug |
indapamide (t2) |
1 |
2005 |
| Drug |
indapamide / losartan |
1 |
2012 |
| Drug |
indapamide/hydrochlorothiazide |
1 |
2013 |
| Other |
index test: functional dynamic contrast enhanced (dce)-mri |
1 |
2016 |
| Other |
individual treatment |
1 |
2013 |
| Procedure |
individualized bp lowering |
1 |
2016 |
| Behavioral |
individualized ic treatment |
1 |
2008 |
| Drug |
indocyanine green retention test |
1 |
2015 |
| Drug |
indomethacin |
1 |
2011 |
| Biological |
infliximab |
1 |
2016 |
| Behavioral |
information |
1 |
2014 |
| Behavioral |
information on high risk factor levels |
1 |
2014 |
| Behavioral |
information on high risk factor levels/lifestyle advice |
1 |
2014 |
| Other |
information pamphlet |
1 |
2015 |
| Behavioral |
information/screening group |
1 |
2014 |
| Other |
informational guide for patients |
1 |
2010 |
| Other |
informational intervention |
1 |
2013 |
| Behavioral |
informational sms-text |
1 |
2013 |
| Drug |
inhaled dry powder treprostinil (liq861) |
1 |
2019 |
| Drug |
inhaled milrinone |
1 |
2012 |
| Drug |
inhaled milrinone 5 mg |
1 |
2012 |
| Drug |
inhaled nitric oxide - 30 mcg |
1 |
2014 |
| Drug |
inhaled nitric oxide - 30 mcg/kg ibw/hr |
1 |
2014 |
| Drug |
inhaled nitric oxide (ino) administration |
1 |
2012 |
| Drug |
inhaled nitric oxide 5,10,15 mcg |
1 |
2014 |
| Drug |
inhaled nitric oxide 5,10,15 mcg/kg ibw/hr |
1 |
2014 |
| Drug |
inhaled nitric oxide 75 mcg |
1 |
2014 |
| Drug |
inhaled nitric oxide 75 mcg/kg ibw/hr |
1 |
2014 |
| Drug |
inhaled nitrite |
1 |
2011 |
| Drug |
inhaled no |
1 |
2012 |
| Drug |
inhaled treprostinil therapy |
1 |
2012 |
| Diagnostic Test |
injected abdominal ct |
1 |
2016 |
| Drug |
ino-8875 |
1 |
2010 |
| Device |
ino pulse - no delivery system |
1 |
2001 |
| Drug |
ino pulse delivery |
1 |
2006 |
| Combination Product |
inopulse |
1 |
2017 |
| Drug |
inp pulse delivery |
1 |
2006 |
| Drug |
ins115644 ophthalmic solution |
1 |
2007 |
| Device |
inspiratory muscle training device |
1 |
2019 |
| Other |
instrumental folk music |
1 |
2017 |
| Device |
integrated hemodynamic management (ihm) - hotman system |
1 |
2011 |
| Drug |
intensified blood pressure control |
1 |
2005 |
| Drug |
intensified thiazide treatment group |
1 |
2017 |
| Other |
intensive 10-week blood pressure screening |
1 |
2006 |
| Other |
intensive blood pressure (bp) lowering |
1 |
2011 |
| Other |
intensive bp arm |
1 |
2013 |
| Other |
intensive care |
1 |
2013 |
| Other |
intensive control |
1 |
2011 |
| Drug |
intensive control of sbp |
1 |
2010 |
| Drug |
intensive control of systolic blood pressure (sbp) |
1 |
2019 |
| Behavioral |
intensive diabetes self-management education |
1 |
2010 |
| Behavioral |
intensive education of low salt diet |
1 |
2012 |
| Drug |
intensive treatment |
1 |
2017 |
| Behavioral |
interactive sms-text |
1 |
2013 |
| Other |
interactive spaced education (ise) — online education |
1 |
2009 |
| Behavioral |
interactive voice response (ivr) automated calls |
1 |
2011 |
| Other |
intermittent hypoxia |
1 |
2011 |
| Behavioral |
internet-based positive psychological intervention |
1 |
2019 |
| Other |
internet-enabled automated self-management program |
1 |
2008 |
| Procedure |
internet access alone |
1 |
2005 |
| Other |
internet survey |
1 |
2012 |
| Behavioral |
intervention-edi |
1 |
2019 |
| Behavioral |
intervention-edi/health coaching |
1 |
2019 |
| Other |
intervention care |
1 |
2009 |
| Procedure |
intervention is blood pressure management approach |
1 |
2010 |
| Procedure |
intervention is blood pressure management approach. |
1 |
2010 |
| Behavioral |
intervention on dcp3 based strategies for hypertension management |
1 |
2020 |
| Behavioral |
intervention on dcp3 based strategies for hypertension management/control |
1 |
2020 |
| Behavioral |
intervention with home bp telemonitoring |
1 |
2005 |
| Behavioral |
intervention with no dietary component - information regarding useful life skills |
1 |
2008 |
| Other |
intradialytic blood pressure slope based ultrafiltration |
1 |
2017 |
| Drug |
intralipid 20% @ 20cc |
1 |
2007 |
| Drug |
intralipid 20% @ 20cc/hour |
1 |
2007 |
| Drug |
intralipid 20%@ 40cc |
1 |
2007 |
| Drug |
intralipid 20%@ 40cc/hour |
1 |
2007 |
| Drug |
intravenous |
1 |
2018 |
| Drug |
intravenous administration of ferric carboxymaltose |
1 |
2013 |
| Drug |
intravenous immunoglobulin |
1 |
2018 |
| Drug |
intravenous levophed |
1 |
2005 |
| Drug |
intravenous magnesium sulfate |
1 |
2020 |
| Drug |
intravenous milrinone |
1 |
2012 |
| Drug |
intravenous nesiritide |
1 |
2005 |
| Drug |
intravenous phenylephrine |
1 |
2005 |
| Drug |
intravenous saline |
1 |
2005 |
| Drug |
intravenous treprostinil |
1 |
2017 |
| Drug |
intravenous/subcutaneous treprostinil; oral treprostinil |
1 |
2018 |
| Behavioral |
intrinsic motivation |
1 |
2011 |
| Behavioral |
introduce care management system in clinics |
1 |
2012 |
| Drug |
inv-144 |
1 |
2011 |
| Diagnostic Test |
invasive blood pressure assessment by radial artery canulation |
1 |
2020 |
| Procedure |
investigate the relationship between in vivo |
1 |
1999 |
| Procedure |
investigate the relationship between in vivo/in vitro vascular responses |
1 |
1999 |
| Procedure |
iop |
1 |
2005 |
| Drug |
iop lowering medications |
1 |
2002 |
| Device |
iphone 4s |
1 |
2015 |
| Drug |
irbesartan-hydrochlorothiazide |
1 |
2005 |
| placebo |
irbesartan-matching placebo |
1 |
2019 |
| Drug |
irbesartan - hydrochlorothiazide |
1 |
2008 |
| Drug |
irbesartan (sr47436) |
1 |
2009 |
| Drug |
irbesartan / amlodipine |
1 |
2009 |
| Drug |
irbesartan 150mg |
1 |
2009 |
| Drug |
irbesartan 150mg / hydrochlorothiazide 12.5mg |
1 |
2009 |
| Drug |
irbesartan sr47436 |
1 |
2016 |
| Drug |
irbesartan, amlodipine |
1 |
2005 |
| Drug |
irbesartan, amlodipine/hydrochlorothiazide |
1 |
2005 |
| Drug |
irbesartan/amlodipine (150/10mg) |
1 |
2012 |
| Drug |
irbesartan/amlodipine (150/5mg) |
1 |
2012 |
| Drug |
irbesartan/amlodipine (300/10mg) |
1 |
2012 |
| Drug |
irbesartan/amlodipine (300/5mg) |
1 |
2012 |
| Drug |
irbesartan/atorvastatin a |
1 |
2011 |
| Drug |
irbesartan/atorvastatin b |
1 |
2011 |
| Drug |
irbesartan/atorvastatin fixed dose combination |
1 |
2016 |
| Drug |
irbesartan/irbesartan-hydrochlorothiazide |
1 |
2005 |
| Drug |
iron sucrose |
1 |
2009 |
| Dietary Supplement |
iron supplement |
1 |
2011 |
| Drug |
ismn |
1 |
2009 |
| Drug |
isoflurane |
1 |
2009 |
| Dietary Supplement |
isomaltulose |
1 |
2019 |
| Other |
isometric handgrip exercise |
1 |
2019 |
| Other |
isometric of the lower limbs |
1 |
2019 |
| Drug |
isosorbide mononitrate (ismn) |
1 |
2009 |
| placebo |
isotonic sodium chloride solution 0.9 % (placebo) |
1 |
2009 |
| Drug |
istalol |
1 |
2008 |
| Drug |
istalol/optive |
1 |
2008 |
| Device |
istent |
1 |
2011 |
| Behavioral |
itec |
1 |
2018 |
| Other |
its treatment |
1 |
2013 |
| Drug |
iv remodulin |
1 |
2013 |
| Drug |
iv sildenafil |
1 |
2012 |
| Drug |
iw-1973 |
1 |
2016 |
| Drug |
iw-1973 oral tablet |
1 |
2017 |
| Behavioral |
iyengar yoga |
1 |
2006 |
| Drug |
jnc-8 |
1 |
2016 |
| Behavioral |
jnc guideline training |
1 |
2014 |
| Drug |
kaleorid, 750mg (trade name), potassium chloride (active substance) |
1 |
2015 |
| Drug |
kar5585 capsules |
1 |
2016 |
| Drug |
kbp-5074 |
1 |
2018 |
| Device |
kci abthera |
1 |
2011 |
| Drug |
kg |
1 |
2007 |
| Drug |
kg ibw |
1 |
2014 |
| Other |
kiwi fruits |
1 |
2009 |
| Behavioral |
knowledge of cardiovascular risk assessment |
1 |
2008 |
| Device |
kona externally focused ultrasound therapy |
1 |
2012 |
| Dietary Supplement |
korean red ginseng (panax ginseng) |
1 |
2008 |
| Drug |
korean red ginseng capsules |
1 |
2013 |
| Dietary Supplement |
korean traditional diets |
1 |
2012 |
| Drug |
krytantek oftenoâ® |
1 |
2017 |
| Other |
l |
1 |
2011 |
| Drug |
l-ascorbate |
1 |
2016 |
| Dietary Supplement |
l-citrulline supplementation |
1 |
2014 |
| Drug |
l-glutamine |
1 |
2010 |
| Dietary Supplement |
l-gsh |
1 |
2013 |
| Drug |
l-nmma |
1 |
2010 |
| Other |
l to 136 mmol |
1 |
2011 |
| Drug |
l50 |
1 |
2011 |
| Drug |
l50/h12.5 |
1 |
2011 |
| Drug |
l50/h12.5/a5 |
1 |
2011 |
| Drug |
l606 (liposomal treprostinil) inhalation solution 51ug |
1 |
2019 |
| Device |
l606 inhalation system |
1 |
2019 |
| Drug |
lacidipine 4 |
1 |
2006 |
| Drug |
lacidipine 4/6 mg (oral) |
1 |
2006 |
| Drug |
lacidipine/amlodipine |
1 |
2007 |
| Dietary Supplement |
lactobacillus paracasei dietary supplement |
1 |
2019 |
| Drug |
lactulose |
1 |
2000 |
| Procedure |
laparoscopic roux-en-y gastric bypass (lrygb) |
1 |
2013 |
| Procedure |
laparoscopic splenectomy/azygoportal disconnection with intraoperative endoscopic variceal ligation |
1 |
2020 |
| Procedure |
laparoscopic splenectomy/pericardial devascularization |
1 |
2018 |
| Procedure |
laparoscopic surgical procedure |
1 |
2014 |
| Other |
lark htn pro |
1 |
2017 |
| Procedure |
laser doppler imaging |
1 |
2005 |
| Other |
laser trabeculoplasty |
1 |
2009 |
| Drug |
lasix 25 |
1 |
2007 |
| Drug |
latanoprost (0.005%) |
1 |
2003 |
| Drug |
latanoprost (0.005%)/timolol (0.5%) |
1 |
2003 |
| Drug |
latanoprost 0.0025% qd |
1 |
2016 |
| Drug |
latanoprost 0.005% (xalatan) |
1 |
2005 |
| Drug |
latanoprost 0.005% / timolol 0,5% fixed combination |
1 |
2008 |
| Drug |
latanoprost 0.005% / timolol 0.5% |
1 |
2009 |
| Drug |
latanoprost 0.005% / timolol 0.5% fixed combination |
1 |
2005 |
| Drug |
latanoprost 0.005% eyedrops |
1 |
2010 |
| Drug |
latanoprost 0.005% qd |
1 |
2016 |
| Drug |
latanoprost 0.005%/timolol 0.005% ophthalmic solution |
1 |
2006 |
| Drug |
latanoprost 0.02% |
1 |
2017 |
| Drug |
latanoprost 100 ug |
1 |
2011 |
| Drug |
latanoprost 125 ug |
1 |
2011 |
| Drug |
latanoprost 50 micrograms |
1 |
2009 |
| Drug |
latanoprost 50 micrograms/ml eye drop solution |
1 |
2009 |
| Drug |
latanoprost 50 ug |
1 |
2011 |
| Drug |
latanoprost 75 ug |
1 |
2011 |
| Drug |
latanoprost ophthalmic solution, 0.005% |
1 |
2008 |
| Drug |
latanoprost punctal plug |
1 |
2009 |
| Drug |
latanoprost punctal plug delivery system |
1 |
2009 |
| Drug |
latanoprost punctal plug delivery system (l-ppds) |
1 |
2013 |
| Drug |
latanoprost, 0.005% (xalatan) |
1 |
2006 |
| Drug |
latanoprost/timolol fixed combination |
1 |
2006 |
| Drug |
latanoprostene bunod |
1 |
2013 |
| Drug |
latanoprostene bunod 0.024% qd |
1 |
2019 |
| Behavioral |
lay health advisor |
1 |
2018 |
| placebo |
lcz696 matching placebo |
1 |
2012 |
| Device |
led bed |
1 |
2019 |
| Device |
lepu renal denervation system |
1 |
2015 |
| placebo |
lercanidipin 10mg placebo |
1 |
2013 |
| Drug |
lercanidipine / enalapril |
1 |
2010 |
| Drug |
lercanidipine / valsartan |
1 |
2010 |
| Drug |
lercanidipine 10mg |
1 |
2013 |
| Drug |
lercanidipine 10mg /valsartan 160mg |
1 |
2013 |
| Drug |
lercanidipine 10mg /valsartan 160mg placebo |
1 |
2013 |
| Drug |
lercanidipine/valsartan |
1 |
2010 |
| Drug |
lercanidipine10mg |
1 |
2013 |
| Drug |
lercanidipine10mg /valsartan 80mg |
1 |
2013 |
| Drug |
lercanidipine10mg /valsartan 80mg placebo |
1 |
2013 |
| Behavioral |
less intensive chw intervention |
1 |
2017 |
| Procedure |
leukocyte activation profile |
1 |
1999 |
| Drug |
levamlodipine besylate |
1 |
2010 |
| Drug |
levamlodipine malate tablets |
1 |
2018 |
| Behavioral |
level 1 resource intensity |
1 |
2011 |
| Behavioral |
level 2 resource intensity |
1 |
2011 |
| Drug |
levobetaxolol eye drops |
1 |
2015 |
| Drug |
levobupivacaine |
1 |
2015 |
| Drug |
levosimendan |
1 |
2018 |
| Drug |
levosimendan 2.5 mg |
1 |
2018 |
| Drug |
levosimendan 2.5 mg/ml injectable solution |
1 |
2018 |
| Drug |
lhw090 |
1 |
2015 |
| Drug |
lidocaine hydrochloride |
1 |
2018 |
| Behavioral |
life style modification |
1 |
2015 |
| Behavioral |
lifeskills workshop intervention |
1 |
2010 |
| Behavioral |
lifestyle advice |
1 |
2014 |
| Behavioral |
lifestyle changes |
1 |
2014 |
| Behavioral |
lifestyle counseling |
1 |
2013 |
| Behavioral |
lifestyle education (le) |
1 |
2011 |
| Behavioral |
lifestyle intervention |
1 |
2015 |
| Behavioral |
lifestyle interventions to lower blood pressure for patients |
1 |
2005 |
| Other |
lifestyle modification |
1 |
2013 |
| Drug |
linagliptin |
1 |
2015 |
| Drug |
linagliptin) |
1 |
2018 |
| Drug |
linagliptin) x 7days |
1 |
2017 |
| Device |
lipids |
1 |
2013 |
| Drug |
lipoic acid |
1 |
2013 |
| Drug |
lipoic acid/omega-3 fatty acids |
1 |
2013 |
| Drug |
liraglutide/placebo |
1 |
2014 |
| Drug |
lisinopril (free combination) |
1 |
2010 |
| Drug |
lisinopril (zestril) |
1 |
2014 |
| Drug |
lisinopril / placebo |
1 |
2008 |
| Drug |
lisinopril 20 mg |
1 |
2015 |
| Drug |
lisinopril 40 mg tablet (eon labs manufacturing inc, usa) |
1 |
2009 |
| Drug |
lisinopril 40 mg tablet (zestril) (zeneca, usa) |
1 |
2009 |
| Drug |
lisinopril 40 mg tablet (zestril) under fed conditions. |
1 |
2009 |
| Drug |
lisinopril 40 mg tablet under fasting conditions. |
1 |
2009 |
| Drug |
lisinopril 40 mg tablet under fed conditions. |
1 |
2009 |
| Drug |
lisinopril monotherapy |
1 |
2010 |
| Drug |
lisinopril, ace-inhibitor |
1 |
2014 |
| Other |
listen music |
1 |
2011 |
| Diagnostic Test |
liver ct |
1 |
2019 |
| Device |
liver stiffness measurement |
1 |
2015 |
| Drug |
lloprost(ventavis,bayq6252, 10 âµg |
1 |
2014 |
| Drug |
lloprost(ventavis,bayq6252, 10 âµg/ml) |
1 |
2014 |
| Drug |
lloprost(ventavis,bayq6252, 20 âµg |
1 |
2014 |
| Drug |
lloprost(ventavis,bayq6252, 20 âµg/ml) |
1 |
2014 |
| Procedure |
lma |
1 |
2012 |
| Drug |
lmwh |
1 |
2019 |
| Other |
loaded breathing training |
1 |
2014 |
| Other |
local heat stress |
1 |
2005 |
| Behavioral |
location-based tailored messaging |
1 |
2017 |
| Drug |
long acting octreotide 10mg |
1 |
2010 |
| Drug |
long acting octreotide 30mg |
1 |
2010 |
| Procedure |
long term oxygen therapy |
1 |
2013 |
| Drug |
lorzaarâ®, once daily |
1 |
2014 |
| Drug |
losartan-potassium |
1 |
2006 |
| Drug |
losartan ( |
1 |
2011 |
| Drug |
losartan (/) amlodipine |
1 |
2011 |
| Drug |
losartan (control) |
1 |
2009 |
| Drug |
losartan / duration of treatment: 6 weeks |
1 |
2006 |
| Drug |
losartan / hydrochlorothiazide |
1 |
2014 |
| Drug |
losartan / hydrochlorothiazide, if necessary |
1 |
2008 |
| Drug |
losartan 100 mg |
1 |
2005 |
| Drug |
losartan 100mg |
1 |
2014 |
| Drug |
losartan 100mg/amlodipine 5mg |
1 |
2014 |
| Drug |
losartan 100mg/hydrochlorothiazide 25mg |
1 |
2014 |
| Drug |
losartan 50 |
1 |
2005 |
| Drug |
losartan 50 mg / hctz 12.5 mg |
1 |
2011 |
| Drug |
losartan 50 mg/hydrochlorothiazide 12.5 mg |
1 |
2005 |
| Drug |
losartan 50/100 mg |
1 |
2005 |
| Drug |
losartan 50/100 mg placebo |
1 |
2005 |
| Drug |
losartan 50mg |
1 |
2014 |
| Drug |
losartan 50mg/amlodipine 5mg |
1 |
2014 |
| Drug |
losartan 50mg/hydrochlorothiazide 12.5mg |
1 |
2014 |
| Drug |
losartan potassium (/ hydrochlorothiazide [hctz] / calcium channel blocker [ccb]) |
1 |
2008 |
| Drug |
losartan potassium (/) hydrochlorothiazide (hctz) |
1 |
2009 |
| Drug |
losartan potassium / hydrochlorothiazide |
1 |
2010 |
| Drug |
losartan potassium / hydrochlorothiazide / amlodipine besylate (mk-0954e) |
1 |
2011 |
| Drug |
losartan potassium hydrochlorothiazide |
1 |
2010 |
| Drug |
losartan, hctz followed by valsartan, amlodipine, hctz |
1 |
2009 |
| Drug |
losartan/amlodipine/hydrochlorothiazide |
1 |
2018 |
| Drug |
losartan/amlodipine/losartan/hydrochlorothiazide |
1 |
2007 |
| Drug |
lotrel (amlodipine |
1 |
2005 |
| Drug |
lotrel (amlodipine/benazepril) |
1 |
2005 |
| Dietary Supplement |
low |
1 |
2009 |
| Drug |
low-dose rtpa |
1 |
2011 |
| Other |
low-frequency passive vibration |
1 |
2013 |
| Behavioral |
low-salt bangladeshi educational programme |
1 |
2008 |
| Behavioral |
low-salt educational programme |
1 |
2008 |
| Dietary Supplement |
low-sodium diet |
1 |
2014 |
| Dietary Supplement |
low-sodium diet with low-sodium bread |
1 |
2017 |
| Dietary Supplement |
low-sodium diet with standard bread |
1 |
2017 |
| Other |
low-sodium, high-potassium salt |
1 |
2013 |
| Dietary Supplement |
low dose fish oil |
1 |
2014 |
| Drug |
low dose of bibr 277 |
1 |
2014 |
| Drug |
low dose of cozaarâ® |
1 |
2014 |
| Drug |
low dose of cozaarâ® / lorzaarâ®, once daily |
1 |
2014 |
| Drug |
low dose of cozaarâ®, once daily |
1 |
2014 |
| Drug |
low dose of losartan |
1 |
2014 |
| Drug |
low dose of micardisâ® |
1 |
2014 |
| Dietary Supplement |
low dose olive oil |
1 |
2014 |
| Drug |
low dose spironolactone |
1 |
2015 |
| Drug |
low dose thiazide type drug |
1 |
2007 |
| Other |
low intensity intervention |
1 |
2008 |
| Dietary Supplement |
low phosphate phase |
1 |
2017 |
| Other |
low polyphenol cocoa extract |
1 |
2010 |
| Other |
low potassium meal |
1 |
2015 |
| Behavioral |
low resource |
1 |
2011 |
| Behavioral |
low salt diet |
1 |
2008 |
| Dietary Supplement |
low sodium salt |
1 |
2013 |
| Dietary Supplement |
low/high salt diets |
1 |
2009 |
| Procedure |
lower body negative pressure |
1 |
2011 |
| Other |
lower body negative pressure (lbnp) |
1 |
2012 |
| Behavioral |
lower leg heat therapy |
1 |
2019 |
| Behavioral |
lowering salt in diet |
1 |
2012 |
| Drug |
lumigan |
1 |
2020 |
| Drug |
lumigan 0.01% |
1 |
2013 |
| Drug |
lumigan 0.03% unit dose |
1 |
2013 |
| Diagnostic Test |
lung ultrasound |
1 |
2019 |
| Drug |
lx7101 (0.125%) |
1 |
2012 |
| Drug |
lx7101 (0.25%) |
1 |
2012 |
| Drug |
lx7101 vehicle |
1 |
2012 |
| Drug |
ly2623091 |
1 |
2014 |
| Device |
macintosh laryngoscopy |
1 |
2017 |
| Drug |
macitentan (act-064992) |
1 |
2008 |
| Drug |
macitentan 10mg |
1 |
2015 |
| Behavioral |
mad dash |
1 |
2016 |
| Dietary Supplement |
magnesium |
1 |
2010 |
| Dietary Supplement |
magnesium chloride |
1 |
2008 |
| Drug |
magnesium l-lactate |
1 |
2006 |
| Drug |
magnesium sulphate |
1 |
2018 |
| Device |
magnetic field generator |
1 |
2008 |
| Device |
magnetic field treatment |
1 |
2018 |
| Radiation |
magnetic resonance imaging |
1 |
2017 |
| Procedure |
magnetic resonance imaging (mri) |
1 |
2010 |
| Device |
magnetic resonance imaging (mri) with exercise |
1 |
2018 |
| Other |
maintaining posture |
1 |
2015 |
| Other |
maintaining posture/energy expenditure |
1 |
2015 |
| Dietary Supplement |
maltodextrin |
1 |
2013 |
| Dietary Supplement |
mana-juice |
1 |
2012 |
| Other |
management |
1 |
2019 |
| Other |
management recommendations |
1 |
2011 |
| Drug |
manidipine 10 mg |
1 |
2008 |
| Drug |
manidipine 10 mg / delapril 30 mg |
1 |
2008 |
| Drug |
manidipine 20 mg |
1 |
2008 |
| Drug |
manp |
1 |
2018 |
| Other |
mantra chikitsa |
1 |
2018 |
| Other |
map goal 102-107 mm hg |
1 |
2020 |
| Other |
map goal less than |
1 |
2020 |
| Other |
map goal less than/equal to 92 mm hg |
1 |
2020 |
| Dietary Supplement |
marealis refined peptide concentrate |
1 |
2012 |
| placebo |
matched placebo capsule for over-encapsulated amlodipine besylate tablet |
1 |
2014 |
| placebo |
matched placebo capsule for over-encapsulated celecoxib capsule |
1 |
2014 |
| placebo |
matched placebo for oe amlodipine besylate tablet |
1 |
2016 |
| placebo |
matched placebo for oe celecoxib capsule |
1 |
2016 |
| placebo |
matching placebo to aliskiren |
1 |
2010 |
| placebo |
matching placebo to ramipril |
1 |
2010 |
| Other |
maximum exercise tests |
1 |
2016 |
| Behavioral |
mb-bp |
1 |
2019 |
| Behavioral |
mb-bp intervention |
1 |
2017 |
| Behavioral |
md cqi-type intervention |
1 |
2005 |
| Device |
mdt-2211 renal denervation system |
1 |
2012 |
| Other |
measure of endothelial function |
1 |
2016 |
| Other |
measurement of arterial pressure |
1 |
2013 |
| Behavioral |
measures vs. standard care |
1 |
2006 |
| Behavioral |
medical adherence education |
1 |
2019 |
| Behavioral |
medical education |
1 |
2005 |
| Drug |
medical management |
1 |
2011 |
| Behavioral |
medical practice improvement |
1 |
2006 |
| Drug |
medical therapy |
1 |
2013 |
| Behavioral |
medication adherence partner |
1 |
2013 |
| Other |
medication optimization intervention |
1 |
2018 |
| Behavioral |
medication therapy management |
1 |
2013 |
| Other |
medisafe |
1 |
2016 |
| Other |
meditation |
1 |
2019 |
| Other |
mediterranean diet |
1 |
2014 |
| Behavioral |
medium |
1 |
2011 |
| Drug |
medium dose of bibr 277 |
1 |
2014 |
| Drug |
medium dose of micardisâ® |
1 |
2014 |
| Behavioral |
medium/level 1 resource intensity |
1 |
2011 |
| Device |
medsignals pillbox |
1 |
2010 |
| Device |
medtronic multi-electrode radiofrequency (rf) renal denervation system |
1 |
2012 |
| Behavioral |
mental health |
1 |
2015 |
| Drug |
menthol |
1 |
2011 |
| Drug |
mepivacaine |
1 |
2017 |
| Drug |
mesenchymal stem cell |
1 |
2014 |
| Procedure |
mesenchymal stem cell delivery with stent placement |
1 |
2014 |
| Drug |
mesna |
1 |
2018 |
| Drug |
metformin pill |
1 |
2017 |
| Device |
methacetin (with breath testing device) |
1 |
2013 |
| Device |
methacetin breath test |
1 |
2014 |
| Drug |
methyltestosterone 5 mg |
1 |
2018 |
| Drug |
metoprolol er |
1 |
2008 |
| Drug |
metoprolol er (tm) |
1 |
2008 |
| Drug |
metoprolol succinate prolonged-release tablet |
1 |
2009 |
| Drug |
metoprolol succinate prolonged-release tablet/felodipine |
1 |
2009 |
| Drug |
metoprolol succinate sustained-release tablet |
1 |
2015 |
| Drug |
metoprolol succinate/nebivolol |
1 |
2009 |
| Drug |
metoprolol tablet (betaloc zok) |
1 |
2014 |
| Drug |
metoprolol tartrate 50 mg |
1 |
2010 |
| Drug |
metoprolol xl |
1 |
2010 |
| Drug |
metoprolol xl 25 mg |
1 |
2009 |
| Drug |
metoprolol xl 25 mg / amlodipine 2.5mg |
1 |
2009 |
| Drug |
metoprolol xl 50mg |
1 |
2009 |
| Drug |
metoprolol xl 50mg / amlodipine 5mg |
1 |
2009 |
| Behavioral |
mglide |
1 |
2018 |
| Drug |
mgv354 ophthalmic suspension |
1 |
2016 |
| placebo |
mgv354 placebo |
1 |
2016 |
| Behavioral |
mhealth |
1 |
2013 |
| Other |
mi-bp |
1 |
2016 |
| Drug |
micardis |
1 |
2007 |
| Drug |
micardis 80 mg |
1 |
2007 |
| Drug |
micardis/80/12.5 |
1 |
2007 |
| Behavioral |
microclinic behavioral health basic program (education-only in classroom setting; no structured social interactions) |
1 |
2013 |
| Behavioral |
microclinic behavioral health full program (education curriculum in classroom setting, |
1 |
2013 |
| Behavioral |
microclinic behavioral health full program (education curriculum in classroom setting,/full social interaction program) |
1 |
2013 |
| Dietary Supplement |
microcrystalline cellulose |
1 |
2012 |
| placebo |
microcrystalline cellulose (placebo) |
1 |
2009 |
| Other |
microparticles |
1 |
2016 |
| Drug |
middle dose ophthalmic solution |
1 |
2014 |
| Other |
milk diet |
1 |
2016 |
| Dietary Supplement |
milk peptides |
1 |
2009 |
| Dietary Supplement |
milk peptides/plant sterols |
1 |
2009 |
| Behavioral |
million hearts abcs 12 months |
1 |
2015 |
| Behavioral |
million hearts abcs 15 months |
1 |
2015 |
| Behavioral |
million hearts abcs 6 months |
1 |
2015 |
| Behavioral |
million hearts abcs 9 months |
1 |
2015 |
| Behavioral |
mindful breathing (mb) intervention |
1 |
2010 |
| Behavioral |
mindfulness |
1 |
2018 |
| Behavioral |
mindfulness-based coaching |
1 |
2019 |
| Behavioral |
mindfulness based stress reduction (mbsr) therapy |
1 |
2009 |
| Behavioral |
mindfulness training |
1 |
2018 |
| Behavioral |
mindfulness/dash diet education |
1 |
2018 |
| Behavioral |
minding goals |
1 |
2016 |
| Dietary Supplement |
mineral supplements |
1 |
1999 |
| Drug |
minocycline |
1 |
2014 |
| Drug |
minocycline 100mg group |
1 |
2014 |
| Drug |
minocycline 200mg group |
1 |
2014 |
| Behavioral |
mint |
1 |
2010 |
| Behavioral |
mint-tlc |
1 |
2010 |
| Procedure |
missing one dose |
1 |
2006 |
| Other |
mixed meal test (mmt) |
1 |
2014 |
| Drug |
mk-3614 |
1 |
2010 |
| Drug |
mk-4618 |
1 |
2011 |
| Drug |
mk-5478 |
1 |
2009 |
| Drug |
mk-7145 |
1 |
2011 |
| Drug |
mk-8150 |
1 |
2012 |
| Drug |
mk-8150 10 mg |
1 |
2012 |
| Drug |
mk-8150 100 mg |
1 |
2012 |
| Drug |
mk-8150 120 mg |
1 |
2012 |
| Drug |
mk-8150 1200 mg |
1 |
2012 |
| Drug |
mk-8150 160 mg |
1 |
2012 |
| Drug |
mk-8150 2.0 mg |
1 |
2012 |
| Drug |
mk-8150 20 mg |
1 |
2012 |
| Drug |
mk-8150 200 mg |
1 |
2012 |
| Drug |
mk-8150 320 mg |
1 |
2012 |
| Drug |
mk-8150 40 mg |
1 |
2012 |
| Drug |
mk-8150 400 mg |
1 |
2012 |
| Drug |
mk-8150 5.0 mg |
1 |
2012 |
| Drug |
mk-8150 50 mg |
1 |
2012 |
| Drug |
mk-8150 500 mg |
1 |
2012 |
| Drug |
mk-8150 60 mg |
1 |
2012 |
| Drug |
mk-8150 600 mg |
1 |
2012 |
| Drug |
mk-8150 90 mg |
1 |
2012 |
| Drug |
mk-8150 900 mg |
1 |
2012 |
| Drug |
mk-8226 bid, 1 mg |
1 |
2010 |
| Drug |
mk-8266 |
1 |
2010 |
| Drug |
mk-8266 0.1 mg |
1 |
2009 |
| Drug |
mk-8266 1.0 mg |
1 |
2009 |
| Drug |
mk-8266 bid, 1.8 mg |
1 |
2010 |
| Drug |
mk-8266 tid, 1.8 mg |
1 |
2010 |
| Drug |
mk-8266 tid, 2.4 mg |
1 |
2010 |
| Drug |
mk-8457 |
1 |
2011 |
| Drug |
mk-954h |
1 |
2011 |
| Drug |
mk0507a, dorzolamide hydrochloride ( |
1 |
2005 |
| Drug |
mk0507a, dorzolamide hydrochloride (/) timolol maleate |
1 |
2005 |
| Drug |
mk0736 |
1 |
2006 |
| Drug |
mk0916 |
1 |
2006 |
| Drug |
mk0954, /duration of treatment : 16 weeks |
1 |
2007 |
| Drug |
mk0954, /duration of treatment : 5 years |
1 |
2006 |
| Drug |
mk0954, losartan potassium |
1 |
2005 |
| Drug |
mk0954, losartan potassium/duration of treatment: 18 weeks |
1 |
2005 |
| Drug |
mk0954a, hydrochlorothiazide (/) losartan potassium |
1 |
2004 |
| Drug |
mk0954a, hydrochlorothiazide (/) losartan potassium / duration of treatment: 12 weeks |
1 |
2006 |
| Drug |
mk0954a, hydrochlorothiazide (/) losartan potassium / duration of treatment: 6 weeks |
1 |
2006 |
| Drug |
mk1809 |
1 |
2009 |
| Drug |
mk3614 |
1 |
2009 |
| Drug |
mk8141 |
1 |
2007 |
| Drug |
ml (azopt) eye drops, suspension |
1 |
2006 |
| Drug |
ml augentropfen im einzeldosisbehaìˆltnis |
1 |
2013 |
| Drug |
ml eye drop solution |
1 |
2009 |
| Drug |
ml eye drops, solution (duotrav) |
1 |
2006 |
| Drug |
ml fixed combination eye drops, suspension |
1 |
2015 |
| Drug |
ml injectable solution |
1 |
2018 |
| Drug |
ml) |
1 |
2014 |
| Other |
mobile application (bp-n-me) |
1 |
2019 |
| Other |
mobile health |
1 |
2017 |
| Device |
mobile health care system (drub) |
1 |
2007 |
| Behavioral |
mobile health monitoring |
1 |
2017 |
| Behavioral |
mobile health technology (short message service) |
1 |
2018 |
| Device |
mobile phone-based self-report system, electronic patient-reported outcomes measure (e-prom) |
1 |
2012 |
| Device |
model 10642 implantable intravascular catheter |
1 |
2011 |
| Behavioral |
moderate-intensity continuous training (mct) |
1 |
2018 |
| Other |
moderate intensity aerobic training |
1 |
2020 |
| Behavioral |
moderate intensity training |
1 |
2005 |
| placebo |
modified citrus pectin (mcp) vs placebo |
1 |
2013 |
| Behavioral |
modified dash |
1 |
2014 |
| Other |
modified pilates group |
1 |
2018 |
| Behavioral |
modified relaxation (mr) |
1 |
2011 |
| Drug |
moduretic (hctz 50mg |
1 |
2017 |
| Drug |
moduretic (hctz 50mg/amiloride hcl 5mg tablets) |
1 |
2017 |
| Behavioral |
monetary incentives |
1 |
2011 |
| Other |
monitor |
1 |
2008 |
| Device |
monitor salt during cooking process |
1 |
2019 |
| Other |
monitor/phone call |
1 |
2008 |
| Other |
monograph for physicians |
1 |
2010 |
| Drug |
monoprost |
1 |
2013 |
| Drug |
monorovaâ® |
1 |
2018 |
| Drug |
monorovaâ® / amlopinâ® |
1 |
2018 |
| Device |
monthly monitoring of weight gain |
1 |
2018 |
| Dietary Supplement |
montmorency tart cherry capsules |
1 |
2018 |
| Behavioral |
more intensive chw intervention |
1 |
2017 |
| Drug |
morphine |
1 |
2014 |
| Behavioral |
motivational interviewing (mint-tlc) |
1 |
2010 |
| Behavioral |
motivational modules |
1 |
2014 |
| Behavioral |
move |
1 |
2015 |
| Drug |
moxifloxacin 400 mg |
1 |
2018 |
| Procedure |
mr imaging |
1 |
2018 |
| Diagnostic Test |
mri examination |
1 |
2019 |
| Other |
ms-guided intervention |
1 |
2017 |
| Other |
mufa rich diet |
1 |
2017 |
| Other |
multi-component interventions |
1 |
2016 |
| Device |
multi band ligator for esophageal varices |
1 |
2009 |
| Behavioral |
multifaceted implementation strategy |
1 |
2018 |
| Drug |
multiple dose, crossover study between single |
1 |
2010 |
| Drug |
multiple dose, crossover study between single/concomitant administrations of amlodipine, losartan,/hydrochlorothiazide |
1 |
2010 |
| Behavioral |
music |
1 |
2014 |
| Other |
music group (gc) |
1 |
2015 |
| Other |
music intervention |
1 |
2016 |
| Behavioral |
music/lifestyle changes |
1 |
2014 |
| Other |
mybp |
1 |
2018 |
| Drug |
mycophenolate mofetil (cellcept) |
1 |
2007 |
| Drug |
mycophenolate mofetil (mmf) |
1 |
2007 |
| Procedure |
myoma removal |
1 |
2009 |
| Drug |
n-acetyl cysteine |
1 |
2019 |
| Drug |
nadolol |
1 |
2007 |
| Drug |
nadolol (1 x 80 mg) tablets (invamed, inc) |
1 |
2009 |
| Device |
naked stents: wallstentâ® (boston scientific), luminexxâ® (bard), zilverâ® (cook), palmaz genesisâ® |
1 |
2007 |
| Device |
naked stents: wallstentâ® (boston scientific), luminexxâ® (bard), zilverâ® (cook), palmaz genesisâ®/smart controlâ® (cordis) |
1 |
2007 |
| Drug |
naproxcinod 375 mg -750 mg -1125 mg bid |
1 |
2008 |
| Drug |
naproxcinod 375 mg bid |
1 |
2008 |
| Drug |
naproxcinod 750 mg bid |
1 |
2008 |
| Drug |
naproxen 250 mg - 500mg -750 mg bid |
1 |
2008 |
| Drug |
naproxen 250 mg bid |
1 |
2008 |
| Drug |
naproxen 500 mg bid |
1 |
2008 |
| Device |
nasal continuous positive airway pressure (ncpap) |
1 |
2014 |
| Device |
nasal high flow (nhf) supplementation |
1 |
2016 |
| Drug |
natrecor |
1 |
2005 |
| Other |
navy beans added to regular diet |
1 |
2008 |
| Device |
ncpap |
1 |
2008 |
| Device |
ncpap nasal continuous positive airway pressure-sub-therapeutic treatment group |
1 |
2013 |
| Device |
ncpap; nasal continuous positive airway pressure. |
1 |
2013 |
| Drug |
ncx 470 |
1 |
2018 |
| Other |
ne |
1 |
2011 |
| Procedure |
near-infrared spectroscopy |
1 |
2011 |
| Drug |
nebilet |
1 |
2009 |
| Drug |
nebivolol 1 |
1 |
2012 |
| Drug |
nebivolol 2 |
1 |
2012 |
| Drug |
nebivolol 5 mg |
1 |
2010 |
| Drug |
nebivolol hydrochloride |
1 |
2005 |
| Drug |
nebivolol i |
1 |
2018 |
| Drug |
nebivolol ii |
1 |
2018 |
| Drug |
nebivolol monotherapy |
1 |
2010 |
| Drug |
nebivolol with concomitant losartan |
1 |
2008 |
| Drug |
nebivolol with concomitant losartan/lisinopril |
1 |
2008 |
| Drug |
nebivolol, valsartan |
1 |
2011 |
| Drug |
nebivolol, valsartan/hydrochlorothiazide |
1 |
2011 |
| Other |
nebivolol/lifestyle modification |
1 |
2013 |
| Drug |
nebivolol/lisinopril (free combination) |
1 |
2010 |
| Drug |
nebivolol/metoprolol succinate |
1 |
2009 |
| Drug |
nebivolol/valsartan 1 |
1 |
2012 |
| Drug |
nebivolol/valsartan 2 |
1 |
2012 |
| Drug |
nebivolol/valsartan 3 |
1 |
2012 |
| Drug |
nebulized magnesium sulfate |
1 |
2020 |
| Dietary Supplement |
neo40 daily |
1 |
2019 |
| Drug |
nesiritide |
1 |
2015 |
| Drug |
netarsudil |
1 |
2017 |
| Drug |
netarsudil ophthalmic solution 0.01% |
1 |
2019 |
| Drug |
netarsudil ophthalmic solution 0.04% |
1 |
2019 |
| placebo |
netarsudil ophthalmic solution placebo |
1 |
2019 |
| Drug |
netarsudil/latanoprost 0.02%/0.005% |
1 |
2017 |
| Device |
network-based home blood pressure monitor |
1 |
2018 |
| Drug |
new medication: enalapril, isradipine, propranolol |
1 |
2009 |
| Drug |
new thermo stable formulation of epoprostenol sodium |
1 |
2011 |
| Drug |
ng-monomethyl-l-arginine (drug) |
1 |
2006 |
| Other |
niche method |
1 |
2018 |
| Drug |
nicotinamide 1000 mg |
1 |
2014 |
| Drug |
nicotinamide 500 mg |
1 |
2014 |
| Drug |
nicotinamide riboside |
1 |
2019 |
| Drug |
nifedipine (adalat cr, baya1040) 40mg bid |
1 |
2008 |
| Drug |
nifedipine (adalat cr, baya1040) 40mg od |
1 |
2008 |
| Drug |
nifedipine (adalat cr, baya1040) 80mg od |
1 |
2008 |
| Drug |
nifedipine (adalat gits, bay1040) |
1 |
2015 |
| Drug |
nifedipine (adalat, bay a1040) |
1 |
2011 |
| Drug |
nifedipine (adalat, bay a1040)/candesartan (atacand, bay 12-9333) |
1 |
2011 |
| Drug |
nifedipine (adalat, baya1040)/valsartan |
1 |
2010 |
| Drug |
nifedipine cr tablets (adalat) |
1 |
2014 |
| Drug |
nifedipine cr tablets (xin ran) |
1 |
2014 |
| Drug |
nifedipine er |
1 |
2020 |
| Drug |
nifedipine gits (adalat, baya1040), 20 mg |
1 |
2011 |
| Drug |
nifedipine gits (adalat, baya1040), 30 mg |
1 |
2011 |
| Drug |
nifedipine gits (adalat, baya1040), 60 mg |
1 |
2011 |
| Drug |
nifedipine gits (adalatâ® xl 30 |
1 |
2009 |
| Drug |
nifedipine gits/candesartan cilexetil fdc(bay98-7106) |
1 |
2013 |
| Drug |
nifedipine xl |
1 |
2007 |
| Drug |
nifedipine, losartan |
1 |
2007 |
| Drug |
nifedipine/candesartan (bay 98-7106) |
1 |
2011 |
| Drug |
nifedipine/telmisartan |
1 |
2008 |
| Drug |
nifidipine |
1 |
2008 |
| Dietary Supplement |
nitrate-depleted beetroot juice |
1 |
2015 |
| Dietary Supplement |
nitrate-free beetroot juice |
1 |
2011 |
| Dietary Supplement |
nitrate depleted beetroot juice |
1 |
2015 |
| Drug |
nitrendipine |
1 |
2008 |
| Drug |
nitrendipine / hydrochlorothiazide, if necessary |
1 |
2008 |
| Drug |
nitric oxide administration |
1 |
2016 |
| Drug |
nitric oxide for inhalation |
1 |
2008 |
| Drug |
nitric oxide generated by the geno nitrosyl delivery system |
1 |
2010 |
| Drug |
nitric oxide/ino pulse delivery |
1 |
2006 |
| Drug |
nitric oxide/inp pulse delivery |
1 |
2006 |
| Drug |
nitric oxide/oxygen |
1 |
2008 |
| Drug |
nitroglycerin transdermal |
1 |
2005 |
| Behavioral |
no active intervention. |
1 |
2007 |
| Behavioral |
no added salt diet |
1 |
2007 |
| Other |
no anti-hypertensive therapy (unless bp is severe) |
1 |
2014 |
| Drug |
no diuretics |
1 |
2005 |
| Other |
no exercise intervention group |
1 |
2019 |
| Procedure |
no gas |
1 |
2018 |
| Behavioral |
no healthy behavior texts |
1 |
2018 |
| Behavioral |
no information on high risk factor levels but lifestyle advice |
1 |
2014 |
| Behavioral |
no information on high risk factor levels, nor lifestyle advice |
1 |
2014 |
| Behavioral |
no itec |
1 |
2018 |
| Behavioral |
no physician appointment |
1 |
2018 |
| Behavioral |
no physician appointment/transportation scheduling |
1 |
2018 |
| Other |
no transmission of the sflt-1 results to the investigator |
1 |
2008 |
| Dietary Supplement |
no ultra |
1 |
2018 |
| Procedure |
noise |
1 |
2016 |
| Drug |
non-arb /day after des implantation |
1 |
2011 |
| Drug |
non-diuretic based hypertension therapy |
1 |
2005 |
| Device |
non-invasive measurement of blood pressure |
1 |
2019 |
| Procedure |
non-invasive measurement of cardiac output (co) |
1 |
2011 |
| Procedure |
non-invasive nitric oxide |
1 |
2005 |
| Procedure |
non-invasive ventilation |
1 |
2011 |
| Other |
non-randomised cohort |
1 |
2014 |
| Drug |
non-ras inhibitor antihypertensive therapy |
1 |
2009 |
| Behavioral |
non-restricted incentives |
1 |
2019 |
| Other |
non-starchy vegetable |
1 |
2017 |
| Other |
non-storytelling dvd |
1 |
2011 |
| Device |
non integrated hemodynamic management (non-ihm) - hotman system |
1 |
2011 |
| Device |
non invasive peripheral blood monitoring |
1 |
2010 |
| Procedure |
non penetrating deep sclerectomy |
1 |
2011 |
| Procedure |
non thiazidic treatment |
1 |
2006 |
| Drug |
norepinephrine |
1 |
2015 |
| Drug |
normal saline 0.9% |
1 |
2008 |
| Drug |
normal saline rinses. |
1 |
2016 |
| Drug |
normal saline solution (nss) |
1 |
2012 |
| Drug |
north american ginseng (panax quinquefolius) |
1 |
2005 |
| Drug |
norvasc 10 mg |
1 |
2007 |
| Dietary Supplement |
nsk-sd (nattokinase) |
1 |
2016 |
| Behavioral |
nurse |
1 |
2005 |
| Other |
nurse-led blood pressure clinic |
1 |
2010 |
| Behavioral |
nurse administered |
1 |
2005 |
| Other |
nurse administered treatment algorithm |
1 |
2008 |
| Behavioral |
nurse behavioral intervention with home bp telemonitoring |
1 |
2005 |
| Behavioral |
nurse case management intervention |
1 |
2006 |
| Behavioral |
nurse education |
1 |
2009 |
| Behavioral |
nurse educator |
1 |
2012 |
| Behavioral |
nurse educator / ehmi |
1 |
2012 |
| Behavioral |
nurse management, home blood pressure monitors, |
1 |
2005 |
| Behavioral |
nurse management, home blood pressure monitors,/a chronic disease self management course. |
1 |
2005 |
| Behavioral |
nurse medication management with home bp telemonitoring |
1 |
2005 |
| Behavioral |
nurse practitioner |
1 |
2013 |
| Behavioral |
nurse practitioner / health coach |
1 |
2013 |
| Behavioral |
nurse practitioner only |
1 |
2013 |
| Behavioral |
nurse/intervention with home bp telemonitoring |
1 |
2005 |
| Behavioral |
nursing consultation |
1 |
2018 |
| Dietary Supplement |
nutraceutical: experimental product |
1 |
2018 |
| Behavioral |
nutrition |
1 |
2017 |
| Behavioral |
nutrition/exercise |
1 |
2017 |
| Other |
nutritional counseling |
1 |
2014 |
| Dietary Supplement |
nutritional counseling a |
1 |
2017 |
| Dietary Supplement |
nutritional counselling b |
1 |
2017 |
| Behavioral |
nutritional strategy |
1 |
2019 |
| Behavioral |
obesity |
1 |
2013 |
| Device |
occlutech afr device |
1 |
2017 |
| Drug |
oe 10 mg amlodipine besylate tablet |
1 |
2016 |
| Drug |
oe 200 mg celecoxib capsule |
1 |
2016 |
| Diagnostic Test |
office blood pressure measurement (obpm) |
1 |
2017 |
| Drug |
ojp-2028 |
1 |
2007 |
| Dietary Supplement |
oligopinâ® |
1 |
2014 |
| Dietary Supplement |
olive leaf extract liquid |
1 |
2013 |
| Drug |
olm 40mg-aml 10mg-hydrochlorothiazide 12.5mg |
1 |
2009 |
| Drug |
olm 40mg-aml 10mg-hydrochlorothiazide 25mg |
1 |
2009 |
| Drug |
olmesartan 10 |
1 |
2019 |
| Drug |
olmesartan 20 mg |
1 |
2019 |
| Drug |
olmesartan 20 mg/amlodipine 5 mg |
1 |
2019 |
| Drug |
olmesartan 40mg-amlodipine 10mg-hydrochlorothiazide 12.5mg |
1 |
2009 |
| Drug |
olmesartan 40mg-amlodipine 10mg-hydrochlorothiazide 25mg |
1 |
2009 |
| Drug |
olmesartan 40mg, ezetimibe |
1 |
2019 |
| Drug |
olmesartan 40mg, ezetimibe/rosuvastatin 10/20mg(combination drug) |
1 |
2019 |
| Drug |
olmesartan alone |
1 |
2005 |
| Drug |
olmesartan alone/in combination with hydrochlorothiazide |
1 |
2005 |
| placebo |
olmesartan matching placebo |
1 |
2012 |
| Drug |
olmesartan medoxomil-hydrochlorothiazide |
1 |
2009 |
| Drug |
olmesartan medoxomil (om)/ hydrochlorothiazide (hctz) 20mg/25mg |
1 |
2007 |
| Drug |
olmesartan medoxomil (om)/ hydrochlorothiazide (hctz) tablets |
1 |
2007 |
| Drug |
olmesartan medoxomil (om)/hydrochlorothiazide (hctz) tablets |
1 |
2007 |
| Drug |
olmesartan medoxomil (om)/hydrochlorothiazide (hctz) tablets/placebo |
1 |
2007 |
| Drug |
olmesartan medoxomil / amlodipine |
1 |
2009 |
| Drug |
olmesartan medoxomil / amlodipine / hydrochlorothiazide / placebo |
1 |
2009 |
| Drug |
olmesartan medoxomil / amlodipine / hydroclororthiazide |
1 |
2009 |
| Drug |
olmesartan medoxomil / amlodipine / hydroclororthiazide / placebo |
1 |
2009 |
| Drug |
olmesartan medoxomil / amlodipine/azelnidipine |
1 |
2007 |
| Drug |
olmesartan medoxomil / hydrochlorothiazide / amlodipine / hydralazine if necessary to control blood pressure |
1 |
2008 |
| Drug |
olmesartan medoxomil / low dose thiazide type drug |
1 |
2007 |
| Drug |
olmesartan medoxomil 40 mg - amlodipine 10 mg |
1 |
2009 |
| Drug |
olmesartan medoxomil combination |
1 |
2008 |
| Drug |
olmesartan medoxomil +azelnidipine |
1 |
2007 |
| Drug |
olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets |
1 |
2005 |
| placebo |
olmesartan medoxomil placebo tablets |
1 |
2015 |
| Drug |
olmesartan medoxomil tablets high dose |
1 |
2009 |
| Drug |
olmesartan medoxomil tablets low dose |
1 |
2009 |
| Drug |
olmesartan medoxomil, amlodipine, hydrochlorothiazide |
1 |
2015 |
| Drug |
olmesartan medoxomil/a ccb |
1 |
2009 |
| Drug |
olmesartan medoxomil/a diuretic |
1 |
2009 |
| Drug |
olmesartan medoxomil/amlodipine |
1 |
2007 |
| Drug |
olmesartan medoxomil/hydrochlorothiazide tablets |
1 |
2007 |
| Drug |
olmesartan, hydrochlorothiazide, amlodipine |
1 |
2009 |
| Drug |
olmesartan/amlodipin |
1 |
2012 |
| Drug |
olmesartan/amlodipine |
1 |
2012 |
| Drug |
olmesartan/amlodipine / hydrochlorothiazide, if necessary. |
1 |
2010 |
| Drug |
olmesartan/azelnidipine |
1 |
2009 |
| Drug |
olmetecâ® |
1 |
2013 |
| Drug |
olmetecâ®/20/12.5mg/placebo |
1 |
2013 |
| Drug |
olomax 20 |
1 |
2019 |
| Drug |
olomax 20/5/10mg |
1 |
2019 |
| Drug |
olomax 20/5/5mg |
1 |
2019 |
| Drug |
olostar tab (olmesartan |
1 |
2019 |
| Drug |
olostar tab (olmesartan/rosuvastatin fdc(fixed dose combination)) |
1 |
2019 |
| Drug |
om |
1 |
2007 |
| Drug |
om 40 |
1 |
2007 |
| Drug |
om/hctz 40/12.5 |
1 |
2007 |
| Drug |
omega-3 fatty acids (fish oil) |
1 |
2012 |
| Dietary Supplement |
omega-3 from vegetal origin |
1 |
2011 |
| Dietary Supplement |
omega 3 |
1 |
2019 |
| Other |
omron wearable device |
1 |
2019 |
| Behavioral |
on-screen computerized decision support alert |
1 |
2018 |
| Behavioral |
on-site blood pressure monitoring |
1 |
2019 |
| Behavioral |
ongoing psychological screening |
1 |
2001 |
| Behavioral |
online sleep education |
1 |
2013 |
| Other |
onsd ultrasound |
1 |
2012 |
| Drug |
opa-6566 |
1 |
2011 |
| Combination Product |
open label extension |
1 |
2017 |
| Procedure |
open surgical procedure |
1 |
2014 |
| Drug |
opsumit 10 mg tablet |
1 |
2018 |
| Dietary Supplement |
optijuice |
1 |
2012 |
| Other |
optima4bp |
1 |
2020 |
| Device |
optima4bp medication management |
1 |
2016 |
| Other |
optimised follow-up |
1 |
2014 |
| Other |
optimization of antihypertensive treatment based on 24-hour abpm |
1 |
2016 |
| Other |
optimization of antihypertensive treatment based on office bp |
1 |
2016 |
| Procedure |
optimized medication regimen |
1 |
2012 |
| Drug |
optive |
1 |
2008 |
| Other |
oral |
1 |
2014 |
| Dietary Supplement |
oral antioxidant |
1 |
2014 |
| Device |
oral appliance |
1 |
2008 |
| Other |
oral fat load |
1 |
2008 |
| Drug |
oral furosemide |
1 |
2018 |
| Drug |
oral hydralazine |
1 |
2005 |
| Drug |
oral hydralazine/intravenous nesiritide |
1 |
2005 |
| Drug |
oral ifetroban |
1 |
2016 |
| Drug |
oral midodrine |
1 |
2005 |
| Drug |
oral selexipag (uptravi) |
1 |
2017 |
| Drug |
oral sildenafil |
1 |
2012 |
| Drug |
oral sildenafil 20 mg |
1 |
2013 |
| Drug |
oral suspension |
1 |
2011 |
| Other |
oral/written information |
1 |
2014 |
| Other |
ordinary salt based- diet |
1 |
2010 |
| Drug |
orosartanâ® 5 |
1 |
2015 |
| Drug |
orosartanâ® 5/160mg |
1 |
2015 |
| Other |
osteopathic manipulative treatment |
1 |
2019 |
| Drug |
ot-730 ophthalmic solution |
1 |
2008 |
| placebo |
ot-730 placebo |
1 |
2008 |
| Drug |
other non-angiotensin ii receptor blocker antihypertensive medications. |
1 |
2008 |
| Drug |
otx-tic |
1 |
2020 |
| Drug |
otx-tp |
1 |
2014 |
| Drug |
over-encapsulated 10 mg amlodipine besylate tablet |
1 |
2014 |
| Drug |
over-encapsulated 200 mg celecoxib capsule |
1 |
2014 |
| Behavioral |
overcoming immunity to change health coaching |
1 |
2016 |
| Behavioral |
owl-hypertension 8 wk trial |
1 |
2019 |
| Other |
pacht-c |
1 |
2017 |
| Other |
palmitate tracer |
1 |
2012 |
| Other |
panel management support |
1 |
2012 |
| Behavioral |
par |
1 |
2011 |
| Drug |
paracetamol |
1 |
2013 |
| Device |
paradise renal denervation system |
1 |
2018 |
| Dietary Supplement |
parenteral emulsion |
1 |
2019 |
| Drug |
paricalcitol |
1 |
2007 |
| Other |
parish nurse visit |
1 |
2007 |
| Drug |
paroxetine |
1 |
2001 |
| Drug |
part 2) 6 wk washout pd part 3) two 8 wk active tx pds |
1 |
2005 |
| Device |
partial (ps) |
1 |
2019 |
| Behavioral |
participation in the educational program after 6 months |
1 |
2007 |
| Behavioral |
participatory patient care planning |
1 |
2016 |
| Device |
particle |
1 |
2018 |
| Behavioral |
patient-centered counseling |
1 |
2005 |
| Behavioral |
patient-held guideline for hypertension |
1 |
2005 |
| Other |
patient-targeted feedback |
1 |
2013 |
| Behavioral |
patient activation measure intervention package |
1 |
2006 |
| Behavioral |
patient education/support |
1 |
2006 |
| Behavioral |
patient educational letter to engage provider in hypertension rx discussion |
1 |
2005 |
| Behavioral |
patient follow-up |
1 |
2008 |
| Behavioral |
patient navigator - nurse team intervention |
1 |
2007 |
| Procedure |
patients with pulmonary arterial hypertension |
1 |
2017 |
| Drug |
pb1046 |
1 |
2018 |
| Drug |
pb1046 injection |
1 |
2018 |
| Drug |
pb1046 subcutaneous injection |
1 |
2017 |
| Behavioral |
pc101 |
1 |
2015 |
| Behavioral |
pc101/mental health |
1 |
2015 |
| Device |
pda blood pressure screening program |
1 |
2005 |
| Device |
pda blood pressure screening program/chart reminder |
1 |
2005 |
| Device |
pedometer |
1 |
2019 |
| Behavioral |
peer coach |
1 |
2016 |
| Behavioral |
peer led |
1 |
2007 |
| Combination Product |
peer support intervention |
1 |
2017 |
| Drug |
peginterferon alpha-2a |
1 |
2005 |
| Drug |
perdipine injection |
1 |
2013 |
| Device |
peregrine system infusion catheter |
1 |
2015 |
| Device |
peregrine system kit (sham procedure) |
1 |
2016 |
| Drug |
perflutren protein-type a microspheres for injection |
1 |
2005 |
| Procedure |
pericardial devascularization |
1 |
2018 |
| Procedure |
perifemoral injection of local anesthetic |
1 |
2017 |
| Drug |
perindopril-indapamide |
1 |
2018 |
| Drug |
perindopril (t1) |
1 |
2005 |
| Drug |
perindopril / amlodipine / if necessary, hydrochlorothiazide |
1 |
2010 |
| Drug |
perindopril / moxonidine |
1 |
2019 |
| Drug |
perindopril arginine |
1 |
2020 |
| Drug |
perindopril erbumine |
1 |
2012 |
| Drug |
perindopril oral tablet |
1 |
2017 |
| Drug |
perindopril/hydrochlorothiazide |
1 |
2016 |
| Drug |
perindopril/perindopril/indapamide |
1 |
2017 |
| Drug |
period with drug (trade name) then period with generic |
1 |
2016 |
| Drug |
period with generic then period with drug (trade name) |
1 |
2016 |
| Device |
perkins applanation tonometry |
1 |
2010 |
| Behavioral |
personal activity intelligence |
1 |
2019 |
| Other |
personal bp monitor |
1 |
2018 |
| Behavioral |
personal health record |
1 |
2012 |
| Behavioral |
personalized brochure |
1 |
2007 |
| Diagnostic Test |
pet-ct imaging with [89zr]-bevacizumab |
1 |
2017 |
| Drug |
pf-00489791 |
1 |
2007 |
| Drug |
pf-03187207 |
1 |
2008 |
| Drug |
pf-03187207 vehicle |
1 |
2008 |
| Drug |
pf-04217329 - high dose |
1 |
2007 |
| Drug |
pf-04217329 - high middle dose |
1 |
2007 |
| Drug |
pf-04217329 - low dose |
1 |
2007 |
| Drug |
pf-04217329 - lowest dose |
1 |
2007 |
| Drug |
pf-04217329 - middle dose |
1 |
2007 |
| Drug |
pf-04217329 - vehicle |
1 |
2007 |
| Drug |
pf-4217329 - highest dose |
1 |
2007 |
| Drug |
pg286 ophthalmic solution 0.5% |
1 |
2013 |
| Drug |
pg324 ophthalmic solution 0.01% |
1 |
2014 |
| Drug |
pge1 (prostacyclin) |
1 |
2006 |
| Drug |
ph-combination therapy |
1 |
2018 |
| Drug |
ph-monotherapy |
1 |
2018 |
| Other |
pharmaceutical care services |
1 |
2010 |
| Drug |
pharmaceutical therapy (no specific therapy; approach guided by the jnc 7 protocol guidelines) |
1 |
2008 |
| Other |
pharmacist-physician collaborative medication therapy management |
1 |
2013 |
| Other |
pharmacist collaborative teams |
1 |
2005 |
| Behavioral |
pharmacist cvd |
1 |
2010 |
| Other |
pharmacist drug therapy management |
1 |
2019 |
| Behavioral |
pharmacist intervention |
1 |
2006 |
| Other |
pharmacy management |
1 |
2008 |
| Behavioral |
pharmacy team monitoring |
1 |
2005 |
| Behavioral |
pharmacy team monitoring/counseling |
1 |
2005 |
| Behavioral |
pharmacy usual care |
1 |
2008 |
| Device |
phc off |
1 |
2016 |
| Device |
phc on |
1 |
2016 |
| Drug |
phentolamine mesylate ophthalmic solution 1% |
1 |
2019 |
| placebo |
phentolamine mesylate ophthalmic solution vehicle (placebo) |
1 |
2019 |
| Drug |
phenylephrine |
1 |
2014 |
| Other |
phone call |
1 |
2008 |
| Behavioral |
physical activity guidelines |
1 |
2019 |
| Behavioral |
physical activity prescription to develop program in group. |
1 |
2013 |
| Behavioral |
physical exercise |
1 |
2014 |
| Behavioral |
physical exercise / physical activity |
1 |
2014 |
| Other |
physical exercises |
1 |
2017 |
| Behavioral |
physical fitness |
1 |
2016 |
| Behavioral |
physical fitness/quality of life |
1 |
2016 |
| Other |
physical therapy |
1 |
2008 |
| Other |
physical therapy/education meetings |
1 |
2008 |
| Other |
physician |
1 |
2005 |
| Behavioral |
physician- |
1 |
2006 |
| Behavioral |
physician-/practice-level financial incentives |
1 |
2006 |
| Behavioral |
physician-level financial incentives |
1 |
2006 |
| Behavioral |
physician-pharmacist collaborative intervention |
1 |
2005 |
| Behavioral |
physician appointment |
1 |
2018 |
| Behavioral |
physician appointment/transportation scheduling |
1 |
2018 |
| Other |
physician information |
1 |
2011 |
| Other |
physician information/management recommendations |
1 |
2011 |
| Behavioral |
physician monitoring of blood pressure |
1 |
2005 |
| Other |
physician/pharmacist collaborative teams |
1 |
2005 |
| Procedure |
physiological-based cord clamping |
1 |
2020 |
| Other |
pilates |
1 |
2017 |
| Device |
pillbox app named alice |
1 |
2014 |
| Drug |
pilocarpine |
1 |
2016 |
| Drug |
pine bark extract (flavangenolâ®) |
1 |
2007 |
| Drug |
pioglitazone/ramipril |
1 |
2008 |
| Drug |
pirfenidone |
1 |
2016 |
| Drug |
piroxicam |
1 |
2008 |
| Drug |
pitavastatin |
1 |
2014 |
| Drug |
pitavastatin 2mg |
1 |
2011 |
| Drug |
pitavastatin 2mg/day after des implantation |
1 |
2011 |
| Drug |
pitavastatin calcium |
1 |
2018 |
| placebo |
pitavastatin, valsartan, placebo |
1 |
2011 |
| Other |
pitso |
1 |
2011 |
| Dietary Supplement |
pl |
1 |
2015 |
| Dietary Supplement |
pl/ex |
1 |
2015 |
| Drug |
pl3994 |
1 |
2008 |
| placebo |
placebo-matching dapagliflozin |
1 |
2010 |
| placebo |
placebo - cap |
1 |
2018 |
| placebo |
placebo #1 |
1 |
2015 |
| placebo |
placebo #2 |
1 |
2015 |
| placebo |
placebo (artificial tears) |
1 |
2006 |
| placebo |
placebo (distilled water) |
1 |
2012 |
| placebo |
placebo (for aliskiren) |
1 |
2010 |
| placebo |
placebo (for hcp1302) |
1 |
2015 |
| placebo |
placebo (for hgp0904) |
1 |
2015 |
| placebo |
placebo (for moxonidine |
1 |
2010 |
| Drug |
placebo (for moxonidine/hydrochlorothiazide) |
1 |
2010 |
| placebo |
placebo (whey protein) |
1 |
2015 |
| placebo |
placebo 6g per day per oral for 28 days |
1 |
2015 |
| placebo |
placebo aliskiren |
1 |
2006 |
| placebo |
placebo amlodipine |
1 |
2006 |
| placebo |
placebo bid |
1 |
2015 |
| placebo |
placebo bid (panel a) |
1 |
2010 |
| placebo |
placebo bid (panel b) |
1 |
2010 |
| placebo |
placebo capsule |
1 |
2011 |
| placebo |
placebo capsules |
1 |
2016 |
| placebo |
placebo chocolate |
1 |
2012 |
| placebo |
placebo comparator (n=24) |
1 |
2017 |
| placebo |
placebo comparator: bread without added beta-glucans |
1 |
2014 |
| placebo |
placebo controls |
1 |
2019 |
| placebo |
placebo eprosartan |
1 |
2012 |
| placebo |
placebo eprosartan mesylate |
1 |
2012 |
| placebo |
placebo evening |
1 |
2012 |
| placebo |
placebo fdc |
1 |
2019 |
| placebo |
placebo first then albuterol |
1 |
2017 |
| placebo |
placebo followed by autologous epcs transfected with human enos |
1 |
2016 |
| placebo |
placebo for |
1 |
2009 |
| placebo |
placebo for aliskiren |
1 |
2009 |
| placebo |
placebo for atorvastatin 40mg |
1 |
2017 |
| placebo |
placebo for azilsartan medoxomil |
1 |
2014 |
| placebo |
placebo for fimasartan 120mg |
1 |
2017 |
| placebo |
placebo for hydrochlorothiazide |
1 |
2016 |
| placebo |
placebo for losartan |
1 |
2014 |
| placebo |
placebo for mk-4618 |
1 |
2011 |
| placebo |
placebo for mk-8457 |
1 |
2011 |
| placebo |
placebo for valsartan |
1 |
2009 |
| placebo |
placebo infusion |
1 |
2008 |
| placebo |
placebo inhalation solution |
1 |
2005 |
| placebo |
placebo macitentan |
1 |
2019 |
| placebo |
placebo magnetic field generator |
1 |
2008 |
| placebo |
placebo matched to enalapril |
1 |
2007 |
| placebo |
placebo matched to valsartan |
1 |
2007 |
| placebo |
placebo matching bibr277 |
1 |
2014 |
| placebo |
placebo matching cs-3150 |
1 |
2019 |
| placebo |
placebo matching dapagliflozin |
1 |
2010 |
| placebo |
placebo matching enalapril |
1 |
2014 |
| placebo |
placebo matching moxifloxacin tablet |
1 |
2019 |
| placebo |
placebo of aliskiren |
1 |
2010 |
| Drug |
placebo of aliskiren/amlodipine 150/2.5 mg |
1 |
2010 |
| Drug |
placebo of aliskiren/amlodipine 150/5 mg |
1 |
2010 |
| placebo |
placebo of amlodipine |
1 |
2010 |
| placebo |
placebo of d013, d326, d337 |
1 |
2020 |
| placebo |
placebo of gastrodia |
1 |
2019 |
| Drug |
placebo of gastrodia/uncaria granule |
1 |
2019 |
| placebo |
placebo of indapamide (p2) |
1 |
2005 |
| placebo |
placebo of perindopril (p1) |
1 |
2005 |
| placebo |
placebo pill |
1 |
2014 |
| placebo |
placebo pills |
1 |
2018 |
| placebo |
placebo powder |
1 |
2017 |
| placebo |
placebo segment |
1 |
2016 |
| placebo |
placebo single iv (intravenous) infusion |
1 |
2013 |
| placebo |
placebo sugar pill |
1 |
2015 |
| placebo |
placebo supplement |
1 |
2011 |
| placebo |
placebo tadalafil |
1 |
2019 |
| placebo |
placebo tid (panel c) |
1 |
2010 |
| placebo |
placebo tid (panel d) |
1 |
2010 |
| placebo |
placebo tid (panel e) |
1 |
2010 |
| Drug |
placebo to aliskiren/amlodipine |
1 |
2008 |
| placebo |
placebo to amlodipine besylate |
1 |
2011 |
| placebo |
placebo to ertuglilflozin 1 |
1 |
2010 |
| Drug |
placebo to ertuglilflozin 1/5 mg |
1 |
2010 |
| placebo |
placebo to ertuglilflozin 25 mg |
1 |
2010 |
| placebo |
placebo to l50 |
1 |
2011 |
| Drug |
placebo to l50/h12.5 |
1 |
2011 |
| Drug |
placebo to l50/h12.5/a5 |
1 |
2011 |
| placebo |
placebo to losartan 100 mg |
1 |
2011 |
| placebo |
placebo to losartan 50 mg |
1 |
2011 |
| placebo |
placebo to losartan potassium |
1 |
2011 |
| placebo |
placebo to match amlodipine |
1 |
2011 |
| placebo |
placebo to match losartan |
1 |
2011 |
| Drug |
placebo to match losartan/amlodipine tablets |
1 |
2011 |
| placebo |
placebo to mk-0954e |
1 |
2011 |
| placebo |
placebo to mk-7145 |
1 |
2011 |
| placebo |
placebo to mk-954h |
1 |
2011 |
| placebo |
placebo to olmesartan |
1 |
2013 |
| placebo |
placebo to ramipril |
1 |
2008 |
| placebo |
placebo to sacubitril |
1 |
2013 |
| Other |
placebo to sacubitril/valsartan (lcz696) |
1 |
2013 |
| placebo |
placebo to telmisartan |
1 |
2009 |
| placebo |
placebo to valsartan |
1 |
2009 |
| placebo |
placebo vedic medical astrology (pma) |
1 |
2019 |
| placebo |
placebo vehicle |
1 |
2016 |
| placebo |
placebo video |
1 |
2011 |
| placebo |
placebo with concomitant losartan |
1 |
2008 |
| Drug |
placebo with concomitant losartan/lisinopril |
1 |
2008 |
| Drug |
placebo/air001 inhalation solution (expansion arm) |
1 |
2008 |
| Drug |
placebo/spironolactone |
1 |
2009 |
| placebo |
placebos morning |
1 |
2012 |
| Dietary Supplement |
plant sterols |
1 |
2009 |
| Drug |
pluscor |
1 |
2007 |
| Drug |
polat-001 |
1 |
2015 |
| Diagnostic Test |
polysomnography assessment |
1 |
2017 |
| Device |
portable blood pressure wrist manometer |
1 |
2007 |
| Behavioral |
positive affect/self-affect induction |
1 |
2005 |
| Behavioral |
positive affect/self-affirmation/motivational interviewing |
1 |
2009 |
| Procedure |
post-pulmonary embolism follow up protocol |
1 |
2018 |
| Drug |
potassium chloride (kcl) |
1 |
2016 |
| Drug |
potassium citrate |
1 |
2018 |
| Drug |
potassium magnesium citrate powder |
1 |
2012 |
| Other |
potato |
1 |
2017 |
| Behavioral |
power training session |
1 |
2018 |
| Drug |
ppar alpha |
1 |
2006 |
| Other |
ppcm asthma |
1 |
2009 |
| Behavioral |
practice-level financial incentives |
1 |
2006 |
| Other |
pranayama |
1 |
2019 |
| Drug |
pravastatin 20mg |
1 |
2011 |
| Drug |
pravastatin 20mg/day after des implantation |
1 |
2011 |
| Drug |
prazosin |
1 |
2007 |
| Drug |
prazosin hydrochloride |
1 |
2005 |
| Device |
prds-001 renal denervation ultrasound system |
1 |
2016 |
| Device |
pre-filled trays |
1 |
2015 |
| Dietary Supplement |
prebiotic |
1 |
2019 |
| Procedure |
precise hepatectomy |
1 |
2012 |
| Device |
precision spectra system |
1 |
2016 |
| Behavioral |
prediction mailing |
1 |
2015 |
| Drug |
prednisone |
1 |
2010 |
| Drug |
preminent (losartan |
1 |
2008 |
| Drug |
preminent (losartan/hydrochlorothiazide combination drug) |
1 |
2008 |
| Procedure |
preoperative acei |
1 |
2010 |
| Procedure |
preoperative acei/arb management |
1 |
2010 |
| Behavioral |
prescriptive consultation |
1 |
2016 |
| Drug |
preservative-free bimatoprost |
1 |
2013 |
| Drug |
preservative-free latanoprost |
1 |
2013 |
| Drug |
preservative-free tafluprost/vehicle |
1 |
2010 |
| Drug |
preservative-free timolol maleate |
1 |
2010 |
| Drug |
preservative free tafluprost opthalmic solution |
1 |
2014 |
| Procedure |
primary arterio-venous vascular access creation |
1 |
2008 |
| Behavioral |
primary care collaboration |
1 |
2010 |
| Other |
primary care provider blood pressure management |
1 |
2020 |
| Other |
primary care provider visit |
1 |
2012 |
| Drug |
primary medical treatment pathway |
1 |
2013 |
| Procedure |
primary selective laser trabeculoplasty treatment pathway |
1 |
2013 |
| Behavioral |
prime time sister circle |
1 |
2020 |
| Other |
printed materials |
1 |
2009 |
| Drug |
pro-122 |
1 |
2017 |
| Drug |
pro tab |
1 |
2013 |
| Drug |
probenecid |
1 |
2006 |
| Drug |
probiotic |
1 |
2009 |
| Dietary Supplement |
probiotic milk fermented with kefir grains |
1 |
2018 |
| Dietary Supplement |
probiotic supplementation |
1 |
2019 |
| Behavioral |
problem solving skills training |
1 |
2013 |
| Procedure |
procedure |
1 |
2014 |
| Behavioral |
profiling performance |
1 |
2005 |
| Behavioral |
program health education |
1 |
2013 |
| Behavioral |
progressive resistance training |
1 |
2020 |
| Device |
prometheus liver dialysis system (fresenius medical care) |
1 |
2009 |
| Behavioral |
promotional gift |
1 |
2007 |
| Drug |
propofol |
1 |
2009 |
| Drug |
propofol/isoflurane |
1 |
2009 |
| Drug |
prostaglandin |
1 |
2007 |
| Other |
prot rich diet |
1 |
2017 |
| Other |
proteus discover |
1 |
2016 |
| Behavioral |
protocol initiate with a |
1 |
2018 |
| Behavioral |
protocol initiate with c |
1 |
2018 |
| Behavioral |
protocol initiate with d |
1 |
2018 |
| Other |
protocolized, pharmacist-delivered ckd action plan |
1 |
2014 |
| Behavioral |
provider audit-feedback, stratified by race |
1 |
2016 |
| Behavioral |
provider audit-feedback, stratified by race/ethnicity |
1 |
2016 |
| Behavioral |
provider education |
1 |
2005 |
| Behavioral |
provider education system to promote patient-centered care |
1 |
2012 |
| Other |
providers |
1 |
2010 |
| Drug |
prx-08066 |
1 |
2006 |
| Procedure |
pse |
1 |
2016 |
| Drug |
pseudoephedrine |
1 |
2005 |
| Other |
ptco2 |
1 |
2018 |
| Device |
ptfe covered stents: fluencyâ® (bard), advanta v12â® (atrium) |
1 |
2007 |
| Device |
ptfe covered stents: fluencyâ® (bard), advanta v12â® (atrium)/viatorrâ® (gore) |
1 |
2007 |
| Drug |
pulmobind |
1 |
2014 |
| Procedure |
pulmonary arterial denervation |
1 |
2014 |
| Device |
pulmonary denervation |
1 |
2018 |
| Procedure |
pulmonary endarteriectomy |
1 |
2017 |
| Other |
pulmonary rehabilitation |
1 |
2018 |
| Other |
pumpkin seed oil |
1 |
2018 |
| Procedure |
pv isolation |
1 |
2013 |
| Procedure |
pv isolation/renal denervation |
1 |
2013 |
| Device |
pwv measurement by ldv |
1 |
2018 |
| Drug |
pyridoxal-5’-phosphate with |
1 |
2005 |
| Drug |
pyridoxal-5’-phosphate with/without ace inhibitor |
1 |
2005 |
| Drug |
qgc001 |
1 |
2014 |
| Drug |
qti571 |
1 |
2014 |
| Other |
quality improvement plan for hypertension control |
1 |
2009 |
| Behavioral |
quality of life |
1 |
2016 |
| Drug |
quartet ldqt |
1 |
2018 |
| Dietary Supplement |
quercetin |
1 |
2012 |
| Drug |
quinapril |
1 |
2005 |
| Drug |
quinapril (accupril) |
1 |
2008 |
| Drug |
quinapril (accupril)/alpha lipoic acid |
1 |
2008 |
| Drug |
quinapril 20 mg |
1 |
2008 |
| Drug |
quinapril 20 mg/hydrochlorothiazide 12.5 mg |
1 |
2008 |
| Drug |
quinapril 40 mg |
1 |
2008 |
| Drug |
qutenza |
1 |
2011 |
| Drug |
qutenza (8% capsaicin) |
1 |
2010 |
| Other |
radio story |
1 |
2014 |
| Device |
radiofrequency ablation instruments |
1 |
2018 |
| Other |
radiofrequency catheter ablation |
1 |
2018 |
| Device |
radiofrequency denervation of renal arteries |
1 |
2016 |
| Device |
radiofrequency denervation of renal arteries/branches |
1 |
2016 |
| Device |
radiofrequency denervation of the main renal arteries |
1 |
2016 |
| Device |
radiofrequency wire (powerwire) |
1 |
2018 |
| Drug |
ramipril-felodipine |
1 |
2007 |
| Drug |
ramipril / felodipine |
1 |
2009 |
| Drug |
ramipril 10 capsule (sandoz) |
1 |
2009 |
| Drug |
ramipril 10 mg capsule (sandoz) |
1 |
2009 |
| Drug |
ramipril, candesartan |
1 |
2006 |
| Drug |
ramipril/hydrochlorothiazide |
1 |
2006 |
| Procedure |
randomized to either a ‘less tight’ group |
1 |
2005 |
| Procedure |
randomized to either a ‘less tight’ group/a ‘tight’ group |
1 |
2005 |
| Drug |
rasburicase |
1 |
2017 |
| Drug |
rauwolfia alkaloids |
1 |
1999 |
| Drug |
rbv |
1 |
2012 |
| Behavioral |
real ppl |
1 |
2009 |
| Other |
recall at home by a community worker |
1 |
2008 |
| Behavioral |
recipes to align with parameters of dash eating plan |
1 |
2019 |
| Behavioral |
recommendation of regular exercise |
1 |
2005 |
| Procedure |
red blood cells auto-transfusion |
1 |
2012 |
| Behavioral |
reduce salt intake |
1 |
2005 |
| Other |
reduced-salt diet |
1 |
2019 |
| Behavioral |
reduced calorie american diet |
1 |
2007 |
| Behavioral |
reduction in financial barrier |
1 |
2005 |
| Behavioral |
reduction of financial barrier |
1 |
2005 |
| Drug |
reference-brinzolamide 1% ophthalmic suspension |
1 |
2015 |
| Drug |
reference (valsartan 80 mg) group |
1 |
2009 |
| Drug |
reference amb (5 mg) |
1 |
2019 |
| Drug |
reference treatment: 1 x 5mg amlodipine tablet |
1 |
2012 |
| Drug |
reference treatment: 1 x 5mg amlodipine tablet/1 x 100mg losartan tablet administered in fasted state |
1 |
2012 |
| Drug |
reference treatment: 5 mg amlodipine |
1 |
2013 |
| Drug |
reference treatment: 5 mg amlodipine / 50 mg losartan |
1 |
2013 |
| Drug |
reference treatment:5 mg amlodipine |
1 |
2013 |
| Drug |
reference treatment:5 mg amlodipine / 100 mg losartan |
1 |
2013 |
| Drug |
reference0912 |
1 |
2009 |
| Other |
referral hypertension specialist |
1 |
2014 |
| Behavioral |
referral of hypertensive patients to the attending physician |
1 |
2017 |
| Other |
referral system |
1 |
2014 |
| Behavioral |
referral to primary care physician for hypertension control |
1 |
2017 |
| Other |
referral to primary care provider for cvd risk management |
1 |
2013 |
| Behavioral |
referral to smoking quit line |
1 |
2017 |
| Behavioral |
rehabilitation |
1 |
2015 |
| Behavioral |
relaxation exercises |
1 |
2019 |
| Drug |
remodulin |
1 |
2016 |
| Other |
remote (text based) surveillance |
1 |
2017 |
| Device |
remote ischaemic conditioning (ric) |
1 |
2017 |
| Other |
remote ischemic preconditioning (ripc) |
1 |
2011 |
| Behavioral |
remote monitoring |
1 |
2018 |
| Behavioral |
remote monitoring / social support |
1 |
2018 |
| Device |
remote patient monitoring |
1 |
2018 |
| Other |
remote telemonitoring |
1 |
2018 |
| Procedure |
renal artery ablation |
1 |
2011 |
| Device |
renal artery ablation catheter (ds3d001, ds3d002) |
1 |
2011 |
| Procedure |
renal artery stenting |
1 |
2010 |
| Device |
renal denervation (symplicity catheter system) |
1 |
2011 |
| Device |
renal denervation (symplicity spyralâ„¢) |
1 |
2020 |
| Device |
renal denervation (symplicityâ® renal denervation system) |
1 |
2009 |
| Device |
renal denervation (vessix) |
1 |
2015 |
| Procedure |
renal denervation therapy |
1 |
2013 |
| Device |
renal denervation using the symplicity renal denervation system |
1 |
2013 |
| Device |
renal denervation with a catheter-based procedure |
1 |
2008 |
| Device |
renal denervation with a catheter-based procedure (symplicityâ® catheter system) |
1 |
2011 |
| Device |
renal denervation with enlightn st. jude medical |
1 |
2012 |
| Device |
renal denervation with paradise recor |
1 |
2012 |
| Device |
renal denervation with symplicity flex medtronic |
1 |
2012 |
| Device |
renal denervation with symplicity flex medtronic/ardian |
1 |
2012 |
| Device |
renal denervation with v2 vessix |
1 |
2012 |
| Procedure |
renal denervation/optimized medication regimen |
1 |
2012 |
| Device |
renal nerve denervation |
1 |
2014 |
| Device |
renal sympathetic denervation (rdn) |
1 |
2016 |
| Device |
renal sympathetic denervation (symplicity ablation catheter, medtronic inc. minneapolis, minnesota, usa) |
1 |
2012 |
| Procedure |
renal sympathetic modification |
1 |
2011 |
| Drug |
renin guided therapeutics-no specific med. any anti-hypertensive med. |
1 |
2008 |
| Drug |
renin treatment-guided therapeutics |
1 |
2014 |
| Device |
reprogramming insoles |
1 |
2015 |
| Other |
research |
1 |
2017 |
| Other |
research on interactions between portal hypertension |
1 |
2016 |
| Other |
research on interactions between portal hypertension/microparticles |
1 |
2016 |
| Other |
resistance |
1 |
2016 |
| Other |
resistance band exercise intervention |
1 |
2019 |
| Other |
resistance exercise |
1 |
2017 |
| Other |
resistance exercise training |
1 |
2011 |
| Other |
resistance exercise training/diet |
1 |
2011 |
| Device |
resperateâ®-intercure ltda |
1 |
2015 |
| Device |
respiratory coherence biofeedback |
1 |
2018 |
| Other |
respiratory muscle training |
1 |
2017 |
| Behavioral |
respiratory training |
1 |
2011 |
| Behavioral |
respiratory/exercise therapy with supplemental oxygen |
1 |
2015 |
| Dietary Supplement |
resveratrol |
1 |
2013 |
| Dietary Supplement |
return of chocolate |
1 |
2010 |
| Behavioral |
revision of congregate meal menus |
1 |
2019 |
| Behavioral |
revision of congregate meal menus/recipes to align with parameters of dash eating plan |
1 |
2019 |
| Dietary Supplement |
rgc |
1 |
2010 |
| Drug |
rhbnp |
1 |
2015 |
| Device |
rheos baroreflex hypertension therapy system |
1 |
2008 |
| Device |
rheosâ® baroreflex hypertension system |
1 |
2007 |
| Dietary Supplement |
riboflavin |
1 |
2020 |
| Drug |
riociguat |
1 |
2017 |
| Drug |
riociguat (adempas, bay63-2521) 1.0 mg |
1 |
2008 |
| Drug |
riociguat (adempas, bay63-2521) 2.5 mg |
1 |
2008 |
| Drug |
riociguat (bay63-2521) |
1 |
2009 |
| Drug |
riociguat oral product |
1 |
2019 |
| Drug |
riociguat pill |
1 |
2019 |
| Drug |
rivaroxaban |
1 |
2019 |
| Drug |
rki983 |
1 |
2007 |
| Drug |
rki983a |
1 |
2009 |
| Drug |
rmjh-111b |
1 |
2016 |
| Other |
room air |
1 |
2011 |
| Drug |
rosiglitazone |
1 |
2008 |
| Drug |
rostafuroxin |
1 |
2006 |
| Drug |
rosuampin 10 |
1 |
2019 |
| Drug |
rosuampin 10/5mg |
1 |
2019 |
| Drug |
rosuampin 20 |
1 |
2019 |
| Drug |
rosuampin 20/5mg |
1 |
2019 |
| Drug |
rosuvastatin (combination drug) |
1 |
2017 |
| Drug |
rosuvastatin 10 |
1 |
2019 |
| Drug |
rosuvastatin combination |
1 |
2014 |
| Drug |
rosuvastatin fdc(fixed dose combination)) |
1 |
2019 |
| placebo |
rosuvastatin placebo |
1 |
2013 |
| Drug |
rosuvastatin/ezetimibe |
1 |
2019 |
| Other |
routine care |
1 |
2007 |
| Procedure |
routine endoscopic procedures |
1 |
2016 |
| Other |
routine intensification of antihypertensive treatment |
1 |
2015 |
| Behavioral |
routine nutrition care |
1 |
2007 |
| Device |
rox anastomotic coupler system (acs) |
1 |
2012 |
| Drug |
s-amlodipine 5mg |
1 |
2012 |
| Drug |
s-amlodipine gentisate |
1 |
2006 |
| Drug |
s-amlodipine, telmisartan |
1 |
2010 |
| Drug |
s-nor (s-amlodipine) 2,5 mg |
1 |
2017 |
| Drug |
s-nor (s-amlodipine) 2,5 mg/5 mg tablet |
1 |
2017 |
| Drug |
sacubitril |
1 |
2013 |
| Drug |
sacubitril/valsartan (lcz696) |
1 |
2013 |
| Drug |
sad448 |
1 |
2007 |
| Drug |
saflutanâ® 15 microgram |
1 |
2013 |
| Drug |
saflutanâ® 15 microgram/ml augentropfen im einzeldosisbehaìˆltnis |
1 |
2013 |
| placebo |
saline (placebo) |
1 |
2013 |
| placebo |
saline placebo inhaler |
1 |
2014 |
| Drug |
salsalate |
1 |
2015 |
| Device |
salt-meter |
1 |
2020 |
| Device |
salt control h equipment to control |
1 |
2019 |
| Device |
salt control h equipment to control/monitor salt during cooking process |
1 |
2019 |
| Procedure |
salt loading |
1 |
2009 |
| Dietary Supplement |
salt pills |
1 |
2018 |
| Behavioral |
salt reduction program |
1 |
2019 |
| Procedure |
samples: serological tests |
1 |
2010 |
| Procedure |
samples: serological tests/culture of mononuclear cells |
1 |
2010 |
| Drug |
sanvarâ® (vapreotide) |
1 |
2006 |
| Drug |
sapropterin |
1 |
2011 |
| Drug |
sapropterin dihydrochloride (6r-bh4) |
1 |
2007 |
| Drug |
sar366234 |
1 |
2015 |
| Other |
sbp 20-30% over baseline |
1 |
2013 |
| Other |
sbp 20-30% under baseline |
1 |
2013 |
| Procedure |
screening for hypertension, lower limb atherosclerosis |
1 |
2008 |
| Procedure |
screening for hypertension, lower limb atherosclerosis/abdominal aortic aneurysm |
1 |
2008 |
| Behavioral |
screening group |
1 |
2014 |
| Other |
secure message reminder |
1 |
2013 |
| Other |
sedentary control group |
1 |
2007 |
| Procedure |
selective endovascular chemical ablation of adrenal gland |
1 |
2018 |
| Behavioral |
self-affect induction |
1 |
2005 |
| Behavioral |
self-affirmation |
1 |
2009 |
| Behavioral |
self-affirmation exercise |
1 |
2009 |
| Behavioral |
self-care cvd risk reduction |
1 |
2013 |
| Behavioral |
self-guided approach |
1 |
2018 |
| Other |
self-guided m.a.p. bp improvement program |
1 |
2019 |
| Behavioral |
self-help intervention program-high blood pressure |
1 |
2007 |
| Behavioral |
self-management |
1 |
2005 |
| Other |
self-management protocol for hypertension care |
1 |
2017 |
| Other |
self-monitoring |
1 |
2017 |
| Other |
self-monitoring-nurse-primary care provider feedback loop |
1 |
2011 |
| Other |
self-monitoring of blood pressure |
1 |
2017 |
| Other |
self-monitoring/self-titration |
1 |
2017 |
| Other |
self-paced programmed instruction (sppi) |
1 |
2009 |
| Behavioral |
self-shopping dash group (s-dash) |
1 |
2017 |
| Other |
self-titration |
1 |
2017 |
| Behavioral |
self monitoring of blood pressure |
1 |
2012 |
| Device |
self monitoring of blood pressure using health gauge device |
1 |
2018 |
| Device |
self monitoring of blood pressure using health gauge device/monthly monitoring of weight gain |
1 |
2018 |
| Drug |
selonsertib |
1 |
2014 |
| Behavioral |
seminar |
1 |
2007 |
| Device |
sensimed triggerfish |
1 |
2009 |
| Drug |
sequence 1 |
1 |
2018 |
| Drug |
sequence 2 |
1 |
2018 |
| Drug |
sequence 3 |
1 |
2018 |
| Drug |
sequence 4 |
1 |
2018 |
| Drug |
sequence 5 |
1 |
2018 |
| Drug |
sequence 6 |
1 |
2018 |
| Other |
sequence: clinical |
1 |
2017 |
| Other |
sequence: clinical/research |
1 |
2017 |
| Other |
sequence: research |
1 |
2017 |
| Other |
sequence: research/clinical |
1 |
2017 |
| Drug |
sequenced antihypertensvie drugs with titrated dosage |
1 |
2018 |
| Drug |
ser100 |
1 |
2013 |
| Drug |
serelaxin |
1 |
2016 |
| Drug |
serelaxin (rlx030) |
1 |
2012 |
| Behavioral |
set of supportive tools |
1 |
2006 |
| Behavioral |
set of supportive tools/measures vs. standard care |
1 |
2006 |
| Drug |
sevelamer, sodium bicarbonate, sodium chloride |
1 |
2016 |
| Drug |
sevikar |
1 |
2012 |
| Drug |
sglt2 inhibitor |
1 |
2019 |
| Drug |
sh k 00641 c - medroxyprogesterone acetate |
1 |
2007 |
| Drug |
sh k 00641 c - medroxyprogesterone acetate / conjugated equine (prempro tm) |
1 |
2007 |
| Device |
sham-cpap |
1 |
2009 |
| Behavioral |
sham comparator - stretching |
1 |
2019 |
| Behavioral |
sham comparator - stretching/relaxation exercises |
1 |
2019 |
| Device |
sham control autoricâ® (sham control) |
1 |
2017 |
| Device |
sham cpap nasal |
1 |
2013 |
| Other |
sham muscle training |
1 |
2017 |
| Drug |
sham o2 (medical air) |
1 |
2018 |
| Procedure |
sham operation |
1 |
2017 |
| Procedure |
sham padn |
1 |
2014 |
| Device |
sham remote ischemic conditioning |
1 |
2018 |
| Other |
sham renal denervation |
1 |
2013 |
| Other |
sham spinal manipulation |
1 |
2009 |
| Other |
sham: applicator without needle |
1 |
2014 |
| Drug |
shape measurement (sonazoid ultrasoud contrast agent) |
1 |
2015 |
| Drug |
shp639 (n=60) |
1 |
2017 |
| Drug |
sildenafil (50 mg) |
1 |
2006 |
| Drug |
sildenafil citrate (uk-92,480) |
1 |
2007 |
| Drug |
sildenafil singly |
1 |
2012 |
| Drug |
sildenafil singly/in association with bosentan |
1 |
2012 |
| Drug |
sildenafil25 mg |
1 |
2010 |
| Procedure |
silence |
1 |
2016 |
| Drug |
silybin |
1 |
2018 |
| Behavioral |
sim ppl |
1 |
2009 |
| Drug |
simbrinza three times daily (tid) |
1 |
2014 |
| Other |
simulating medical insurance reform |
1 |
2018 |
| Other |
simultaneous determination of paco2 |
1 |
2018 |
| Other |
simultaneous determination of paco2/ptco2 |
1 |
2018 |
| Device |
sirolimus-eluting stent |
1 |
2011 |
| Device |
sit-stand workstation |
1 |
2015 |
| Drug |
sitagliptin (dpp4 inhibitor) |
1 |
2011 |
| Drug |
sitaxsentan |
1 |
2010 |
| Drug |
sitaxsentan sodium |
1 |
2004 |
| Other |
six portions of fruit |
1 |
2011 |
| Other |
six portions of fruit/vegetables per day (one of which must be berries)/50g dark chocolate. |
1 |
2011 |
| Drug |
sk&f-105517 (coreg cr fdc) |
1 |
2007 |
| placebo |
sk3530 100mg, placebo, amlodipine |
1 |
2008 |
| Procedure |
skin biopsy |
1 |
2010 |
| Behavioral |
sleep apnea treatment |
1 |
2009 |
| Behavioral |
sleep enhancement |
1 |
2017 |
| Behavioral |
sleep healthy using the internet |
1 |
2015 |
| Behavioral |
sleep timing |
1 |
2017 |
| Other |
slow-paced respiration therapy |
1 |
2014 |
| Drug |
slow sodium tablets |
1 |
2012 |
| Procedure |
slt |
1 |
2010 |
| Behavioral |
smart |
1 |
2008 |
| Device |
smart controlâ® (cordis) |
1 |
2007 |
| Behavioral |
smart phone telemonitoring hbp |
1 |
2014 |
| Behavioral |
smart phone telemonitoring hbp / enhanced usual care |
1 |
2014 |
| Behavioral |
smartphone-based tool |
1 |
2013 |
| Device |
smartphone-linked hbpm |
1 |
2019 |
| Device |
smartphone-linked hbpm/associated app |
1 |
2019 |
| Device |
smartphone (mobile app) |
1 |
2014 |
| Device |
smartphone text messaging |
1 |
2017 |
| Behavioral |
smash |
1 |
2018 |
| Behavioral |
smask |
1 |
2016 |
| Behavioral |
smi |
1 |
2006 |
| Behavioral |
smoking cessation |
1 |
2008 |
| Behavioral |
sms |
1 |
2018 |
| Behavioral |
sms reminders of medicines intake |
1 |
2017 |
| Other |
sms text reminders |
1 |
2010 |
| Other |
soccer exercise |
1 |
2012 |
| Other |
soccer exercise/continued daily lifestyle |
1 |
2012 |
| Behavioral |
social incentives-based program |
1 |
2019 |
| Behavioral |
social support |
1 |
2018 |
| Behavioral |
sodium-restricted diet (srd) |
1 |
2009 |
| Behavioral |
sodium intake reduction |
1 |
2017 |
| Drug |
sodium nitrite |
1 |
2017 |
| Drug |
sodium nitrite inhalation solution |
1 |
2008 |
| Drug |
sodium nitroprusside |
1 |
2004 |
| Dietary Supplement |
sodium phosphate |
1 |
2016 |
| Other |
sodium restricted meals |
1 |
2019 |
| Behavioral |
sodium watcher program-hypertension |
1 |
2019 |
| Drug |
sof |
1 |
2012 |
| Drug |
sonovue |
1 |
2011 |
| Drug |
sotagliflozin (sar439954) |
1 |
2018 |
| Dietary Supplement |
soy protein |
1 |
2008 |
| Dietary Supplement |
soybean peptides |
1 |
2019 |
| Drug |
sparc0912 |
1 |
2009 |
| Drug |
sparc0913 |
1 |
2009 |
| Behavioral |
special intervention |
1 |
2012 |
| Behavioral |
specialist care consultation |
1 |
2016 |
| Other |
speech therapy |
1 |
2017 |
| Drug |
spermidine |
1 |
2020 |
| Drug |
sph3127 tablet dose 1 |
1 |
2018 |
| Drug |
sph3127 tablet dose 2 |
1 |
2018 |
| Drug |
sph3127 tablet dose 3 |
1 |
2018 |
| placebo |
sph3127 tablet placebo |
1 |
2018 |
| Device |
sphygmomanometer |
1 |
2019 |
| Other |
spinal manipulation |
1 |
2009 |
| Drug |
spironolactone captopril carvedilol |
1 |
2005 |
| Drug |
spironolactone pill |
1 |
2016 |
| Other |
spironolactone, dyslipidemic therapy with ezetamide |
1 |
2008 |
| Drug |
spironolactone/carvedilol |
1 |
2016 |
| Dietary Supplement |
spirulina |
1 |
2015 |
| Device |
spleen elastography |
1 |
2015 |
| Device |
spleen stiffness measurement |
1 |
2015 |
| Drug |
spp100 |
1 |
2005 |
| Drug |
spp100 (aliskiren) |
1 |
2007 |
| Drug |
spp635 |
1 |
2007 |
| Drug |
spp635 (drug) |
1 |
2006 |
| Device |
st. jude medical renal artery ablation system: rf ablation generator (ibi 1500t11.5) |
1 |
2011 |
| Device |
st. jude medical renal artery ablation system: rf ablation generator (ibi 1500t11.5)/renal artery ablation catheter (ds3d001, ds3d002) |
1 |
2011 |
| Drug |
standard-dose rtpa |
1 |
2011 |
| Other |
standard arterial line |
1 |
2019 |
| Other |
standard bp arm |
1 |
2013 |
| Behavioral |
standard care regimen 12 months |
1 |
2015 |
| Behavioral |
standard care regimen 15 months |
1 |
2015 |
| Behavioral |
standard care regimen 18 months |
1 |
2015 |
| Behavioral |
standard care regimen 21 months |
1 |
2015 |
| Behavioral |
standard care regimen 24 months |
1 |
2015 |
| Behavioral |
standard care regimen 27 months |
1 |
2015 |
| Behavioral |
standard care regimen 9 months |
1 |
2015 |
| Other |
standard control |
1 |
2011 |
| Drug |
standard control of sbp |
1 |
2010 |
| Drug |
standard control of systolic blood pressure (sbp) |
1 |
2019 |
| Other |
standard dosing of labetalol |
1 |
2019 |
| Device |
standard hbpm |
1 |
2019 |
| Behavioral |
standard lifestyle modification |
1 |
2014 |
| Behavioral |
standard lifestyle modification / modified dash |
1 |
2014 |
| Other |
standard medical therapy |
1 |
2016 |
| Drug |
standard of care iv antihypertensive |
1 |
2008 |
| Other |
standard of care medical management |
1 |
2010 |
| Other |
standard postpartum care without nsaids |
1 |
2019 |
| Other |
standard protocol of fluid management in hemodialysis |
1 |
2017 |
| Other |
standardized meals |
1 |
2009 |
| Behavioral |
star intervention |
1 |
2010 |
| Drug |
statin) |
1 |
2019 |
| Drug |
statin, amlodipine |
1 |
2008 |
| Behavioral |
step count prescription |
1 |
2011 |
| Other |
step down strategy |
1 |
2018 |
| Other |
story-telling dvd |
1 |
2011 |
| Behavioral |
storytelling |
1 |
2015 |
| Behavioral |
storytelling intervention |
1 |
2018 |
| Other |
strawberry beverage |
1 |
2009 |
| Other |
strength training group |
1 |
2017 |
| Other |
strengthen the performance appraisal system |
1 |
2018 |
| Other |
strengthened referral network from community to referral hospital levels |
1 |
2019 |
| Behavioral |
stress management |
1 |
2018 |
| Behavioral |
stress management training |
1 |
2009 |
| Other |
stretch exercise |
1 |
2013 |
| Other |
stretching exercise |
1 |
2019 |
| Other |
stretching exercises |
1 |
2017 |
| Other |
stretching training |
1 |
2012 |
| Behavioral |
structured educational program |
1 |
2007 |
| Drug |
study #1: spironolactone (sp), titrated dose |
1 |
2006 |
| Diagnostic Test |
study population |
1 |
2018 |
| Drug |
study treatment 1 wb007 |
1 |
2019 |
| Drug |
study treatment 2 wb007 |
1 |
2019 |
| Drug |
study treatment 3 wb007 |
1 |
2019 |
| Drug |
study# 2 chlorthalidone (ctd), fixed dose |
1 |
2006 |
| Drug |
study# 2 irbsesartan (ir), fixed dose |
1 |
2006 |
| Drug |
study# 2 spironolactone (sp), fixed dose |
1 |
2006 |
| Drug |
study#1: chlorthalidone (ctd), titrated dose |
1 |
2006 |
| Other |
subacute hypoxic exposures |
1 |
2013 |
| Drug |
subconjunctival injection of liposomal latanoprost |
1 |
2013 |
| Drug |
subcutaneous treprostinil; oral treprostinil |
1 |
2018 |
| Drug |
subject’s habitual pga monotherapy |
1 |
2014 |
| Other |
submaximal exercises |
1 |
2012 |
| Other |
subspecialty care |
1 |
2015 |
| Drug |
substance p |
1 |
2018 |
| Drug |
substance p, |
1 |
2011 |
| Dietary Supplement |
sucrose |
1 |
2019 |
| Behavioral |
supervised isometric handgrip training |
1 |
2019 |
| Other |
supplemental oxygen |
1 |
2011 |
| Procedure |
supplemental oxygen via a mask |
1 |
2012 |
| Behavioral |
support for the family health team |
1 |
2012 |
| Behavioral |
supportive educative nursing intervention |
1 |
2010 |
| Device |
surround sound externally focused therapeutic ultrasound |
1 |
2013 |
| Procedure |
sustained hand grip |
1 |
2013 |
| Behavioral |
swimming |
1 |
2018 |
| Device |
symapcath iâ„¢ catheter |
1 |
2016 |
| Device |
symapcath iâ„¢ catheter/sympioneer s1â„¢ stimulator/generator |
1 |
2016 |
| Procedure |
sympathetic renal denervation |
1 |
2014 |
| Device |
sympioneer s1â„¢ stimulator |
1 |
2016 |
| Device |
symplicty(tm) catheter system |
1 |
2008 |
| Behavioral |
system level leadership intervention |
1 |
2016 |
| Other |
system to support self-management of hypertension |
1 |
2018 |
| Drug |
t-2345 |
1 |
2014 |
| Dietary Supplement |
tablets each containing of 1000mg elemental calcium (mega-calcium sandoz) |
1 |
2007 |
| Drug |
tadalafil- tablet |
1 |
2011 |
| Drug |
tadalafil- tablet/oral suspension |
1 |
2011 |
| Drug |
tadalafil 40 mg |
1 |
2019 |
| Drug |
tadalafil/ambrisentan upfront combination therapy |
1 |
2010 |
| Behavioral |
taekwondo training |
1 |
2018 |
| Drug |
tafluprost 0.0015% eyedrops |
1 |
2010 |
| Drug |
tafluprost 15âµg |
1 |
2017 |
| Drug |
tafluprost 15âµg/ml |
1 |
2017 |
| Drug |
tafluprost ophthalmic solution 0.0015% |
1 |
2011 |
| Behavioral |
tai chi tailored for improving balance (balance) |
1 |
2020 |
| Behavioral |
tai chi tailored for lowering blood pressure (pressure) |
1 |
2020 |
| Behavioral |
tailored physical activity intervention |
1 |
2005 |
| Behavioral |
tailored sms-text message support |
1 |
2015 |
| Behavioral |
tailored telephone-based case management |
1 |
2009 |
| Drug |
tak-536ccb |
1 |
2014 |
| Drug |
tak-536ccb / hydrochlorothiazide |
1 |
2014 |
| Drug |
tak-536ccb tablet |
1 |
2014 |
| Drug |
tak-536tch |
1 |
2015 |
| Drug |
tak-536tch tablet |
1 |
2014 |
| Drug |
tamoxifen |
1 |
2018 |
| Drug |
tamsulosin hydrochloride |
1 |
2005 |
| Other |
target blood pressure |
1 |
2005 |
| Other |
target of blood pressure |
1 |
2003 |
| Behavioral |
targeted esteem diet |
1 |
2014 |
| Behavioral |
targeted incentives |
1 |
2019 |
| Drug |
taurin 6g per day per oral for 28 days |
1 |
2015 |
| Diagnostic Test |
tcd |
1 |
2020 |
| Behavioral |
teaching mindfulness-based stress reduction strategies |
1 |
2012 |
| Behavioral |
teaching: individual (5606) |
1 |
2016 |
| Behavioral |
technology-based component |
1 |
2018 |
| Device |
technology-based self-management model |
1 |
2016 |
| Behavioral |
techsupport |
1 |
2018 |
| Drug |
tegaderm |
1 |
2011 |
| Device |
tele-health home monitoring |
1 |
2010 |
| Device |
tele-health home monitoring/trestle telephone coaching |
1 |
2010 |
| Other |
telehealth care |
1 |
2016 |
| Device |
telemedical blood pressure monitoring |
1 |
2006 |
| Behavioral |
telemedical home blood pressure measurements |
1 |
2015 |
| Procedure |
telemonitoring/telemedicine |
1 |
2011 |
| Other |
telemonitors |
1 |
2008 |
| Other |
telemonitors/pharmacy management |
1 |
2008 |
| Behavioral |
telepharmacist intervention |
1 |
2015 |
| Procedure |
telephone |
1 |
2005 |
| Behavioral |
telephone behavioral education |
1 |
2005 |
| Behavioral |
telephone health coaching |
1 |
2017 |
| Procedure |
telephone/face-to-face care management |
1 |
2005 |
| Drug |
telminuvoâ®tab. 40 |
1 |
2014 |
| Drug |
telminuvoâ®tab. 40/2.5mg |
1 |
2014 |
| Drug |
telmisartan / amlodipine / rosuvastatin |
1 |
2016 |
| Drug |
telmisartan / hctz |
1 |
2013 |
| Drug |
telmisartan / rosuvastatin |
1 |
2016 |
| Drug |
telmisartan 20 mg |
1 |
2006 |
| Drug |
telmisartan 40 mg/hydrochlorothiazide 12.5 mg |
1 |
2005 |
| Drug |
telmisartan 80 |
1 |
2009 |
| Drug |
telmisartan 80 mg / hydrochlorothiazide 12.5 mg |
1 |
2005 |
| Drug |
telmisartan 80 mg/hctz 12.5 mg |
1 |
2006 |
| Drug |
telmisartan 80 mg/hydrochlorothiazide 25 mg |
1 |
2005 |
| Drug |
telmisartan 80mg / amlodipine 5mg / chlorthalidone 25mg |
1 |
2018 |
| placebo |
telmisartan placebo |
1 |
2013 |
| Drug |
telmisartan, high dose |
1 |
2014 |
| Drug |
telmisartan, low dose |
1 |
2014 |
| Drug |
telmisartan, valsartan |
1 |
2002 |
| Drug |
telmisartan/ ramipril |
1 |
2009 |
| Drug |
telmisartan/amlodipine 40/5 mg fixed combination |
1 |
2008 |
| Drug |
telmisartan/amlodipine 40/5mg |
1 |
2015 |
| Drug |
telmisartan/amlodipine 40/5mg placebo |
1 |
2015 |
| Drug |
telmisartan/amlodipine 80/5 mg (fdc) |
1 |
2015 |
| Drug |
telmisartan/amlodipine 80/5 mg fixed combination |
1 |
2008 |
| Drug |
telmisartan/amlodipine 80/5mg |
1 |
2015 |
| Drug |
telmisartan/amlodipine 80/5mg placebo |
1 |
2015 |
| Drug |
telmisartan/amlodipine combination tablet |
1 |
2011 |
| Drug |
telmisartan/amlodipine fixed dose combination |
1 |
2010 |
| Drug |
telmisartan/amlodipine/hydrochlorothiazide |
1 |
2016 |
| Drug |
telmisartan/metformin |
1 |
2007 |
| Drug |
telmisartan/with hydrochlorothiazide (80/12.5 mg) |
1 |
2005 |
| Drug |
telmisartan40 |
1 |
2008 |
| Drug |
telmisartan40/amlodipine5 |
1 |
2008 |
| Drug |
telmisartan80 |
1 |
2008 |
| Drug |
telmisartan80/amlodipine5 |
1 |
2008 |
| Drug |
telmisartan80mg |
1 |
2010 |
| Drug |
telmisartan80mg/amlodipine 5mg |
1 |
2010 |
| Drug |
telmisartan80mg/amlodipine5mg |
1 |
2010 |
| Drug |
telmitrendâ®tab. 80mg |
1 |
2014 |
| Drug |
temisartan/amlodipine |
1 |
2017 |
| Drug |
temisartan/amlodipine/rosuvastatin (combination drug) |
1 |
2017 |
| Drug |
temisartan/rosuvastatin |
1 |
2017 |
| Procedure |
temporary right ventricular pacing |
1 |
2019 |
| Drug |
terazosin |
1 |
2008 |
| Drug |
terbogrel high dose |
1 |
2014 |
| Drug |
terbogrel low dose |
1 |
2014 |
| Drug |
terlipressin |
1 |
2006 |
| Drug |
terlipressin acetate |
1 |
2012 |
| Drug |
terlipressin/then dummy |
1 |
2006 |
| Drug |
test-brinzolamide 1% ophthalmic suspension |
1 |
2015 |
| Drug |
tetrahydrobiopterin |
1 |
2005 |
| Drug |
tetrastarch (voluven) |
1 |
2009 |
| Behavioral |
text message medication reminders |
1 |
2011 |
| Behavioral |
text messages |
1 |
2018 |
| Behavioral |
the dash diet |
1 |
2007 |
| Device |
the hotmanâ® system |
1 |
2012 |
| Behavioral |
the low glycemic index diet |
1 |
2007 |
| Device |
the mobile health platform |
1 |
2014 |
| Device |
the paradiseâ® renal denervation ultrasound system |
1 |
2016 |
| Device |
the peregrine system infusion catheter |
1 |
2014 |
| Procedure |
the symplicitytm renal denervation system |
1 |
2012 |
| Drug |
then dummy |
1 |
2006 |
| Drug |
theophylline |
1 |
2012 |
| Drug |
theophylline/bambuterol |
1 |
2012 |
| Diagnostic Test |
therapeutic drug monitoring |
1 |
2017 |
| Other |
therapeutic education hta vasc |
1 |
2011 |
| Behavioral |
therapeutic lifestyle changes (mint-tlc) |
1 |
2010 |
| Device |
therasorbâ® - ig flex |
1 |
2012 |
| Device |
thermocoolâ®rcatheter |
1 |
2013 |
| Drug |
thiazide |
1 |
2020 |
| Drug |
thiazide-like diuretics |
1 |
2020 |
| Drug |
thiazide candesartan |
1 |
2005 |
| Drug |
thiazide diuretics |
1 |
2005 |
| Drug |
thiazide treatment group |
1 |
2017 |
| Drug |
thiazide/thiazide-like diuretics |
1 |
2020 |
| Drug |
thiazides |
1 |
2006 |
| Drug |
thiotepa |
1 |
2018 |
| Device |
threshold |
1 |
2012 |
| Drug |
timolol-dorzolamide fixed combination |
1 |
2012 |
| Drug |
timolol (0.5%) |
1 |
2003 |
| Drug |
timolol 0,5% fixed combination |
1 |
2008 |
| Drug |
timolol 0.005% ophthalmic solution |
1 |
2006 |
| Drug |
timolol 0.05% eye drops |
1 |
2007 |
| Drug |
timolol 0.5% bid |
1 |
2015 |
| Drug |
timolol 0.5% fixed combination |
1 |
2005 |
| Drug |
timolol 0.5% fixed combination eye drops (duotrav) |
1 |
2007 |
| Drug |
timolol 0.5% fixed combination ophthalmic suspension |
1 |
2011 |
| Drug |
timolol 0.5% maleate fixed combination |
1 |
2011 |
| Drug |
timolol 0.5% ophthalmic solution (timoptic) |
1 |
2008 |
| Drug |
timolol 0.5% ophthalmic suspension |
1 |
2011 |
| Drug |
timolol 0.5%) |
1 |
2010 |
| Drug |
timolol 5 mg/ml eye drops, solution |
1 |
2006 |
| Drug |
timolol fixed combination. |
1 |
2009 |
| Drug |
timolol formulation a fixed combination ophthalmic solution |
1 |
2010 |
| Drug |
timolol gel-forming solution (tgfs) |
1 |
2003 |
| Drug |
timolol gel forming solution, 0.5% |
1 |
2008 |
| Drug |
timolol hemihydrate |
1 |
2008 |
| Drug |
timolol maleate 0.5% bid |
1 |
2019 |
| Drug |
timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy. |
1 |
2009 |
| Drug |
timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy |
1 |
2009 |
| Drug |
timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy. |
1 |
2009 |
| Drug |
timolol maleate 0.5% fixed combination ophthalmic suspension |
1 |
2014 |
| Drug |
timolol maleate fixed combination solution |
1 |
2009 |
| Drug |
timolol maleate gel forming solution |
1 |
2008 |
| Drug |
timolol maleate in sorbate |
1 |
2008 |
| Drug |
timolol maleate ophthalmic gel forming solution, 0.5% |
1 |
2006 |
| Drug |
timolol maleate ophthalmic solution |
1 |
2008 |
| Drug |
timolol maleate ophthalmic solution, 0.5% |
1 |
2007 |
| Drug |
timolol maleate solution |
1 |
2011 |
| Drug |
timolol ophthalmic suspension |
1 |
2007 |
| Drug |
timolol/ fdc/ placebo/ tafluprost |
1 |
2011 |
| Drug |
timolol/tafluprost |
1 |
2011 |
| Drug |
tjo-002 |
1 |
2018 |
| Drug |
tocilizumab |
1 |
2015 |
| Drug |
topical high dose of de-126 ophthalmic solution |
1 |
2017 |
| Drug |
topical low dose of de-126 ophthalmic solution |
1 |
2017 |
| Drug |
topical medium dose of de-126 ophthalmic solution |
1 |
2017 |
| Drug |
topical ocular hypotensive eye drops. |
1 |
1999 |
| Drug |
topical ultra-low dose of de-126 ophthalmic solution |
1 |
2017 |
| Drug |
topiramate |
1 |
2005 |
| Drug |
torasemide 5mg tablet |
1 |
2017 |
| Drug |
torasemide immediate release (loop diuretic) |
1 |
2006 |
| Drug |
torasemide prolonged release (loop diuretic) |
1 |
2006 |
| Drug |
torsemide |
1 |
2016 |
| Diagnostic Test |
tos |
1 |
2020 |
| Diagnostic Test |
tos/tcd |
1 |
2020 |
| Radiation |
total body irradiation |
1 |
2018 |
| Procedure |
total egds |
1 |
2013 |
| Procedure |
total egds/ endoscopy |
1 |
2013 |
| Drug |
trabodenoson |
1 |
2013 |
| Drug |
trabodenoson 3.0% |
1 |
2016 |
| Drug |
trabodenoson 3.0% / latanoprost 0.005% qd |
1 |
2016 |
| Drug |
trabodenoson 3.0% qd |
1 |
2015 |
| Drug |
trabodenoson 4.5% bid |
1 |
2015 |
| Drug |
trabodenoson 6.0% |
1 |
2016 |
| Drug |
trabodenoson 6.0% / latanoprost 0.0025% qd |
1 |
2016 |
| Drug |
trabodenoson 6.0% / latanoprost 0.005% qd |
1 |
2016 |
| Drug |
trabodenoson 6.0% qd |
1 |
2015 |
| Other |
tracing |
1 |
2008 |
| Other |
tracing/recall at home by a community worker |
1 |
2008 |
| Drug |
traclear |
1 |
2013 |
| Drug |
tracleerâ® |
1 |
2006 |
| Other |
traditional pilates group |
1 |
2018 |
| Drug |
traditional triple antihypertensive treatment |
1 |
2018 |
| Other |
training |
1 |
2018 |
| Behavioral |
transcendental meditation program |
1 |
2008 |
| Device |
transcranial direct-current stimulation (tdcs) |
1 |
2018 |
| Device |
transcutaneous electrical nerve stimulation |
1 |
2011 |
| Procedure |
transhepatic portosystemic shunt |
1 |
2015 |
| Procedure |
transjugular hvpg measurement |
1 |
2018 |
| Procedure |
transjugular intrahepatic portosystemic shunt (tips) |
1 |
2007 |
| Device |
transmedial psychoeducational program to improve adherence full |
1 |
2019 |
| Device |
transmedial psychoeducational program to improve adherence full/partial (ps) |
1 |
2019 |
| Other |
transmission of sflt-1 results to the investigator |
1 |
2008 |
| Procedure |
transplantation of lungs obtained from non-heart-beating donors (nhbds) after ex-vivo perfusion w |
1 |
2012 |
| Procedure |
transplantation of lungs obtained from non-heart-beating donors (nhbds) after ex-vivo perfusion w/ steen solutionâ„¢ |
1 |
2012 |
| Behavioral |
transportation scheduling |
1 |
2018 |
| Device |
travalert dosing aid |
1 |
2007 |
| Drug |
travatan |
1 |
2008 |
| Drug |
travatan 0.004% |
1 |
2013 |
| Drug |
travoprost (0.004%) |
1 |
2003 |
| Drug |
travoprost (travatan) |
1 |
2006 |
| Drug |
travoprost 0.004% (bak-preserved) eye drops, solution |
1 |
2009 |
| Drug |
travoprost 0.004% (polyquad-preserved) eye drops, solution |
1 |
2009 |
| Drug |
travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution |
1 |
2013 |
| Drug |
travoprost 0.004% / timolol 0.5% ophthalmic solution |
1 |
2006 |
| Drug |
travoprost 0.004% / timolol maleate 0.5% |
1 |
2008 |
| Drug |
travoprost 0.004% bak-free |
1 |
2012 |
| Drug |
travoprost 0.004% eye drops |
1 |
2007 |
| Drug |
travoprost 0.004% ophthalmic solution (travatan) |
1 |
2008 |
| Drug |
travoprost 0.004% ophthalmic solution travatan zâ® |
1 |
2014 |
| Drug |
travoprost 0.004% with |
1 |
2006 |
| Drug |
travoprost 0.004% with/without bak |
1 |
2006 |
| Drug |
travoprost 0.004%/brinzolamide 1% |
1 |
2007 |
| Drug |
travoprost 0.004%/timolol 0.5% |
1 |
2009 |
| Drug |
travoprost 0.004%/timolol 0.5% fixed combination eye drops (duotrav) |
1 |
2007 |
| Drug |
travoprost 0.004%/timolol maleate 0.5% ophthalmic solution |
1 |
2006 |
| Drug |
travoprost 004% sterile ophthalmic solution |
1 |
2009 |
| Drug |
travoprost 40 mcg |
1 |
2006 |
| Drug |
travoprost 40 mcg/ml / timolol 5 mg/ml eye drops, solution (duotrav) |
1 |
2006 |
| Drug |
travoprost aps 40 micrograms |
1 |
2009 |
| Drug |
travoprost aps 40 micrograms/ml eye drop solution |
1 |
2009 |
| Drug |
travoprost ophthalmic solution (new formulation) |
1 |
2008 |
| Drug |
travoprost ophthalmic solution, 0.00013% |
1 |
2011 |
| Drug |
travoprost ophthalmic solution, 0.00033% |
1 |
2011 |
| Drug |
travoprost ophthalmic solution, 0.0008% |
1 |
2008 |
| Drug |
travoprost ophthalmic solution, 0.0012% |
1 |
2008 |
| Drug |
travoprost ophthalmic solution, 0.00267% |
1 |
2011 |
| Drug |
travoprost ophthalmic solution, 0.003% |
1 |
2011 |
| Drug |
travoprost ophthalmic solution, 0.004% (new formulation) |
1 |
2012 |
| Drug |
travoprost solution vehicle |
1 |
2014 |
| Drug |
travoprost, investigational |
1 |
2006 |
| Drug |
travoprost/brinzolamide |
1 |
2007 |
| Drug |
travoprost/timolol maleate fixed combination solution |
1 |
2009 |
| Drug |
trc150094 |
1 |
2017 |
| Drug |
treatment a |
1 |
2010 |
| Drug |
treatment a (fimasartan, linagliptin) |
1 |
2018 |
| Other |
treatment algorithm:caduet, amlodipine, acei-arb combo dose, a-blocker, b-blocker |
1 |
2008 |
| Other |
treatment algorithm:caduet, amlodipine, acei-arb combo dose, a-blocker, b-blocker/spironolactone, dyslipidemic therapy with ezetamide |
1 |
2008 |
| Drug |
treatment b |
1 |
2010 |
| Drug |
treatment b (fimasartan |
1 |
2018 |
| Drug |
treatment b (fimasartan/linagliptin) |
1 |
2018 |
| Drug |
treatment c |
1 |
2010 |
| Other |
treatment contract |
1 |
2008 |
| Drug |
treatment d |
1 |
2010 |
| Drug |
treatment e |
1 |
2010 |
| Drug |
treatment f |
1 |
2010 |
| Dietary Supplement |
treatment group 1(dietary intervention) |
1 |
2012 |
| Other |
treatment group 2(dietary |
1 |
2012 |
| Other |
treatment group 2(dietary/exercise intervention) |
1 |
2012 |
| Procedure |
treatment of elevated asleep sbp mean |
1 |
2018 |
| Drug |
treatment with aldactone |
1 |
2014 |
| Drug |
treprostinil diolamine |
1 |
2012 |
| Drug |
treprostinil inhalations |
1 |
2010 |
| Drug |
treprostinil injectable product |
1 |
2019 |
| Device |
trestle telephone coaching |
1 |
2010 |
| Behavioral |
trestletree telephone coaching |
1 |
2010 |
| Dietary Supplement |
trial 1: fatty acids, omega-3; trial 2: mineral supplements |
1 |
1999 |
| Drug |
triamterene |
1 |
1999 |
| Drug |
triatec 10 mg |
1 |
2007 |
| Drug |
triatec 5 mg |
1 |
2007 |
| Drug |
triatec hct 5 |
1 |
2007 |
| Drug |
trimetazidine |
1 |
2017 |
| Other |
triple combination |
1 |
2019 |
| Device |
tug |
1 |
2016 |
| Other |
two portions of fruit |
1 |
2011 |
| Other |
two portions of fruit/vegetables per day (excluding berries/dark chocolate) |
1 |
2011 |
| Drug |
two separated drugs(arb(angiotensin â…¡ receptor blocker) |
1 |
2019 |
| Drug |
two separated drugs(arb(angiotensin â…¡ receptor blocker)/statin) |
1 |
2019 |
| Behavioral |
two servings of dairy snacks |
1 |
2007 |
| Drug |
tyvaso inhalation solution |
1 |
2011 |
| Device |
uaobp |
1 |
2018 |
| Drug |
ubenimex |
1 |
2016 |
| Behavioral |
uc |
1 |
2006 |
| Other |
ultrafiltration |
1 |
2003 |
| Device |
ultrasonic cardiac output monitor (uscom) system |
1 |
2016 |
| Device |
ultrasound |
1 |
2016 |
| Procedure |
ultrasound-guided intermittent large-volume paracentesis |
1 |
2019 |
| Device |
ultrasound denervation of the main renal arteries |
1 |
2016 |
| Drug |
uncaria granule |
1 |
2019 |
| Behavioral |
uncertainty reduction |
1 |
2005 |
| Drug |
unfixed latanoprost |
1 |
2005 |
| Drug |
unfixed latanoprost/timolol |
1 |
2005 |
| Other |
unloaded breathing training |
1 |
2014 |
| Behavioral |
unsupervised exercise program |
1 |
2016 |
| Behavioral |
uplift |
1 |
2017 |
| Other |
upper extremity aerobic exercise training |
1 |
2015 |
| Drug |
urapidil |
1 |
2015 |
| Behavioral |
urban zen integrative therapy (uzit) |
1 |
2017 |
| Other |
use of blood pressure lowering medication at bedtime |
1 |
2016 |
| Other |
use of blood pressure lowering medication in the morning |
1 |
2016 |
| Procedure |
use of non-dilated retinal photography |
1 |
2009 |
| Behavioral |
use of telephone-based interactive voice recognition system |
1 |
2007 |
| Behavioral |
user-driven group |
1 |
2017 |
| Other |
usual-salt diet |
1 |
2019 |
| Behavioral |
usual - take your bp meds as you usually do |
1 |
2007 |
| Behavioral |
usual care (uc) control condition |
1 |
2010 |
| Other |
usual care group |
1 |
2019 |
| Other |
usual care. |
1 |
2008 |
| Drug |
ut-15 |
1 |
1999 |
| Drug |
ut-15c |
1 |
2010 |
| Drug |
ut-15c (treprostinil diethanolamine) |
1 |
2012 |
| Drug |
ut-15c sr (treprostinil diethanolamine) |
1 |
2010 |
| Radiation |
uva radiation |
1 |
2012 |
| Procedure |
vagus nerve-preserving group |
1 |
2018 |
| Drug |
val489 |
1 |
2012 |
| placebo |
val489 matching placebo |
1 |
2012 |
| Drug |
valsaltan, amlodipine |
1 |
2010 |
| Drug |
valsartan (160 mg |
1 |
2019 |
| Drug |
valsartan (160 mg/d) |
1 |
2019 |
| Drug |
valsartan (val489) |
1 |
2011 |
| Drug |
valsartan / amlodipine / hctz |
1 |
2006 |
| Drug |
valsartan / amlodipine 40/2.5 mg |
1 |
2007 |
| Drug |
valsartan / amlodipine 40/5 mg |
1 |
2007 |
| Drug |
valsartan / amlodipine 80/2.5 mg |
1 |
2007 |
| Drug |
valsartan / amlodipine 80/5 mg |
1 |
2007 |
| Drug |
valsartan / amlodipine besilate |
1 |
2007 |
| Drug |
valsartan / hydrochlorothiazide |
1 |
2006 |
| Drug |
valsartan / simvastatin |
1 |
2005 |
| Drug |
valsartan 0.25 mg |
1 |
2007 |
| Drug |
valsartan 0.25 mg/kg |
1 |
2007 |
| Drug |
valsartan 1 |
1 |
2012 |
| Drug |
valsartan 1.0 mg |
1 |
2007 |
| Drug |
valsartan 1.0 mg/kg |
1 |
2007 |
| Drug |
valsartan 160 mg / hydrochlorothiazide 25 mg |
1 |
2005 |
| Drug |
valsartan 160 mg capsules |
1 |
2007 |
| Drug |
valsartan 160 mg/hydrochlorothiazide 25 mg |
1 |
2005 |
| Drug |
valsartan 160mg daily |
1 |
2007 |
| Drug |
valsartan 160mg od; moxonidine 400mcg od |
1 |
2007 |
| Drug |
valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg |
1 |
2014 |
| Drug |
valsartan 160mg/hct 25mg |
1 |
2008 |
| Drug |
valsartan 2 |
1 |
2012 |
| Drug |
valsartan 3 |
1 |
2012 |
| Drug |
valsartan 320 mg |
1 |
2005 |
| Drug |
valsartan 4.0 mg |
1 |
2007 |
| Drug |
valsartan 4.0 mg/kg |
1 |
2007 |
| Drug |
valsartan 80mg |
1 |
2013 |
| Drug |
valsartan 80mg daily |
1 |
2007 |
| placebo |
valsartan 80mg placebo |
1 |
2013 |
| placebo |
valsartan placebo |
1 |
2015 |
| Drug |
valsartan, 80 mg once-a-day |
1 |
2007 |
| Drug |
valsartan, amlodipine, hctz |
1 |
2009 |
| Drug |
valsartan, enalapril |
1 |
2006 |
| Drug |
valsartan, fluvastatin |
1 |
2005 |
| Drug |
valsartan, hydrochlorothiazide |
1 |
2006 |
| Drug |
valsartan, hydrochlorothiazide/amlodipine |
1 |
2006 |
| Drug |
valsartan, valsartan |
1 |
2005 |
| Drug |
valsartan, valsartan hct |
1 |
2005 |
| Drug |
valsartan, valsartan/hydrochlorothiazide |
1 |
2005 |
| Drug |
valsartan//- hydrochlorothiazide |
1 |
2007 |
| Drug |
valsartan/aliskiren |
1 |
2008 |
| Drug |
valsartan/amlodipine 160/5 mg |
1 |
2009 |
| Drug |
valsartan/amlodipine 80/5 mg tablets |
1 |
2008 |
| Drug |
valsartan/amlodipine combination |
1 |
2006 |
| Drug |
valsartan/amlodipine combination, valsartan, amlodipine |
1 |
2006 |
| Drug |
valsartan/amlodipine/hydrochlorothiazide(hctz) |
1 |
2007 |
| Drug |
valsartan/atenolol |
1 |
2005 |
| Drug |
valsartan/hydrochlorothiazide (80mg/12.5mg) |
1 |
2007 |
| Drug |
valsartan/hydrochlorothiazide (hctz) |
1 |
2007 |
| Drug |
valsartan/hydrochlorothiazide (hctz) - combination arm |
1 |
2009 |
| Drug |
valsartan/hydrochlorothiazide (hctz) - monotherapy |
1 |
2009 |
| Drug |
valsartan/simvastatin |
1 |
2006 |
| Drug |
valsartan/with hydrochlorothiazide (160/12.5mg) |
1 |
2005 |
| Drug |
valsartant treatment |
1 |
2006 |
| Drug |
valsartin |
1 |
2005 |
| Behavioral |
vamos program - active life improving health |
1 |
2014 |
| Drug |
varenicline |
1 |
2009 |
| Drug |
vasomera (pb1046) |
1 |
2012 |
| Drug |
vasopressin - low dose |
1 |
2010 |
| Drug |
vasopressin - very low dose |
1 |
2010 |
| Combination Product |
vedic medical astrology |
1 |
2019 |
| Dietary Supplement |
vegetable juice supplement |
1 |
2017 |
| Other |
vegetables per day (excluding berries |
1 |
2011 |
| Other |
vegetables per day (one of which must be berries) |
1 |
2011 |
| Drug |
vehicle of de-126 ophthalmic solution, high dose of de-126 ophthalmic solution |
1 |
2017 |
| Drug |
vehicle ophthalmic solution |
1 |
2013 |
| Procedure |
venesection |
1 |
2009 |
| Device |
venous sinus stenting (serenity river) |
1 |
2018 |
| Other |
ventilation strategy |
1 |
2008 |
| Device |
ventripoint medical system |
1 |
2011 |
| Drug |
verapamil sr |
1 |
2005 |
| Drug |
verapamil sr/trandolapril/hydrochlorothiazide (hctz) |
1 |
2005 |
| Other |
verbal patient education on hypertension |
1 |
2013 |
| Dietary Supplement |
verum |
1 |
2014 |
| Behavioral |
very low carbohydrate, ketogenic diet |
1 |
2018 |
| Device |
viatorrâ® (gore) |
1 |
2007 |
| Other |
video |
1 |
2016 |
| Behavioral |
video-assisted coaching |
1 |
2010 |
| Other |
vietnam national hypertension program |
1 |
2018 |
| Drug |
vildagliptin |
1 |
2013 |
| Drug |
vildagliptin 50 mg |
1 |
2017 |
| Other |
virtual hypertension clinic |
1 |
2010 |
| Drug |
viscum album ethanolic extract manufactured according to homoeopathic pharmacopoeia of india (h.p.i.) |
1 |
2012 |
| Drug |
vision5 product |
1 |
2013 |
| Procedure |
visual acuity |
1 |
2005 |
| Dietary Supplement |
vitamin d-3 (cholecalciferol), 2000 iu |
1 |
2012 |
| Dietary Supplement |
vitamin d (cholecalciferol) |
1 |
2010 |
| placebo |
vitamin d placebo |
1 |
2012 |
| Dietary Supplement |
vitamin d/calcium |
1 |
2020 |
| placebo |
vitamin d3 placebo |
1 |
2016 |
| Dietary Supplement |
vivomixxâ® |
1 |
2019 |
| Behavioral |
volunteer-led pharmacy sessions with feedback to physicians |
1 |
2005 |
| Drug |
vs101 insert dose a |
1 |
2014 |
| Drug |
vs101 insert dose b |
1 |
2014 |
| Drug |
vs101 insert dose c |
1 |
2014 |
| Dietary Supplement |
vsl3 |
1 |
2009 |
| Device |
waist |
1 |
2013 |
| Device |
waist/hip circumference |
1 |
2013 |
| Behavioral |
wait list control group |
1 |
2017 |
| Behavioral |
walking |
1 |
2019 |
| Behavioral |
walking (behavior) |
1 |
2006 |
| Other |
walking exercise |
1 |
2019 |
| Behavioral |
walking intervention |
1 |
2014 |
| Behavioral |
walking program |
1 |
2009 |
| Behavioral |
walking training |
1 |
2015 |
| Dietary Supplement |
walnuts |
1 |
2016 |
| Dietary Supplement |
water |
1 |
2010 |
| Dietary Supplement |
watermelon extract |
1 |
2010 |
| Procedure |
web-based care management |
1 |
2005 |
| Behavioral |
web-based educational |
1 |
2014 |
| Behavioral |
web-based educational/motivational modules |
1 |
2014 |
| Behavioral |
web-based intervention |
1 |
2006 |
| Behavioral |
web-based lifestyle counseling messages |
1 |
2008 |
| Behavioral |
weekly sessions |
1 |
2016 |
| Behavioral |
wellth smartphone app |
1 |
2019 |
| Behavioral |
whatsapp message |
1 |
2020 |
| Dietary Supplement |
wheat bran |
1 |
2012 |
| Dietary Supplement |
whey protein |
1 |
2008 |
| Dietary Supplement |
whey protein isolate |
1 |
2013 |
| Dietary Supplement |
whitechocolate |
1 |
2011 |
| Behavioral |
who cvd risk assessment package |
1 |
2013 |
| Other |
whole body vibration training/diet |
1 |
2012 |
| Other |
whole hemp seed protein |
1 |
2018 |
| Other |
whole hemp seed protein/bioactive peptides |
1 |
2018 |
| Device |
wireless esophageal capsule endoscopy ( pillcam eso2) |
1 |
2012 |
| Drug |
with hydrochlorothiazide (160 |
1 |
2005 |
| Drug |
with hydrochlorothiazide (80 |
1 |
2005 |
| Drug |
without ace inhibitor |
1 |
2005 |
| Drug |
without add-on chlorthalidone |
1 |
2008 |
| Drug |
without add-on hydrochlorothiazide |
1 |
2008 |
| Drug |
without bak |
1 |
2006 |
| Drug |
without chlorthalidone |
1 |
2008 |
| Other |
worksite screening for dm, htn |
1 |
2015 |
| Other |
worksite screening for dm, htn/hyperlipidemia |
1 |
2015 |
| Other |
written |
1 |
2013 |
| Other |
written information |
1 |
2014 |
| Other |
written/verbal patient education on hypertension/its treatment |
1 |
2013 |
| Drug |
xalacom (kp2035) |
1 |
2006 |
| Drug |
xalacom (latanoprost-timolol ophthalmic drops) |
1 |
2009 |
| Drug |
xalatanâ® |
1 |
2019 |
| Drug |
xoma 985 |
1 |
2012 |
| Drug |
yh16410 |
1 |
2013 |
| placebo |
yh16410 placebo |
1 |
2013 |
| Drug |
yh22162 |
1 |
2015 |
| Drug |
yh22162 40 |
1 |
2015 |
| Drug |
yh22162 40/5/12.5 mg |
1 |
2015 |
| Drug |
yh22162 40/5/12.5 mg placebo |
1 |
2015 |
| Drug |
yh22162 80 |
1 |
2015 |
| Drug |
yh22162 80/5/25 mg |
1 |
2015 |
| Drug |
yh22162 80/5/25 mg placebo |
1 |
2015 |
| Drug |
yhp1701 |
1 |
2017 |
| Drug |
yhr1703 |
1 |
2017 |
| Drug |
yhr1704 |
1 |
2017 |
| Other |
yoga |
1 |
2013 |
| Other |
yoga at home |
1 |
2011 |
| Behavioral |
yoga exercise program |
1 |
2009 |
| Other |
yoga group with supervision (trainer) |
1 |
2011 |
| Behavioral |
yoga lifestyle intervention |
1 |
2008 |
| Other |
yoga poses |
1 |
2017 |
| Behavioral |
yoga session |
1 |
2020 |
| Behavioral |
yoga with asana (yoga postures) |
1 |
2016 |
| Behavioral |
yoga without asana (yoga postures) |
1 |
2016 |
| Other |
yogic practice |
1 |
2012 |
| Drug |
zamicastat |
1 |
2020 |
| Drug |
zanidip |
1 |
2012 |
| Drug |
zofenopril, calcium salt, (1(r*),2alpha,4alpha)-isomer |
1 |
2020 |